

SARS-CoV-2 variants, spike mutations and immune esc

Nature Reviews Microbiology

19, 409-424

DOI: [10.1038/s41579-021-00573-0](https://doi.org/10.1038/s41579-021-00573-0)

Citation Report

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS, California, USA. <i>Emerging Infectious Diseases</i> , 2021, 27, 2720-2723.	2.0	43
2	Synthesis of low-molecular weight fucoidan derivatives and their binding abilities to SARS-CoV-2 spike proteins. <i>RSC Medicinal Chemistry</i> , 2021, 12, 2016-2021.	1.7	9
3	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants. <i>Glycobiology</i> , 2022, 32, 60-72.	1.3	16
4	Emergence of COVID-19 variants among ChAdOx1 nCoV-19 (recombinant) vaccine recipients. <i>Indian Journal of Medical Research</i> , 2021, 153, 559-561.	0.4	1
5	SARS-CoV-2 spike protein N501Y mutation causes differential species transmissibility and antibody sensitivity: a molecular dynamics and alchemical free energy study. <i>Molecular Systems Design and Engineering</i> , 2021, 6, 964-974.	1.7	8
18	Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro. <i>Journal of Infectious Diseases</i> , 2021, 224, 1109-1114.	1.9	56
20	Has SARS-CoV-2 reached peak fitness?. <i>Nature Medicine</i> , 2021, 27, 1323-1324.	15.2	21
27	Bisppecific repurposed medicines targeting the viral and immunological arms of COVID-19. <i>Scientific Reports</i> , 2021, 11, 13208.	1.6	24
34	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	5.7	64
37	Relevance of BET Family Proteins in SARS-CoV-2 Infection. <i>Biomolecules</i> , 2021, 11, 1126.	1.8	11
38	SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. <i>Frontiers in Immunology</i> , 2021, 12, 701501.	2.2	157
48	Longitudinal study of a SARS-CoV-2 infection in an immunocompromised patient with X-linked agammaglobulinemia. <i>Journal of Infection</i> , 2021, 83, 607-635.	1.7	11
51	Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 74, 1623-1630.	2.9	42
58	SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. <i>Eurosurveillance</i> , 2021, 26, .	3.9	31
62	Interpreting estimates of coronavirus disease 2019 (COVID-19) vaccine efficacy and effectiveness to inform simulation studies of vaccine impact: a systematic review. <i>Wellcome Open Research</i> , 0, 6, 185.	0.9	17
64	Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. <i>Vaccines</i> , 2021, 9, 836.	2.1	15
67	The Effect of Azithromycin Plus Zinc Sulfate on ACE2 Expression through $\text{I}\beta\text{B}\beta$ of Human Respiratory Cells in SARS-CoV-2: In Vitro Study. <i>Covid</i> , 2021, 1, 263-275.	0.7	1
68	Contamination of Hospital Surfaces with Bacterial Pathogens under the Current COVID-19 Outbreak. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9042.	1.2	6

#	ARTICLE	IF	CITATIONS
77	SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes. <i>Microorganisms</i> , 2021, 9, 1744.	1.6	16
84	Molecular Level Dissection of Critical Spike Mutations in SARS-CoV-2 Variants of Concern (VOCs): A Simplified Review. <i>ChemistrySelect</i> , 2021, 6, 7981-7998.	0.7	18
88	Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q. <i>Viruses</i> , 2021, 13, 1693.	1.5	69
94	Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses. <i>Viruses</i> , 2021, 13, 1579.	1.5	14
95	Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). <i>Clinical Infectious Diseases</i> , 2022, 75, e1128-e1136.	2.9	323
98	Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary. <i>Journal of Infection</i> , 2021, 83, 559-564.	1.7	66
99	SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. <i>Viruses</i> , 2021, 13, 1687.	1.5	57
100	The rapid adaptation of SARS-CoV-2—rise of the variants: transmission and resistance. <i>Journal of Microbiology</i> , 2021, 59, 807-818.	1.3	18
101	De novo Design of SARS-CoV-2 Main Protease Inhibitors. <i>Synlett</i> , 2022, 33, 458-463.	1.0	6
102	Small Structural Proteins E and M Render the SARS-CoV-2 Pseudovirus More Infectious and Reveal the Phenotype of Natural Viral Variants. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9087.	1.8	11
103	Genomic Variation and Diversification in Begomovirus Genome in Implication to Host and Vector Adaptation. <i>Plants</i> , 2021, 10, 1706.	1.6	17
105	Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals. <i>MSphere</i> , 2021, 6, e0057121.	1.3	2
106	mRNA vaccines for infectious diseases: principles, delivery and clinical translation. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 817-838.	21.5	577
107	Repetitive saliva-based mass screening as a tool for controlling SARS-CoV-2 transmission in nursing homes. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	1.3	11
110	A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance. <i>ELife</i> , 2021, 10, .	2.8	23
111	Biology and Pathogenesis of SARS-CoV-2: Understandings for Therapeutic Developments against COVID-19. <i>Pathogens</i> , 2021, 10, 1218.	1.2	4
113	Î±-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 757691.	2.2	2
115	The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. <i>EBioMedicine</i> , 2021, 71, 103544.	2.7	38

#	ARTICLE	IF	CITATIONS
118	Nutrition and COVID-19. <i>British Journal of Nutrition</i> , 2022, 127, 1441-1442.	1.2	4
120	Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting. <i>Diagnostics</i> , 2021, 11, 1788.	1.3	8
121	Mutation Rates, Mutation Frequencies, and Proofreading-Repair Activities in RNA Virus Genetics. <i>Viruses</i> , 2021, 13, 1882.	1.5	66
124	COVID-19 Vaccines: Current Conditions and Future Prospects. <i>Biology</i> , 2021, 10, 960.	1.3	14
125	Reinfections are more frequent than currently considered in countries with high incidence of COVID-19 cases due to stringent definitions. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	4
126	COVID-19 and oral diseases: Assessing manifestations of a new pathogen in oral infections. <i>International Reviews of Immunology</i> , 2022, 41, 423-437.	1.5	12
127	Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA. <i>Molecular Biomedicine</i> , 2021, 2, 29.	1.7	10
128	SARS-CoV-2 Spike Protein Mutations and Escape from Antibodies: A Computational Model of Epitope Loss in Variants of Concern. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4687-4700.	2.5	26
130	An ultrapotent pan- β -coronavirus lineage B (β -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	4.8	25
132	Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 743325.	1.2	10
134	Analysis of digital fences against COVID-19. <i>Health and Technology</i> , 2021, 11, 1-4.	2.1	9
136	The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 737083.	2.2	18
141	Atomistic Simulations and In Silico Mutational Profiling of Protein Stability and Binding in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Molecular Determinants of Mutational Escape Mechanisms. <i>ACS Omega</i> , 2021, 6, 26354-26371.	1.6	11
142	SARS-CoV2 Infection Alters Tryptophan Catabolism and Phospholipid Metabolism. <i>Metabolites</i> , 2021, 11, 659.	1.3	14
146	The Evolving Faces of the SARS-CoV-2 Genome. <i>Viruses</i> , 2021, 13, 1764.	1.5	15
148	Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?. <i>International Immunopharmacology</i> , 2021, 101, 108200.	1.7	20
149	SARS-CoV-2 Variants Are Selecting for Spike Protein Mutations That Increase Protein Stability. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4152-4155.	2.5	14
151	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778

#	ARTICLE	IF	CITATIONS
153	Current status of therapeutic monoclonal antibodies against SARS-CoV-2. PLoS Pathogens, 2021, 17, e1009885.	2.1	79
154	Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. Briefings in Bioinformatics, 2022, 23, .	3.2	16
156	The Immune Response to SARS-CoV-2 and Variants of Concern. Viruses, 2021, 13, 1911.	1.5	18
160	A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern <i>In Vitro</i> and <i>In Vivo</i>. Journal of Virology, 2021, 95, e0112621.	1.5	13
163	Structural biology of SARS-CoV-2 and implications for therapeutic development. Nature Reviews Microbiology, 2021, 19, 685-700.	13.6	259
165	Modeling the population effects of escape mutations in SARS-CoV-2 to guide vaccination strategies. Epidemics, 2021, 36, 100484.	1.5	7
166	Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants. Journal of Virology, 2021, 95, e0143721.	1.5	24
167	Trapping and Detection of Single Viruses in an Optofluidic Chip. ACS Sensors, 2021, 6, 3445-3450.	4.0	18
168	Cloning of a Passage-Free SARS-CoV-2 Genome and Mutagenesis Using Red Recombination. International Journal of Molecular Sciences, 2021, 22, 10188.	1.8	30
172	Wave-wise comparative genomic study for revealing the complete scenario and dynamic nature of COVID-19 pandemic in Bangladesh. PLoS ONE, 2021, 16, e0258019.	1.1	13
173	Monitoring the SARS-CoV-2 pandemic: screening algorithm with single nucleotide polymorphism detection for the rapid identification of established and emerging variants. Clinical Microbiology and Infection, 2022, 28, 124-129.	2.8	23
174	A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 243-257.	2.7	35
175	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity, 2021, 54, 2893-2907.e5.	6.6	107
176	Effect of control measures on the pattern of COVID-19 Epidemics in Japan. PeerJ, 2021, 9, e12215.	0.9	4
177	Temporal Analysis of SARS-CoV-2 Variants during the COVID-19 Pandemic in Nepal. Covid, 2021, 1, 423-434.	0.7	9
178	The rise in cases of mucormycosis, candidiasis and aspergillosis amidst COVID19. Fungal Biology Reviews, 2021, 38, 67-91.	1.9	22
179	Different Strategies for the Identification of SARS-CoV-2 Variants in the Laboratory Practice. Genes, 2021, 12, 1428.	1.0	8
181	Computational decomposition reveals reshaping of the SARS-CoV-2-ACE2 interface among viral variants expressing the N501Y mutation. Journal of Cellular Biochemistry, 2021, 122, 1863-1872.	1.2	17

#	ARTICLE	IF	CITATIONS
183	A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants. <i>Frontiers in Immunology</i> , 2021, 12, 730766.	2.2	7
184	Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	44
185	Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections. <i>BMC Medicine</i> , 2021, 19, 255.	2.3	137
186	Gastrointestinal symptoms in patients with COVID-19: Is there a relationship with mortality and new variations of SARS-CoV-2?. <i>World Journal of Gastroenterology</i> , 2021, 27, 6345-6347.	1.4	0
187	The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation. <i>Journal of Molecular Biology</i> , 2022, 434, 167280.	2.0	92
188	Does immune recognition of SARS-CoV2 epitopes vary between different ethnic groups?. <i>Virus Research</i> , 2021, 305, 198579.	1.1	10
189	Structural insights into global mutations in the ligand-binding domain of VAR2CSA and its implications on placental malaria vaccine. <i>International Journal of Infectious Diseases</i> , 2021, 112, 35-39.	1.5	2
190	Mutations Associated with SARS-CoV-2 Variants of Concern, Benin, Early 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, 2889-2903.	2.0	10
191	Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. <i>Emerging Microbes and Infections</i> , 2021, 10, 1574-1588.	3.0	18
192	Emerging SARS-CoV-2 Variants Can Potentially Break Set Epidemiological Barriers in COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	5
196	Epidemiology of SARS-CoV-2 and Emergence of UK Variant in Zintan City of Libya. <i>Open Journal of Epidemiology</i> , 2021, 11, 349-359.	0.2	0
197	Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies. <i>Zoological Research</i> , 2021, 42, 789-791.	0.9	28
198	Infection and infectivity: Utility of rapid antigen tests for the diagnosis of COVID-19. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 46-48.	0.5	4
199	Genetic diversity of SARS-CoV-2 in South America: demographic history and structuration signals. <i>Archives of Virology</i> , 2021, 166, 3357-3371.	0.9	3
200	Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection. <i>Viruses</i> , 2021, 13, 2003.	1.5	16
201	Receptor-Loaded Virion Endangers GPCR Signaling: Mechanistic Exploration of SARS-CoV-2 Infections and Pharmacological Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10963.	1.8	4
203	SARS-CoV-2 Infection in Fully Vaccinated Individuals of Old Age Strongly Boosts the Humoral Immune Response. <i>Frontiers in Medicine</i> , 2021, 8, 746644.	1.2	8
204	The challenges of COVID-19 Delta variant: Prevention and vaccine development. <i>MedComm</i> , 2021, 2, 846-854.	3.1	37

#	ARTICLE	IF	CITATIONS
206	A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. <i>MBio</i> , 2021, 12, e0247321.	1.8	35
207	Molecular Analysis and Genome Sequencing of SARS-Cov-2 during Second Wave 2021 Revealed Variant Diversity in India. <i>Journal of Pure and Applied Microbiology</i> , 0, , .	0.3	1
208	Rostered routine testing for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare workersâ€” Do we detect more?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	1.4	2
209	The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2673-2675.	4.8	25
210	Extracellular pH, osmolarity, temperature and humidity could discourage SARS-CoV-2 cell docking and propagation <i>via</i> intercellular signaling pathways. <i>PeerJ</i> , 2021, 9, e12227.	0.9	3
212	Supplementing SARS-CoV-2 genomic surveillance with PCR-based variant detection for real-time actionable information, the Netherlands, June to July 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	5
213	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021, 6, 1433-1442.	5.9	94
216	SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways. <i>Expert Review of Vaccines</i> , 2022, 21, 69-81.	2.0	22
217	The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. <i>Interface Focus</i> , 2021, 11, 20210008.	1.5	24
218	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3
220	The global epidemic of SARS-CoV-2 variants and their mutational immune escape. <i>Journal of Medical Virology</i> , 2022, 94, 847-857.	2.5	80
222	Epidemiological Analysis of SARS-CoV-2 Transmission Dynamics in the State of Odisha, India: A Yearlong Exploratory Data Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11203.	1.2	0
223	Variant Prediction by Analyzing RdRp/S Gene Double or Low Amplification Pattern in Allplex SARS-CoV-2 Assay. <i>Diagnostics</i> , 2021, 11, 1854.	1.3	12
225	Molecular Insights on the Possible Role of Annexin A2 in COVID-19 Pathogenesis and Post-Infection Complications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11028.	1.8	7
226	COVID-19 Mortality Risk Correlates Inversely with Vitamin D3 Status, and a Mortality Rate Close to Zero Could Theoretically Be Achieved at 50 ng/mL 25(OH)D3: Results of a Systematic Review and Meta-Analysis. <i>Nutrients</i> , 2021, 13, 3596.	1.7	60
228	Receptor binding domainâ€™IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1885-1894.	2.7	13
229	Personalized therapy: can it tame the COVID-19 monster?. <i>Personalized Medicine</i> , 2021, 18, 583-593.	0.8	4
231	SARS-CoV-2 Virusâ€™Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10836.	1.8	25

#	ARTICLE	IF	CITATIONS
232	Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies. <i>Virus Genes</i> , 2021, 57, 502-509.	0.7	3
234	Wastewater-Based Epidemiology for Cost-Effective Mass Surveillance of COVID-19 in Low- and Middle-Income Countries: Challenges and Opportunities. <i>Water (Switzerland)</i> , 2021, 13, 2897.	1.2	30
235	Structural Insights on the SARS-CoV-2 Variants of Concern Spike Glycoprotein: A Computational Study With Possible Clinical Implications. <i>Frontiers in Genetics</i> , 2021, 12, 773726.	1.1	3
240	COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. <i>International Journal of Biological Macromolecules</i> , 2021, , .	3.6	14
241	Development of a Multiplex Tandem PCR (MT-PCR) Assay for the Detection of Emerging SARS-CoV-2 Variants. <i>Viruses</i> , 2021, 13, 2028.	1.5	19
243	Clinical Presentation of a COVID-19 Delta Variant Patient: Case Report and Literature Review. <i>Cureus</i> , 2021, 13, e18603.	0.2	5
244	Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients. <i>EBioMedicine</i> , 2021, 73, 103626.	2.7	43
245	Translational suppression of SARS-COV-2 ORF8 protein mRNA as a Viable therapeutic target against COVID-19: Computational studies on potential roles of isolated compounds from <i>Clerodendrum volubile</i> leaves. <i>Computers in Biology and Medicine</i> , 2021, 139, 104964.	3.9	2
246	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1305-1320.	5.7	123
247	Dysregulated Inflammation During Obesity: Driving Disease Severity in Influenza Virus and SARS-CoV-2 Infections. <i>Frontiers in Immunology</i> , 2021, 12, 770066.	2.2	26
248	COVID-19 Vaccine Booster: To Boost or Not to Boost. <i>Infectious Disease Reports</i> , 2021, 13, 924-929.	1.5	78
249	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. <i>Npj Vaccines</i> , 2021, 6, 128.	2.9	102
250	Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19. <i>ACS Central Science</i> , 2021, 7, 1980-1985.	5.3	91
251	RT-qPCR assays for SARS-CoV-2 variants of concern in wastewater reveals compromised vaccination-induced immunity. <i>Water Research</i> , 2021, 207, 117808.	5.3	39
252	SERS-PCR assays of SARS-CoV-2 target genes using Au nanoparticles-internalized Au nanodimple substrates. <i>Biosensors and Bioelectronics</i> , 2022, 197, 113736.	5.3	32
255	COVID-19 Mechanisms in the Human Bodyâ€™What We Know So Far. <i>Frontiers in Immunology</i> , 2021, 12, 693938.	2.2	40
256	Harnessing stress granule formation by small molecules to inhibit the cellular replication of SARS-CoV-2. <i>Chemical Communications</i> , 2021, 57, 12476-12479.	2.2	7
257	Evaluation of using Parametric and Non-parametric Machine Learning Algorithms for Covid-19 Forecasting. <i>International Journal of Advanced Computer Science and Applications</i> , 2021, 12, .	0.5	4

#	ARTICLE	IF	CITATIONS
258	Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 747830.	2.2	69
259	An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARS-CoV-2 Activity. <i>ChemistrySelect</i> , 2021, 6, 11502-11527.	0.7	8
260	Rapid Response to SARS-CoV-2 in Aotearoa New Zealand: Implementation of a Diagnostic Test and Characterization of the First COVID-19 Cases in the South Island. <i>Viruses</i> , 2021, 13, 2222.	1.5	4
261	The impact of public health interventions in the Nordic countries during the first year of SARS-CoV-2 transmission and evolution. <i>Eurosurveillance</i> , 2021, 26, .	3.9	8
263	First whole genome analysis of the novel coronavirus (SARS-CoV-2) obtained from COVID-19 patients from five districts in Western Serbia. <i>Epidemiology and Infection</i> , 0, , 1-31.	1.0	5
264	Myeloid dysregulation and therapeutic intervention in COVID-19. <i>Seminars in Immunology</i> , 2021, 55, 101524.	2.7	9
266	Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 2214.	1.5	16
267	RCSB Protein Data Bank resources for structure-facilitated design of mRNA vaccines for existing and emerging viral pathogens. <i>Structure</i> , 2022, 30, 55-68.e2.	1.6	10
268	Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 7967-7989.	2.4	40
269	Looking for a needle in a haystack. SARS-CoV-2 variant characterization in sewage. <i>Current Opinion in Environmental Science and Health</i> , 2021, 24, 100308.	2.1	5
270	Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum. <i>New England Journal of Medicine</i> , 2021, 385, 2397-2399.	13.9	178
271	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
272	Circulation and Evolution of SARS-CoV-2 in India: Let the Data Speak. <i>Viruses</i> , 2021, 13, 2238.	1.5	8
273	COVID-19 and Selenium Deficiency: a Systematic Review. <i>Biological Trace Element Research</i> , 2022, 200, 3945-3956.	1.9	42
274	Current Insights Into Respiratory Virus Transmission and Potential Implications for Infection Control Programs. <i>Annals of Internal Medicine</i> , 2021, 174, 1710-1718.	2.0	45
275	Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients; A systematic review and meta-analysis. <i>American Journal of Emergency Medicine</i> , 2022, 51, 267-279.	0.7	41
277	Alternative methods to detect SARS-CoV-2 antibodies. <i>Clinics in Laboratory Medicine</i> , 2021, 42, 57-73.	0.7	0
278	Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2. <i>Pathogens</i> , 2021, 10, .	1.2	3

#	ARTICLE	IF	CITATIONS
279	Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage. <i>Virus Research</i> , 2022, 308, 198629.	1.1	6
280	Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets. <i>Biomedicine and Pharmacotherapy</i> , 2022, 145, 112420.	2.5	78
281	Environmental Surveillance for SARS-CoV-2 in Two Restaurants from a Mid-scale City that Followed U.S. CDC Reopening Guidance. <i>Aerosol and Air Quality Research</i> , 2022, 22, 210304.	0.9	3
282	Insights into the evolutionary and prophylactic analysis of SARS-CoV-2: A review. <i>Journal of Virological Methods</i> , 2022, 300, 114375.	1.0	2
283	Anti-SARS-CoV-1 and α^2 nanobody engineering towards avidity-inspired therapeutics. <i>Nano Today</i> , 2022, 42, 101350.	6.2	16
284	SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high seroprevalence. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100112.	1.5	18
285	Effect of multimodal imaging on Covid-19 and lung cancer classification via deep learning. , 2021, , .		1
286	D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 9035-9045.	1.7	34
288	Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. <i>Emerging Microbes and Infections</i> , 2022, 11, 18-29.	3.0	25
289	Hotspot Mutations in SARS-CoV-2. <i>Frontiers in Genetics</i> , 2021, 12, 753440.	1.1	14
290	SCoV2-MD: a database for the dynamics of the SARS-CoV-2 proteome and variant impact predictions. <i>Nucleic Acids Research</i> , 2022, 50, D858-D866.	6.5	17
291	Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines—A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters. <i>Viruses</i> , 2021, 13, 2290.	1.5	7
292	Infection and transmission of ancestral SARS-CoV-2 and its alpha variant in pregnant white-tailed deer. <i>Emerging Microbes and Infections</i> , 2022, 11, 95-112.	3.0	77
293	Metaviromic identification of discriminative genomic features in SARS-CoV-2 using machine learning. <i>Patterns</i> , 2022, 3, 100407.	3.1	4
297	When Do We Need Massive Computations to Perform Detailed COVID-19 Simulations?. <i>Advanced Theory and Simulations</i> , 2022, 5, 2100343.	1.3	8
301	Elucidating important structural features for the binding affinity of spike α -SARS-CoV-2 neutralizing antibody complexes. <i>Proteins: Structure, Function and Bioinformatics</i> , 2022, 90, 824-834.	1.5	16
302	The Dominance of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 and Its Sublineages and Associations with Mortality during the COVID-19 Pandemic in India between 2020 and 2021. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 142-149.	0.6	12
304	The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 751778.	2.2	142

#	ARTICLE	IF	CITATIONS
305	Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight. <i>Viruses</i> , 2021, 13, 2295.	1.5	13
310	An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants. <i>Viruses</i> , 2021, 13, 2302.	1.5	32
311	In Silico Identification and Clinical Validation of a Novel Long Non-Coding RNA/mRNA/miRNA Molecular Network for Potential Biomarkers for Discriminating SARS CoV-2 Infection Severity. <i>Cells</i> , 2021, 10, 3098.	1.8	10
313	Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance. <i>Current Opinion in Pharmacology</i> , 2022, 62, 64-73.	1.7	29
314	Genome-wide identification and prediction of SARS-CoV-2 mutations show an abundance of variants: Integrated study of bioinformatics and deep neural learning. <i>Informatics in Medicine Unlocked</i> , 2021, 27, 100798.	1.9	5
315	Robust Representation and Efficient Feature Selection Allows for Effective Clustering of SARS-CoV-2 Variants. <i>Algorithms</i> , 2021, 14, 348.	1.2	16
316	The Newfangled Upsurge of Double Mutant SARS-CoV-2 Virus in 2021-Current Scenario and Inspecting Ahead. <i>Recent Advances in Anti-Infective Drug Discovery</i> , 2021, 16, 175-178.	0.4	3
317	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. <i>Biomedicines</i> , 2021, 9, 1740.	1.4	16
318	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
319	Debulking SARS-CoV-2 in saliva using angiotensin converting enzyme 2 in chewing gum to decrease oral virus transmission and infection. <i>Molecular Therapy</i> , 2022, 30, 1966-1978.	3.7	39
320	The Impact of Mutations on the Pathogenic and Antigenic Activity of SARS-CoV-2 during the First Wave of the COVID-19 Pandemic: A Comprehensive Immunoinformatics Analysis. <i>Vaccines</i> , 2021, 9, 1410.	2.1	5
321	Increased B Cell Selection Stringency In Germinal Centers Can Explain Improved COVID-19 Vaccine Efficacies With Low Dose Prime or Delayed Boost. <i>Frontiers in Immunology</i> , 2021, 12, 776933.	2.2	24
323	Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2021, 12, 732693.	2.2	5
324	Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease. <i>Cells</i> , 2021, 10, 3367.	1.8	42
325	Mutation-Induced Long-Range Allosteric Interactions in the Spike Protein Determine the Infectivity of SARS-CoV-2 Emerging Variants. <i>ACS Omega</i> , 2021, 6, 31305-31320.	1.6	8
327	Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19. <i>Journal of Medical Virology</i> , 2022, 94, 1300-1314.	2.5	32
329	Comparative structural analyses of selected spike protein-RBD mutations in SARS-CoV-2 lineages. <i>Immunologic Research</i> , 2022, 70, 143-151.	1.3	13
330	A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue. <i>Diagnostics</i> , 2021, 11, 2092.	1.3	6

#	ARTICLE	IF	CITATIONS
331	Common Laboratory Mice Are Susceptible to Infection with the SARS-CoV-2 Beta Variant. <i>Viruses</i> , 2021, 13, 2263.	1.5	21
332	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. <i>Vaccines</i> , 2021, 9, 1317.	2.1	35
333	Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. <i>PLoS ONE</i> , 2021, 16, e0260283.	1.1	1
334	Evolutionary and Antigenic Profiling of the Tendentious D614G Mutation of SARS-CoV-2 in Gujarat, India. <i>Frontiers in Genetics</i> , 2021, 12, 764927.	1.1	0
335	Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. <i>Nature</i> , 2022, 602, 300-306.	13.7	428
337	Fabrication of chitosan-coated mixed spinel ferrite integrated with graphene oxide (GO) for magnetic extraction of viral RNA for potential detection of SARS-CoV-2. <i>Applied Physics A: Materials Science and Processing</i> , 2021, 127, 960.	1.1	8
338	Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12412.	1.8	15
341	Molecular and Serological Characterization of the SARS-CoV-2 Delta Variant in Bangladesh in 2021. <i>Viruses</i> , 2021, 13, 2310.	1.5	9
345	E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody. <i>International Immunopharmacology</i> , 2022, 102, 108424.	1.7	31
346	In-silico screening of naturally derived phytochemicals against SARS-CoV Main protease. <i>Environmental Science and Pollution Research</i> , 2022, 29, 26775-26791.	2.7	5
347	Denaturation of the SARS-CoV-2 spike protein under non-thermal microwave radiation. <i>Scientific Reports</i> , 2021, 11, 23373.	1.6	7
348	Toward a next-generation diagnostic tool: A review on emerging isothermal nucleic acid amplification techniques for the detection of SARS-CoV-2 and other infectious viruses. <i>Analytica Chimica Acta</i> , 2022, 1209, 339338.	2.6	24
349	Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. <i>Lancet, The</i> , 2021, 398, 2126-2128.	6.3	1,057
350	MALDI MS-Based Investigations for SARS-CoV-2 Detection. <i>Biochem</i> , 2021, 1, 250-278.	0.5	12
351	Tracking the amino acid changes of spike proteins across diverse host species of severe acute respiratory syndrome coronavirus 2. <i>IScience</i> , 2022, 25, 103560.	1.9	5
352	Molecular Basis of SARS-CoV-2 Nsp1-Induced Immune Translational Shutdown as Revealed by All-Atom Simulations. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 11745-11750.	2.1	7
353	SARS-CoV-2 introduction and lineage dynamics across three epidemic peaks in Southern Brazil: massive spread of P.1. <i>Infection, Genetics and Evolution</i> , 2021, 96, 105144.	1.0	14
354	Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern. <i>Journal of Chemical Theory and Computation</i> , 2021, 17, 7972-7979.	2.3	57

#	ARTICLE	IF	CITATIONS
355	Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. <i>ACS Infectious Diseases</i> , 2022, 8, 29-58.	1.8	32
356	COVID-19 variants that escape vaccine immunity: Global and Indian context—are more vaccines needed?. <i>Journal of Biosciences</i> , 2021, 46, 1.	0.5	2
357	Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity. <i>Journal of the American Chemical Society</i> , 2021, 143, 20697-20709.	6.6	87
359	Evolutionary Dynamics of Indels in SARS-CoV-2 Spike Glycoprotein. <i>Evolutionary Bioinformatics</i> , 2021, 17, 117693432110646.	0.6	5
360	Clinical severe acute respiratory syndrome coronavirus 2 isolation and antiviral testing. <i>Antiviral Chemistry and Chemotherapy</i> , 2021, 29, 204020662110610.	0.3	4
361	A rigorous framework for detecting SARS-CoV-2 spike protein mutational ensemble from genomic and structural features. <i>Current Research in Structural Biology</i> , 2021, 3, 290-300.	1.1	17
362	Fundamentals of genomic epidemiology, lessons learned from the coronavirus disease 2019 (COVID-19) pandemic, and new directions. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2021, 1, .	0.2	5
363	The adaptation of SARS-CoV-2 to humans. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2022, 116, e210127.	0.8	4
364	Phylogenetic pattern of genetic clusters, paradigm shift on spatio-temporal distribution of clades, and impact of spike glycoprotein mutations of SARS-CoV-2 isolates from India. <i>Journal of Global Infectious Diseases</i> , 2021, 13, 164.	0.2	3
365	SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD. <i>Immune Network</i> , 2021, 21, e39.	1.6	3
366	3D hierarchically porous magnetic molybdenum trioxide@gold nanospheres as a nanogap-enhanced Raman scattering biosensor for SARS-CoV-2. <i>Nanoscale Advances</i> , 2022, 4, 871-883.	2.2	19
367	Mutational and phylogenetic analyses of the two lineages of the Omicron variant. <i>Journal of Medical Virology</i> , 2022, 94, 1777-1779.	2.5	68
369	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Mutational Pattern in the Fourth Pandemic Phase in Greece. <i>Current Issues in Molecular Biology</i> , 2022, 44, 329-335.	1.0	3
370	Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters. <i>Frontiers in Immunology</i> , 2021, 12, 788235.	2.2	11
371	Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy. <i>Journal of Autoimmunity</i> , 2022, 127, 102792.	3.0	96
372	Probing the formation, structure and free energy relationships of M protein dimers of SARS-CoV-2. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 573-582.	1.9	9
373	SARS-CoV-2 B.1.619 and B.1.620 Lineages, South Korea, 2021. <i>Emerging Infectious Diseases</i> , 2022, 28, 415-419.	2.0	10
374	SARS-CoV-2 Circulation, Guinea, March 2020–July 2021. <i>Emerging Infectious Diseases</i> , 2022, 28, 457-460.	2.0	4

#	ARTICLE	IF	CITATIONS
375	Scanning the RBD-ACE2 molecular interactions in Omicron variant. <i>Biochemical and Biophysical Research Communications</i> , 2022, 592, 18-23.	1.0	47
376	Rapid and accurate detection of SARS-CoV-2 mutations using a Cas12a-based sensing platform. <i>Biosensors and Bioelectronics</i> , 2022, 198, 113857.	5.3	31
377	A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients. <i>Gene</i> , 2022, 813, 146113.	1.0	8
378	The Delta variant mutations in the receptor binding domain of SARS-CoV-2 show enhanced electrostatic interactions with the ACE2. <i>Medicine in Drug Discovery</i> , 2022, 13, 100114.	2.3	31
379	A fractal scaling analysis of the SARS-CoV-2 genome sequence. <i>Biomedical Signal Processing and Control</i> , 2022, 73, 103433.	3.5	4
380	SARS-CoV-2 genome quantification in wastewaters at regional and city scale allows precise monitoring of the whole outbreaks dynamics and variants spreading in the population. <i>Science of the Total Environment</i> , 2022, 810, 152213.	3.9	45
381	Searching and designing potential inhibitors for SARS-CoV-2 Mpro from natural sources using atomistic and deep-learning calculations. <i>RSC Advances</i> , 2021, 11, 38495-38504.	1.7	11
382	Hybrid Immunity Versus Vaccine-Induced Immunity Against SARS CoV2 in Patients With Autoimmune Rheumatic Diseases. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
383	Genomic Diversification of Long Polynucleotide Fragments Is a Signature of Emerging SARS-CoV-2 Variants of Concern. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
384	Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2. <i>Pathogens</i> , 2021, 10, 1076.	1.2	7
385	Single-Chained Fragment Variable (scFv) Recombinant as a Potential Receptor for SARS-CoV-2 Biosensor Based on Surface Plasmon Resonance (SPR). , 2021, , .		0
386	SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 430.	7.1	197
390	INMI1 Zika Virus NS4B Antagonizes the Interferon Signaling by Suppressing STAT1 Phosphorylation. <i>Viruses</i> , 2021, 13, 2448.	1.5	17
391	Monitoring of SARS-CoV-2 Variants by Wastewater-Based Surveillance as a Sustainable and Pragmatic Approachâ€”A Case Study of Jaipur (India). <i>Water (Switzerland)</i> , 2022, 14, 297.	1.2	11
392	A Genomic Snapshot of the SARS-CoV-2 Pandemic in the Balearic Islands. <i>Frontiers in Microbiology</i> , 2021, 12, 803827.	1.5	3
393	Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant. <i>Science Advances</i> , 2022, 8, eabm0300.	4.7	6
394	Human genetic and immunological determinants of critical COVID-19 pneumonia. <i>Nature</i> , 2022, 603, 587-598.	13.7	216
395	Rapid Biosensor of SARS-CoV-2 Using Specific Monoclonal Antibodies Recognizing Conserved Nucleocapsid Protein Epitopes. <i>Viruses</i> , 2022, 14, 255.	1.5	8

#	ARTICLE	IF	CITATIONS
396	Evolutionary Landscapes of Host-Virus Arms Races. <i>Annual Review of Immunology</i> , 2022, 40, 271-294.	9.5	24
397	First Identification of the New Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant (B.1.1.529) in Italy. <i>Clinical Infectious Diseases</i> , 2022, 75, 522-524.	2.9	17
398	Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?. <i>Molecular Neurobiology</i> , 2022, 59, 1850-1861.	1.9	76
400	Searching for escape-resistant anti-SARS-CoV-2 neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	2
401	Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. <i>Cell</i> , 2022, 185, 1025-1040.e14.	13.5	243
403	Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein. <i>Emerging Microbes and Infections</i> , 2022, 11, 351-367.	3.0	19
404	In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein. <i>Frontiers in Immunology</i> , 2021, 12, 782506.	2.2	24
405	Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 212-226.	3.0	6
406	Human Nasal Epithelial Cells Sustain Persistent SARS-CoV-2 Infection <i>In Vitro</i> , despite Eliciting a Prolonged Antiviral Response. <i>MBio</i> , 2022, 13, e0343621.	1.8	12
407	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. <i>Science</i> , 2022, 375, 183-192.	6.0	91
408	Collaboration between Clinical and Academic Laboratories for Sequencing SARS-CoV-2 Genomes. <i>Journal of Clinical Microbiology</i> , 2022, 60, JCM0128821.	1.8	4
410	A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. <i>Cell Reports</i> , 2022, 38, 110368.	2.9	82
412	SARS-CoV-2 variants of concern display enhanced intrinsic pathogenic properties and expanded organ tropism in mouse models. <i>Cell Reports</i> , 2022, 38, 110387.	2.9	32
416	The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance. <i>Cell Reports</i> , 2022, 38, 110218.	2.9	148
418	The puzzling mutational landscape of the SARS-CoV-2 variant Omicron. <i>Journal of Medical Virology</i> , 2022, 94, 2019-2025.	2.5	63
420	Prisoners of variants, or free to act as prisoners of swabs? The case of Italy. <i>Journal of Medical Virology</i> , 2022, 94, 2334-2335.	2.5	1
423	From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. <i>Nano-Micro Letters</i> , 2022, 14, 41.	14.4	26
424	Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia. <i>Vaccines</i> , 2022, 10, 180.	2.1	17

#	ARTICLE	IF	CITATIONS
425	Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp). <i>Molecules</i> , 2022, 27, 801.	1.7	5
426	An encodable multiplex microsphere-phase amplification sensing platform detects SARS-CoV-2 mutations. <i>Biosensors and Bioelectronics</i> , 2022, 203, 114032.	5.3	7
427	Critical Mutations of the SARS-CoV-2 Virus. <i>WSEAS Transactions on Biology and Biomedicine</i> , 2022, 19, 22-30.	0.3	1
429	Allosteric perspective on the mutability and druggability of the SARS-CoV-2 Spike protein. <i>Structure</i> , 2022, 30, 590-607.e4.	1.6	24
431	COVID-19: Testing Landscape Post-Infection, -Vaccination, and Future Perspectives. <i>Viral Immunology</i> , 2022, 35, 5-14.	0.6	0
432	Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. <i>Cell Host and Microbe</i> , 2022, 30, 69-82.e10.	5.1	42
433	Identification of SARS-CoV-2 Variants and Their Clinical Significance in Hefei, China. <i>Frontiers in Medicine</i> , 2021, 8, 784632.	1.2	9
435	Emergence of SARS-CoV-2 Variants in the World: How Could This Happen?. <i>Life</i> , 2022, 12, 194.	1.1	25
436	The mutational dynamics of the SARS-CoV-2 virus in serial passages in vitro. <i>Virologica Sinica</i> , 2022, 37, 198-207.	1.2	12
437	Delayed Antiviral Immune Responses in Severe Acute Respiratory Syndrome Coronavirus Infected Pregnant Mice. <i>Frontiers in Microbiology</i> , 2021, 12, 806902.	1.5	7
440	Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents. <i>Emerging Microbes and Infections</i> , 2022, 11, 567-572.	3.0	39
441	Equitable access to COVID-19 vaccines makes a life-saving difference to all countries. <i>Nature Human Behaviour</i> , 2022, 6, 207-216.	6.2	85
442	A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19. <i>Covid</i> , 2022, 2, 148-167.	0.7	34
443	Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission. <i>Cell Host and Microbe</i> , 2022, 30, 373-387.e7.	5.1	138
444	Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. <i>Science</i> , 2022, 375, .	6.0	68
445	Implications of the Immune Polymorphisms of the Host and the Genetic Variability of SARS-CoV-2 in the Development of COVID-19. <i>Viruses</i> , 2022, 14, 94.	1.5	7
447	Prediction of the Effects of Nonsynonymous Variants on SARS-CoV-2 Proteins. <i>F1000Research</i> , 0, 11, 9.	0.8	0
448	Emergence of a novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India. <i>Journal of Infection and Public Health</i> , 2022, 15, 42-50.	1.9	3

#	ARTICLE	IF	CITATIONS
449	Seasonal Betacoronavirus Antibodiesâ€™ Expansion Post-BNT161b2 Vaccination Associates with Reduced SARS-CoV-2 VoC Neutralization. <i>Journal of Clinical Immunology</i> , 2022, 42, 448-458.	2.0	7
450	A perspective on the applications of furin inhibitors for the treatment of SARS-CoV-2. <i>Pharmacological Reports</i> , 2022, 74, 425-430.	1.5	10
451	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	1.2	15
452	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	1.8	154
454	Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign. <i>European Journal of Public Health</i> , 2022, , .	0.1	35
455	Transmission dynamics and mutational prevalence of the novel Severe acute respiratory syndrome coronavirusâ€™2 Omicron Variant of Concern. <i>Journal of Medical Virology</i> , 2022, 94, 2160-2166.	2.5	34
457	The Pathogenetic Dilemma of Post-COVID-19 Mucormycosis in India. , 2022, 13, 24.		9
458	The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 78.	1.5	64
459	SARS-CoV-2 Variants and Clinical Outcomes: A Systematic Review. <i>Life</i> , 2022, 12, 170.	1.1	39
460	Two Cases of Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections Caused by the Omicron Variant (B.1.1.529 Lineage) in International Travelers to Japan. <i>Clinical Infectious Diseases</i> , 2022, 75, e354-e356.	2.9	12
461	Characterization of the novel SARSâ€™CoVâ€™2 Omicron (B.1.1.529) variant of concern and its global perspective. <i>Journal of Medical Virology</i> , 2022, 94, 1738-1744.	2.5	225
462	SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. <i>Cell</i> , 2022, 185, 847-859.e11.	13.5	590
463	Predicting spike protein NTD mutations of SARS-CoV-2 causing immune evasion by molecular dynamics simulations. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 3410-3419.	1.3	2
464	Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction. <i>BMC Molecular and Cell Biology</i> , 2022, 23, 2.	1.0	10
466	Omicron: the highly mutational COVID-19 variant with immune escape. <i>Pan African Medical Journal</i> , 2022, 41, 84.	0.3	2
468	New Coronavirus Variants are Creating More Challenges to Global Healthcare System: A Brief Report on the Current Knowledge. <i>BMC Clinical Pathology</i> , 2022, 15, 2632010X2210755.	0.7	85
469	Regional and temporal coordinated mutation patterns in SARS-CoV-2 spike protein revealed by a clustering and network analysis. <i>Scientific Reports</i> , 2022, 12, 1128.	1.6	28
471	Finger stick blood test to assess postvaccination <scp>SARSâ€™CoV</scp>â€™2 neutralizing antibody response against variants. <i>Bioengineering and Translational Medicine</i> , 2022, 7, .	3.9	7

#	ARTICLE	IF	CITATIONS
472	Transmissibility of SARS-CoV-2 among fully vaccinated individuals. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 17-18.	4.6	1
473	Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 830527.	2.2	165
474	Intra-host SARS-CoV-2 single-nucleotide variants emerged during the early stage of COVID-19 pandemic forecast population fixing mutations. <i>Journal of Infection</i> , 2022, 84, 722-746.	1.7	4
475	Immune dynamics of SARS-CoV-2 virus evolution. <i>International Journal of Molecular and Immunology</i> , 0, 7, 3-15.	0.0	2
479	Limited spread of a rare spike E484K-harboring SARS-CoV-2 in Marseille, France. <i>Archives of Virology</i> , 2022, 167, 583.	0.9	3
480	Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. <i>IScience</i> , 2022, 25, 103659.	1.9	16
481	Predicted HLA Class I and Class II Epitopes From Licensed Vaccines Are Largely Conserved in New SARS-CoV-2 Omicron Variant of Concern. <i>Frontiers in Immunology</i> , 2022, 13, 832889.	2.2	3
482	Fine-tuning the spike: role of the nature and topology of the glycan shield in the structure and dynamics of the SARS-CoV-2 S. <i>Chemical Science</i> , 2022, 13, 386-395.	3.7	58
483	Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients. <i>Transfusion and Apheresis Science</i> , 2022, 61, 103355.	0.5	9
485	The Emergence of SARS-CoV-2 Variants of Concern Is Driven by Acceleration of the Substitution Rate. <i>Molecular Biology and Evolution</i> , 2022, 39, .	3.5	78
488	Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding. <i>Viruses</i> , 2022, 14, 295.	1.5	12
490	Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 824-837.	1.9	49
492	Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 799-811.	1.9	10
493	Omicron variant of SARS-CoV-2 imposes a new challenge for the global public health. <i>Biosafety and Health</i> , 2022, 4, 147-149.	1.2	33
494	Emergence of Omicron third lineage BA.3 and its importance. <i>Journal of Medical Virology</i> , 2022, 94, 1808-1810.	2.5	126
495	Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant. <i>Journal of Medical Virology</i> , 2022, 94, 1876-1885.	2.5	55
498	Structural Comparison and Drug Screening of Spike Proteins of Ten SARS-CoV-2 Variants. <i>Research</i> , 2022, 2022, 9781758.	2.8	15
499	The emergence, dynamics and significance of SARS-CoV-2 variants. <i>New Microbes and New Infections</i> , 2022, 45, 100962.	0.8	5

#	ARTICLE	IF	CITATIONS
500	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. <i>Journal of Thoracic Oncology</i> , 2022, 17, 661-674.	0.5	9
501	Variant analysis of SARS-CoV-2 strains with phylogenetic analysis and the Coronavirus Antiviral and Resistance Database. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 157-167.	0.6	2
502	COVID-19 Pathogenesis and Clinical Manifestations. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 231-249.	1.9	21
503	It is not the time to relax yet: masks are still needed for the Omicron variant of SARS-CoV-2. <i>Public Health</i> , 2022, 205, e21-e22.	1.4	6
504	Deep mutational scanning for therapeutic antibody engineering. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 123-135.	4.0	18
505	Human Milk Oligosaccharides: Potential Applications in COVID-19. <i>Biomedicines</i> , 2022, 10, 346.	1.4	15
506	CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant. <i>Viruses</i> , 2022, 14, 305.	1.5	2
507	SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 373-385.	1.1	24
508	Quantifying the effect of government interventions and virus mutations on transmission advantage during COVID-19 pandemic. <i>Journal of Infection and Public Health</i> , 2022, 15, 338-342.	1.9	6
509	Charge Matters: Mutations in Omicron Variant Favor Binding to Cells. <i>ChemBioChem</i> , 2022, 23, e202100681.	1.3	62
510	Mutations in the receptor-binding domain of human SARS CoV-2 spike protein increases its affinity to bind human ACE-2 receptor. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 2368-2381.	2.0	7
511	The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges. <i>Journal of Infection and Public Health</i> , 2022, 15, 228-240.	1.9	122
512	Multiplex PCR Assays for Identifying all Major Severe Acute Respiratory Syndrome Coronavirus 2 Variants. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 309-319.	1.2	36
513	Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein. <i>Virus Research</i> , 2022, 310, 198674.	1.1	24
514	Feature selection reveal peripheral blood parameter's changes between COVID-19 infections patients from Brazil and Ecuador. <i>Infection, Genetics and Evolution</i> , 2022, 98, 105228.	1.0	4
515	Immunoediting in SARS-CoV-2: Mutual relationship between the virus and the host. <i>International Immunopharmacology</i> , 2022, 105, 108531.	1.7	1
516	Transmission of SARS-CoV-2 infections and exposure in surfaces, points and wastewaters: A global one health perspective. <i>Case Studies in Chemical and Environmental Engineering</i> , 2022, 5, 100184.	2.9	15
517	Colloidal stability of polymer coated zwitterionic Au nanoparticles in biological media. <i>Inorganica Chimica Acta</i> , 2022, 534, 120820.	1.2	6

#	ARTICLE	IF	CITATIONS
518	Versatile role of ACE2-based biosensors for detection of SARS-CoV-2 variants and neutralizing antibodies. <i>Biosensors and Bioelectronics</i> , 2022, 203, 114034.	5.3	30
519	Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. <i>Environmental Research</i> , 2022, 209, 112816.	3.7	189
520	The Influence of New SARS-CoV-2 Variant Omicron (B.1.1.529) on Vaccine Efficacy, its Correlation to Delta Variants: A Computational Approach. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
521	Direct Comparison of RT-ddPCR and Targeted Amplicon Sequencing for SARS-CoV-2 Mutation Monitoring in Wastewater. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
522	Virus-specific editing identification approach reveals the landscape of A-to-I editing and its impacts on SARS-CoV-2 characteristics and evolution. <i>Nucleic Acids Research</i> , 2022, 50, 2509-2521.	6.5	23
523	Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. <i>Lancet Microbe</i> , The, 2022, 3, e274-e283.	3.4	51
524	A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1850.	1.8	4
525	Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. <i>Nature Communications</i> , 2022, 13, 688.	5.8	23
526	COVID-19 oral antivirals stewardship: establishing game rules before game starting. <i>Infection Control and Hospital Epidemiology</i> , 2022, , 1-7.	1.0	1
527	Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants. <i>Nature Medicine</i> , 2022, 28, 1083-1094.	15.2	127
528	Third waves of the COVID-19 pandemic: Prominence of initial public health Interference. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	6
530	Identification of Hypericin as a Candidate Repurposed Therapeutic Agent for COVID-19 and Its Potential Anti-SARS-CoV-2 Activity. <i>Frontiers in Microbiology</i> , 2022, 13, 828984.	1.5	15
532	Global Mutational Sweep of SARS-CoV-2: From Chaos to Order. <i>Frontiers in Microbiology</i> , 2022, 13, 820919.	1.5	6
533	Construction and characterization of two SARS-CoV-2 minigenome replicon systems. <i>Journal of Medical Virology</i> , 2022, 94, 2438-2452.	2.5	10
536	The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters. <i>PLoS Pathogens</i> , 2022, 18, e1009914.	2.1	26
537	The Fight Against Severe COVID-19: Can Parasitic Worms Contribute?. <i>Frontiers in Immunology</i> , 2022, 13, 849465.	2.2	3
539	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2022, 14, eabi9215.	5.8	123
540	Development and validation of a high throughput SARS-CoV-2 whole genome sequencing workflow in a clinical laboratory. <i>Scientific Reports</i> , 2022, 12, 2054.	1.6	13

#	ARTICLE	IF	CITATIONS
541	In Silico Molecular Characterization of Human TMPRSS2 Protease Polymorphic Variants and Associated SARS-CoV-2 Susceptibility. <i>Life</i> , 2022, 12, 231.	1.1	5
543	The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. <i>Journal of Medical Virology</i> , 2022, 94, 2376-2383.	2.5	322
546	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. <i>Cell</i> , 2022, 185, 896-915.e19.	13.5	189
547	Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. <i>Science</i> , 2022, 375, 678-680.	6.0	303
548	Genome sequence analysis of SARS-COV-2 isolated from a COVID-19 patient in Erbil, Iraq. <i>Applied Nanoscience (Switzerland)</i> , 2022, , 1-7.	1.6	2
549	Comparison of SARS-CoV-2 Evolution in Paediatric Primary Airway Epithelial Cell Cultures Compared with Vero-Derived Cell Lines. <i>Viruses</i> , 2022, 14, 325.	1.5	5
550	Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2. <i>Frontiers in Medicine</i> , 2022, 9, 811004.	1.2	3
551	SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1716.	1.8	107
552	The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. <i>Cell</i> , 2022, 185, 447-456.e11.	13.5	736
553	Targeting stem-loop 1 of the SARS-CoV-2 5' UTR to suppress viral translation and Nsp1 evasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	56
554	Prevalence and circulation patterns of SARS-CoV-2 variants in European sewage mirror clinical data of 54 European cities. <i>Water Research</i> , 2022, 214, 118162.	5.3	45
555	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	77
557	Known Cellular and Receptor Interactions of Animal and Human Coronaviruses: A Review. <i>Viruses</i> , 2022, 14, 351.	1.5	11
558	Probing marine brown macroalgal phlorotannins as antiviral candidate against SARS-CoV-2: molecular docking and dynamics simulation approach. <i>Molecular Diversity</i> , 2022, 26, 3205-3224.	2.1	11
560	Cryo-EM structure of the SARS-CoV-2 Omicron spike. <i>Cell Reports</i> , 2022, 38, 110428.	2.9	82
561	A protease-activatable luminescent biosensor and reporter cell line for authentic SARS-CoV-2 infection. <i>PLoS Pathogens</i> , 2022, 18, e1010265.	2.1	28
563	Escherichia coli recombinant expression of SARS-CoV-2 protein fragments. <i>Microbial Cell Factories</i> , 2022, 21, 21.	1.9	7
564	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. <i>Frontiers in Immunology</i> , 2022, 13, 801522.	2.2	73

#	ARTICLE	IF	CITATIONS
565	Modelling of Waning of Immunity and Reinfection Induced Antibody Boosting of SARS-CoV-2 in Manaus, Brazil. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1729.	1.2	2
566	Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak. <i>Cell</i> , 2022, 185, 485-492.e10.	13.5	38
567	Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. <i>Science Immunology</i> , 2022, 7, eabo2202.	5.6	337
568	Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. <i>Nature Communications</i> , 2022, 13, 742.	5.8	71
569	Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 42.	7.1	25
570	Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. <i>New England Journal of Medicine</i> , 2022, 386, 531-543.	13.9	274
571	Characterization of the First SARS-CoV-2 Isolates from Aotearoa New Zealand as Part of a Rapid Response to the COVID-19 Pandemic. <i>Viruses</i> , 2022, 14, 366.	1.5	7
572	Analysis of SARS-CoV-2 Variants From 24,181 Patients Exemplifies the Role of Globalization and Zoonosis in Pandemics. <i>Frontiers in Microbiology</i> , 2021, 12, 786233.	1.5	46
573	The Coronavirus pandemic – 2022: Viruses, variants & vaccines. <i>Cytokine and Growth Factor Reviews</i> , 2022, 63, 1-9.	3.2	31
574	Targeting the RBD of Omicron Variant (B.1.1.529) with Medicinal Phytocompounds to Abrogate the Binding of Spike Glycoprotein with the hACE2 Using Computational Molecular Search and Simulation Approach. <i>Biology</i> , 2022, 11, 258.	1.3	8
575	A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 766821.	2.2	15
578	Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa. <i>Journal of Medical Virology</i> , 2022, 94, 1728-1733.	2.5	193
579	Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. <i>Current Microbiology</i> , 2022, 79, 20.	1.0	48
580	Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. <i>Infection</i> , 2022, 50, 309-325.	2.3	112
581	Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. <i>Nature</i> , 0, , .	13.7	90
582	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 0, , .	13.7	104
583	The emergence, genomic diversity and global spread of SARS-CoV-2. <i>Nature</i> , 2021, 600, 408-418.	13.7	249
584	Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta. <i>Nature</i> , 2022, 602, 307-313.	13.7	79

#	ARTICLE	IF	CITATIONS
585	Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. <i>Nature</i> , 2022, 602, 657-663.	13.7	1,350
586	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 2022, 602, 654-656.	13.7	928
607	Rapid assessment of SARS-CoV-2 evolved variants using virus-like particles. <i>Science</i> , 2021, 374, 1626-1632.	6.0	216
608	A Paradigm Shift in the Combination Changes of SARS-CoV-2 Variants and Increased Spread of Delta Variant (B.1.617.2) across the World. , 2022, 13, 927.		11
609	Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 29.	1.8	35
610	Omicron SARS-CoV-2 Variant Spike Protein Shows an Increased Affinity to the Human ACE2 Receptor: An In Silico Analysis. <i>Pathogens</i> , 2022, 11, 45.	1.2	44
611	Prediction of SARS-CoV-2 Variant Lineages Using the S1-Encoding Region Sequence Obtained by PacBio Single-Molecule Real-Time Sequencing. <i>Viruses</i> , 2021, 13, 2544.	1.5	12
612	Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. <i>Science</i> , 2021, , eabl6251.	6.0	12
613	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. <i>Science</i> , 2021, , eabm0811.	6.0	10
614	COVID-19 variants that escape vaccine immunity: Global and Indian context-are more vaccines needed?. <i>Journal of Biosciences</i> , 2021, 46, .	0.5	0
615	B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies. <i>International Journal of Biological Sciences</i> , 2022, 18, 1844-1851.	2.6	34
616	A study of computational and conceptual complexities of compartment and agent based models. <i>Networks and Heterogeneous Media</i> , 2022, 17, 359.	0.5	5
617	ChAdOx1 nCoV-19, BNT162b2 and CoronaVac Vaccines Do Not Induce as Strong Neutralising Antibodies with Broad Variant Protection as Infection and Suggest Vaccines that Induce Broader Sterilising Immunity are Essential to Stop the Pandemic. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
618	AI-powered drug repurposing for developing COVID-19 treatments. , 2024, , 144-154.		4
619	Management of Healthcare Resources in the Gauteng Province, South Africa, During the COVID-19 Pandemic. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
620	Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide. <i>Chemical Science</i> , 2022, 13, 3027-3034.	3.7	19
621	Levels of SARS-CoV-2 Antibodies Among Fully-Vaccinated Individuals With Delta or Omicron Variant Breakthrough Infections: A Prospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
623	Immune Response to Viruses. , 2022, , 429-444.		3

#	ARTICLE	IF	CITATIONS
624	Cold atmospheric plasma for preventing infection of viruses that use ACE2 for entry. <i>Theranostics</i> , 2022, 12, 2811-2832.	4.6	8
625	Structure, genomic analysis, and pathogenesis of SARS-CoV-2. , 2022, , 37-60.		0
626	A protein vaccine with Alum/c-GAMP/poly(I:C) rapidly boosts robust immunity against SARS-CoV-2 and variants of concern. <i>Chemical Communications</i> , 2022, 58, 3925-3928.	2.2	9
631	Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. <i>New England Journal of Medicine</i> , 2022, 386, 1397-1408.	13.9	1,346
632	Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac093.	0.4	3
633	Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination. <i>Vaccines</i> , 2022, 10, 279.	2.1	10
635	Comparative Genomics and Characterization of SARS-CoV-2 P.1 (Gamma) Variant of Concern From Amazonas, Brazil. <i>Frontiers in Medicine</i> , 2022, 9, 806611.	1.2	10
637	A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice. <i>Frontiers in Immunology</i> , 2022, 13, 844837.	2.2	13
638	SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy. <i>MBio</i> , 2022, 13, e0322721.	1.8	48
639	Phage-Displayed Mimotopes of SARS-CoV-2 Spike Protein Targeted to Authentic and Alternative Cellular Receptors. <i>Viruses</i> , 2022, 14, 384.	1.5	10
644	SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. <i>Science</i> , 2022, 375, 782-787.	6.0	60
645	CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva. <i>Journal of Medical Microbiology</i> , 2022, 71, .	0.7	19
646	Evolutionary dynamics of SARS-CoV-2 circulating in Yogyakarta and Central Java, Indonesia: sequence analysis covering furin cleavage site (FCS) region of the spike protein. <i>International Microbiology</i> , 2022, 25, 531-540.	1.1	2
647	Potential Anti-SARS-CoV-2 Activity of Pentosan Polysulfate and Mucopolysaccharide Polysulfate. <i>Pharmaceuticals</i> , 2022, 15, 258.	1.7	20
648	Immune transcriptome analysis of COVID-19 patients infected with SARS-CoV-2 variants carrying the E484K escape mutation identifies a distinct gene module. <i>Scientific Reports</i> , 2022, 12, 2784.	1.6	15
649	The mathematical and machine learning models to forecast the COVID-19 outbreaks in Bangladesh. <i>Journal of Interdisciplinary Mathematics</i> , 2022, 25, 753-772.	0.4	4
651	Personal care formulations demonstrate virucidal efficacy against multiple SARS-CoV-2 variants of concern: Implications for hand hygiene and public health. <i>PLOS Global Public Health</i> , 2022, 2, e0000228.	0.5	5
653	Analytical Methods for the Determination of Major Drugs Used for the Treatment of COVID-19. A Review. <i>Critical Reviews in Analytical Chemistry</i> , 2023, 53, 1698-1732.	1.8	5

#	ARTICLE	IF	CITATIONS
654	A Comparison of Seegene Technologies Novaplex SARS-CoV-2 Variants I, II, and IV Assays with Spike Gene Sequencing for Detection of Known Severe Acute Respiratory Syndrome Coronavirus 2 Variants. <i>Journal of Molecular Diagnostics</i> , 2022, , .	1.2	8
656	Emergence in southern France of a new SARS-CoV-2 variant harbouring both N501Y and E484K substitutions in the spike protein. <i>Archives of Virology</i> , 2022, 167, 1185-1190.	0.9	39
657	Assessment of Mutations Associated With Genomic Variants of SARS-CoV-2: RT-qPCR as a Rapid and Affordable Tool to Monitoring Known Circulating Variants in Chile, 2021. <i>Frontiers in Medicine</i> , 2022, 9, 841073.	1.2	2
660	Initial Proportion and Dynamic of B.1.1.7 SARS-CoV-2 in a Large City in the West of Germany. <i>Biomedicine Hub</i> , 2022, 7, 36-41.	0.4	0
661	Phage Display-Derived Compounds Displace hACE2 from Its Complex with SARS-CoV-2 Spike Protein. <i>Biomedicines</i> , 2022, 10, 441.	1.4	4
662	Delta Variant with P681R Critical Mutation Revealed by Ultra-Large Atomic-Scale Ab Initio Simulation: Implications for the Fundamentals of Biomolecular Interactions. <i>Viruses</i> , 2022, 14, 465.	1.5	11
663	Neutralization of SARS-CoV-2 Variants by rVSV- $\hat{\Gamma}$ G-Spike-Elicited Human Sera. <i>Vaccines</i> , 2022, 10, 291.	2.1	19
664	Population Genomics Approaches for Genetic Characterization of SARS-CoV-2 Lineages. <i>Frontiers in Medicine</i> , 2022, 9, 826746.	1.2	7
666	Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD. <i>Cell Discovery</i> , 2022, 8, 16.	3.1	18
667	Emergence and spread of a sub-lineage of SARS-CoV-2 Alpha variant B.1.1.7 in Europe, and with further evolution of spike mutation accumulations shared with the Beta and Gamma variants. <i>Virus Evolution</i> , 2022, 8, veac010.	2.2	10
668	Whole genome sequence analysis showing unique SARS-CoV-2 lineages of B.1.524 and AU.2 in Malaysia. <i>PLoS ONE</i> , 2022, 17, e0263678.	1.1	8
669	Inactivation of SARS-CoV-2 and COVID-19 Patient Samples for Contemporary Immunology and Metabolomics Studies. <i>ImmunoHorizons</i> , 2022, 6, 144-155.	0.8	5
672	Association Between Red Blood Cell Distribution Width and COVID-19 Severity in Delta Variant SARS-CoV-2 Infection. <i>Frontiers in Medicine</i> , 2022, 9, 837411.	1.2	6
673	Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 61.	7.1	12
674	Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 2903-2934.	1.9	19
675	Analysis of the Neutralizing Activity of Antibodies Targeting Open or Closed SARS-CoV-2 Spike Protein Conformations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2078.	1.8	5
676	Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2022, 13, 822159.	2.2	19
677	Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes. <i>Medical Review</i> , 2022, 2, 3-22.	0.3	7

#	ARTICLE	IF	CITATIONS
678	SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. <i>Frontiers in Medicine</i> , 2022, 9, 815389.	1.2	96
681	Identification of cell type specific ACE2 modifiers by CRISPR screening. <i>PLoS Pathogens</i> , 2022, 18, e1010377.	2.1	9
682	Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials. <i>Frontiers in Pharmacology</i> , 2022, 13, 833174.	1.6	6
683	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103.	2.6	9
684	Structural Dynamics and Molecular Evolution of the SARS-CoV-2 Spike Protein. <i>MBio</i> , 2022, 13, e0203021.	1.8	10
685	Plant-Derived Antiviral Compounds as Potential Entry Inhibitors against Spike Protein of SARS-CoV-2 Wild-Type and Delta Variant: An Integrative in Silico Approach. <i>Molecules</i> , 2022, 27, 1773.	1.7	3
686	Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1. <i>Journal of Virology</i> , 2022, 96, e0024922.	1.5	36
687	SARS-CoV-2 variants and spike mutations involved in second wave of COVID-19 pandemic in India. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	1.3	7
688	Comparative characterization of SARS-CoV-2 variants of concern and mouse-adapted strains in mice. <i>Journal of Medical Virology</i> , 2022, 94, 3223-3232.	2.5	12
689	The dynamics of circulating SARS-CoV-2 lineages in Bogor and surrounding areas reflect variant shifting during the first and second waves of COVID-19 in Indonesia. <i>PeerJ</i> , 2022, 10, e13132.	0.9	9
691	Does Omicron mild? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies. <i>Journal of Medical Virology</i> , 2022, 94, 3521-3539.	2.5	20
693	Free Zinc as a Predictive Marker for COVID-19 Mortality Risk. <i>Nutrients</i> , 2022, 14, 1407.	1.7	20
694	Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. <i>Nature Communications</i> , 2022, 13, 1699.	5.8	34
695	Molecular SARS-CoV-2 surveillance in Bavaria shows no Omicron transmission before the end of November 2021. <i>Infection</i> , 2022, 50, 761-766.	2.3	2
697	VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern. <i>Vaccines</i> , 2022, 10, 435.	2.1	8
700	The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines. <i>Health Policy and Technology</i> , 2022, 11, 100619.	1.3	7
701	A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 685-715.	2.0	30
702	Digital PCR Applications in the SARS-CoV-2/COVID-19 Era: a Roadmap for Future Outbreaks. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0016821.	5.7	26

#	ARTICLE	IF	CITATIONS
704	Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2122954119.	3.3	57
705	Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant. BMC Medicine, 2022, 20, 102.	2.3	67
706	Diagnostic Value of a SARS-CoV-2 Rapid Test Kit for Detection of Neutralizing Antibodies as a Point-of-Care Surveillance Test. Microbiology Spectrum, 2022, 10, e0099321.	1.2	3
708	Optimization of SARS-CoV-2 Pseudovirion Production in Lentivirus Backbone With a Novel Liposomal System. Frontiers in Pharmacology, 2022, 13, 840727.	1.6	4
709	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. Open Forum Infectious Diseases, 2022, 9, ofac124.	0.4	25
710	Genomic Snapshot of SARS-CoV-2 in Migrants Entering Through Mediterranean Sea Routes. Frontiers in Public Health, 2022, 10, 846115.	1.3	0
711	Impact of the SARS-CoV-2 Delta Variant on the Psychological States and Health-Related Quality of Life in Patients With Crohn's Disease. Frontiers in Medicine, 2022, 9, 795889.	1.2	1
713	Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell entry process, and cytokine storm in COVID-19. Journal of Cellular Biochemistry, 2022, 123, 964-986.	1.2	8
714	Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion. MBio, 2022, 13, e0009922.	1.8	22
716	High avidity of vaccine-induced immunoglobulin G against SARS-CoV-2: potential relevance for protective humoral immunity. Exploration of Immunology, 0, , 133-156.	1.7	7
717	Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 Reinfections After a Second Wave With Predominance of Lambda in Lima and Callao, Peru. Open Forum Infectious Diseases, 2022, 9, .	0.4	2
718	Multi-omics in COVID-19: Seeing the unseen but overlooked in the clinic. Cell Reports Medicine, 2022, 3, 100580.	3.3	9
719	Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes. Communications Medicine, 2022, 2, .	1.9	32
720	Active surveillance and early detection of community transmission of SARS-CoV-2 Mu variant (B.1.621) in the Brazilian Amazon. Journal of Medical Virology, 2022, 94, 3410-3415.	2.5	6
721	Biparatopic antibodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance. EMBO Reports, 2022, 23, e54199.	2.0	30
722	Aptamers as promising nanotheranostic tools in the COVID-19 pandemic era. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1785.	3.3	13
723	AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2. BMC Medicine, 2022, 20, 128.	2.3	17
724	Antigen-Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD. Frontiers in Molecular Biosciences, 2022, 9, 797132.	1.6	3

#	ARTICLE	IF	CITATIONS
725	Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. <i>Science Translational Medicine</i> , 2022, 14, eabm3410.	5.8	49
727	Variation in the prevalence of cough symptoms 4–5 days after infection with SARS-CoV-2 between seasons with different prevalent strains. <i>Journal of General and Family Medicine</i> , 2022, 23, 248-254.	0.3	3
728	Anti-inflammatory, Antiallergic and COVID-19 Main Protease (M ^{pro}) Inhibitory Activities of Butenolides from a Marine-Derived Fungus <i>Aspergillus costaricensis</i> . <i>ChemistrySelect</i> , 2022, 7, .	0.7	7
729	SARS-CoV-2 variants, immune escape, and countermeasures. <i>Frontiers of Medicine</i> , 2022, 16, 196-207.	1.5	39
730	Protective Immunity of the Primary SARS-CoV-2 Infection Reduces Disease Severity Post Re-Infection with Delta Variants in Syrian Hamsters. <i>Viruses</i> , 2022, 14, 596.	1.5	6
731	Exploring SARS-CoV-2 Delta variant spike protein receptor-binding domain (RBD) as a target for tanshinones and antimalarials. <i>Natural Product Research</i> , 2022, 36, 6150-6155.	1.0	4
732	Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons. <i>PLoS ONE</i> , 2022, 17, e0261045.	1.1	70
735	Humoral immune responses against SARS-CoV-2 in transplantation: Actionable biomarker or misplaced trust?. <i>American Journal of Transplantation</i> , 2022, , .	2.6	1
737	Conserved Pattern and Potential Role of Recurrent Deletions in SARS-CoV-2 Evolution. <i>Microbiology Spectrum</i> , 2022, 10, e0219121.	1.2	9
739	Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 261-282.	0.7	5
740	SARS-CoV-2 spike E156G/I ¹⁵⁷⁻¹⁵⁸ mutations contribute to increased infectivity and immune escape. <i>Life Science Alliance</i> , 2022, 5, e202201415.	1.3	24
741	Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening. <i>Antiviral Research</i> , 2022, 199, 105268.	1.9	15
742	Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity. <i>Nature Reviews Microbiology</i> , 2022, 20, 251-252.	13.6	96
743	Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodies. <i>European Journal of Immunology</i> , 2022, 52, 970-977.	1.6	10
744	A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern. <i>Viruses</i> , 2022, 14, 597.	1.5	22
745	Circulation of SARS-CoV-2 Variants among Children from November 2020 to January 2022 in Trieste (Italy). <i>Microorganisms</i> , 2022, 10, 612.	1.6	8
746	Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies. <i>Clinical Microbiology and Infection</i> , 2022, , .	2.8	5
747	Continuous genomic diversification of long polynucleotide fragments drives the emergence of new SARS-CoV-2 variants of concern. , 2022, 1, .		4

#	ARTICLE	IF	CITATIONS
748	Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms. <i>Cells</i> , 2022, 11, 1182.	1.8	10
749	Phylogenetic analysis of 17271 Indian SARS-CoV-2 genomes to identify temporal and spatial hotspot mutations. <i>PLoS ONE</i> , 2022, 17, e0265579.	1.1	3
750	Rapid and Quantitative <i>In Vitro</i> Evaluation of SARS-CoV-2 Neutralizing Antibodies and Nanobodies. <i>Analytical Chemistry</i> , 2022, 94, 4504-4512.	3.2	3
751	Omicron variant (B.1.1.529) of SARS-CoV-2: understanding mutations in the genome, S-glycoprotein, and antibody-binding regions. <i>GeroScience</i> , 2022, 44, 619-637.	2.1	39
752	Tracking SARS-CoV-2 Mutations & Variants Through the COG-UK-Mutation Explorer. <i>Virus Evolution</i> , 2022, 8, veac023.	2.2	19
753	Rocaglates as Antivirals: Comparing the Effects on Viral Resistance, Anti-Coronaviral Activity, RNA-Clamping on eIF4A and Immune Cell Toxicity. <i>Viruses</i> , 2022, 14, 519.	1.5	4
754	COVID-19 vaccination: The road ahead. <i>Science</i> , 2022, 375, 1127-1132.	6.0	134
755	The inherent flexibility of receptor binding domains in SARS-CoV-2 spike protein. <i>ELife</i> , 2022, 11, .	2.8	40
756	Singing Is a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case-Control Study of Karaoke-Related Coronavirus Disease 2019 Outbreaks in 2 Cities in Hokkaido, Japan, Linked by Whole Genome Analysis. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac158.	0.4	6
757	Clinical development and approval of COVID-19 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 609-619.	2.0	26
758	Breakthrough Infections and Omicron Variant: Dealing with the Dilemma. <i>Indian Journal of Medical Biochemistry</i> , 2022, 25, 00-00.	0.1	0
760	Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives. <i>Journal of Drug Targeting</i> , 2022, , 1-11.	2.1	5
761	Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. <i>Journal of Microbiology</i> , 2022, 60, 255-267.	1.3	9
762	Mutations of Omicron Variant at the Interface of the Receptor Domain Motif and Human Angiotensin-Converting Enzyme-2. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2870.	1.8	18
763	COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines. <i>Inflammation Research</i> , 2022, 71, 377-396.	1.6	11
764	Peptide microarrays coupled to machine learning reveal individual epitopes from human antibody responses with neutralizing capabilities against SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2022, 11, 1037-1048.	3.0	10
765	Inferring transmission fitness advantage of SARS-CoV-2 variants of concern from wastewater samples using digital PCR, Switzerland, December 2020 through March 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	12
766	Genomic profiles of vaccine breakthrough SARS-CoV-2 strains from Odisha, India. <i>International Journal of Infectious Diseases</i> , 2022, 119, 111-113.	1.5	1

#	ARTICLE	IF	CITATIONS
767	High Asymptomatic Carriage With the Omicron Variant in South Africa. <i>Clinical Infectious Diseases</i> , 2022, 75, e289-e292.	2.9	74
768	Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern. <i>Life Science Alliance</i> , 2022, 5, e202101322.	1.3	3
770	A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases. <i>Journal of Nanobiotechnology</i> , 2022, 20, 101.	4.2	47
771	Persistence of Naturally Acquired and Functional SARS-CoV-2 Antibodies in Blood Donors One Year after Infection. <i>Viruses</i> , 2022, 14, 637.	1.5	12
772	Employing chunk size adaptation to overcome concept drift. <i>Journal of Universal Computer Science</i> , 2022, 28, 249-268.	0.6	2
773	Conservation and Enhanced Binding of SARS-CoV-2 Omicron Spike Protein to Coreceptor Neuropilin-1 Predicted by Docking Analysis. <i>Infectious Disease Reports</i> , 2022, 14, 243-249.	1.5	17
774	Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 951-972.	2.0	4
775	Comparative Analysis of SARS-CoV-2 Variants of Concern, Including Omicron, Highlights Their Common and Distinctive Amino Acid Substitution Patterns, Especially at the Spike ORF. <i>Viruses</i> , 2022, 14, 707.	1.5	30
777	Evaluation of the rapid antigen detection test STANDARD F COVID-19 Ag FIA for diagnosing SARS-CoV-2: experience from an Emergency Department. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 103, 115683.	0.8	5
778	Design of SARS-CoV-2 Variant-Specific PCR Assays Considering Regional and Temporal Characteristics. <i>Applied and Environmental Microbiology</i> , 2022, 88, e0228921.	1.4	12
779	Neutrophil Extracellular Traps in Severe SARS-CoV-2 Infection: A Possible Impact of LPS and (1 α) ³ -1,25-D-glucan in Blood from Gut Translocation. <i>Cells</i> , 2022, 11, 1103.	1.8	16
780	First cases of infection with the 21L/BA.2 Omicron variant in Marseille, France. <i>Journal of Medical Virology</i> , 2022, 94, 3421-3430.	2.5	19
781	Impact of B.1.617 and RBD SARS-CoV-2 variants on vaccine efficacy: An in-silico approach. <i>Indian Journal of Medical Microbiology</i> , 2022, 40, 413-419.	0.3	1
782	Infection fatality rate and infection attack rate of COVID-19 in South American countries. <i>Infectious Diseases of Poverty</i> , 2022, 11, 40.	1.5	12
783	Elucidating Design Principles for Engineering Cell-Derived Vesicles to Inhibit SARS-CoV-2 Infection. <i>Small</i> , 2022, 18, e2200125.	5.2	6
785	SARS-CoV-2 variants and vulnerability at the global level. <i>Journal of Medical Virology</i> , 2022, 94, 2986-3005.	2.5	79
786	SARS-CoV-2 Testing in the Community: Testing Positive Samples with the TaqMan SARS-CoV-2 Mutation Panel To Find Variants in Real Time. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0240821.	1.8	7
787	Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile. <i>Nature Microbiology</i> , 2022, 7, 524-529.	5.9	22

#	ARTICLE	IF	CITATIONS
788	Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 62, 128629.	1.0	131
789	Molecular epidemiological features of SARS-CoV-2 in Japan, 2020â€“1. <i>Virus Evolution</i> , 2022, 8, veac034.	2.2	9
791	Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2. <i>Future Microbiology</i> , 2022, 17, 417-424.	1.0	11
792	RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104043.	1.9	19
793	The basis of mink susceptibility to SARS-CoV-2 infection. <i>Journal of Applied Genetics</i> , 2022, 63, 543-555.	1.0	5
794	Omicron: Understanding the latest variant of SARSâ€“CoVâ€“2 and strategies for tackling the infection. <i>ChemBioChem</i> , 2022, , .	1.3	4
796	Direct comparison of RT-ddPCR and targeted amplicon sequencing for SARS-CoV-2 mutation monitoring in wastewater. <i>Science of the Total Environment</i> , 2022, 833, 155059.	3.9	29
797	Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain. <i>Antiviral Research</i> , 2022, 200, 105290.	1.9	3
798	Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models. <i>Science Translational Medicine</i> , 2022, 14, eabm0899.	5.8	68
799	Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 227.	2.4	20
800	Persistent Lung Injury and Prothrombotic State in Long COVID. <i>Frontiers in Immunology</i> , 2022, 13, 862522.	2.2	15
801	Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage. <i>Infection, Genetics and Evolution</i> , 2022, 99, 105254.	1.0	21
802	Characteristic analysis of Omicronâ€“included SARSâ€“CoVâ€“2 variants of concern. <i>MedComm</i> , 2022, 3, e129.	3.1	3
803	Antigenicity comparison of SARSâ€“CoVâ€“2 Omicron sublineages with other variants contained multiple mutations in RBD. <i>MedComm</i> , 2022, 3, e130.	3.1	18
804	There is nothing exempt from the peril of mutation â€“ The Omicron spike. <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112756.	2.5	11
805	High viral loads: what drives fatal cases of COVID-19 in vaccinees? â€“ an autopsy study. <i>Modern Pathology</i> , 2022, 35, 1013-1021.	2.9	5
806	Interferon antagonists encoded by SARS-CoV-2 at a glance. <i>Medical Microbiology and Immunology</i> , 2023, 212, 125-131.	2.6	20
807	Interaction of surface glycoprotein of SARS-CoV-2 variants of concern with potential drug candidates: A molecular docking study. <i>F1000Research</i> , 0, 11, 400.	0.8	1

#	ARTICLE	IF	CITATIONS
808	Prevalence and Drivers of COVID-19 Vaccine Booster Hesitancy Among German University Students and Employees. <i>Frontiers in Public Health</i> , 2022, 10, 846861.	1.3	26
809	A global picture: therapeutic perspectives for COVID-19. <i>Immunotherapy</i> , 2022, 14, 351-371.	1.0	56
810	Differential transcriptomic landscapes of multiple organs from SARS-CoV-2 early infected rhesus macaques. <i>Protein and Cell</i> , 2022, 13, 920-939.	4.8	9
811	Role of genomics in combating COVID-19 pandemic. <i>Gene</i> , 2022, 823, 146387.	1.0	20
812	The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape. <i>International Journal of Biological Macromolecules</i> , 2022, 208, 105-125.	3.6	41
813	Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern. <i>EBioMedicine</i> , 2022, 79, 103997.	2.7	29
814	Fast detection of SARS-CoV-2 variants including Omicron using one-step RT-PCR and Sanger sequencing. <i>Journal of Virological Methods</i> , 2022, 304, 114512.	1.0	18
815	Rapid detection and tracking of Omicron variant of SARS-CoV-2 using CRISPR-Cas12a-based assay. <i>Biosensors and Bioelectronics</i> , 2022, 205, 114098.	5.3	36
816	The status and analysis of common mutations found in the SARS-CoV-2 whole genome sequences from Bangladesh. <i>Gene Reports</i> , 2022, 27, 101608.	0.4	2
817	Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 25, 225-235.	1.8	12
818	Effect of insilico predicted and designed potential siRNAs on inhibition of SARS-CoV-2 in HEK-293 cells. <i>Journal of King Saud University - Science</i> , 2022, 34, 101965.	1.6	4
819	Probing the mutation independent interaction of DNA probes with SARS-CoV-2 variants through a combination of surface-enhanced Raman scattering and machine learning. <i>Biosensors and Bioelectronics</i> , 2022, 208, 114200.	5.3	31
820	FRET-based hACE2 receptor mimic peptide conjugated nanoprobe for simple detection of SARS-CoV-2. <i>Chemical Engineering Journal</i> , 2022, 442, 136143.	6.6	12
822	Emerging SARS-CoV-2 Genotypes Show Different Replication Patterns in Human Pulmonary and Intestinal Epithelial Cells. <i>Viruses</i> , 2022, 14, 23.	1.5	16
823	Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity. <i>Viruses</i> , 2021, 13, 2537.	1.5	11
825	A Novel High-Throughput Nanopore-Sequencing-Based Strategy for Rapid and Automated S-Protein Typing of SARS-CoV-2 Variants. <i>Viruses</i> , 2021, 13, 2548.	1.5	5
827	The COVID-19 surge in Indonesia: what we learned and what to expect. <i>Breathe</i> , 2021, 17, 210146.	0.6	4
828	Omicron variant of SARS-CoV-2- A virus of concern. <i>IP Indian Journal of Immunology and Respiratory Medicine</i> , 2021, 6, 207-209.	0.1	0

#	ARTICLE	IF	CITATIONS
833	MicroRNA-Mediated Regulation of the Virus Cycle and Pathogenesis in the SARS-CoV-2 Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13192.	1.8	10
837	Cost-Effective Method to Perform SARS-CoV-2 Variant Surveillance: Detection of Alpha, Gamma, Lambda, Delta, Epsilon, and Zeta in Argentina. <i>Frontiers in Medicine</i> , 2021, 8, 755463.	1.2	11
841	Simplified Point-of-Care Full SARS-CoV-2 Genome Sequencing Using Nanopore Technology. <i>Microorganisms</i> , 2021, 9, 2598.	1.6	13
843	HLA-A*02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses. <i>Cell Reports</i> , 2021, 37, 110167.	2.9	18
844	Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 763460.	2.2	16
845	Protective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization. <i>Viruses</i> , 2021, 13, 2440.	1.5	8
847	The atomic portrait of SARS-CoV-2 as captured by cryo-electron microscopy. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 25-34.	1.6	6
848	Administration of HeberFERON in Patients with Persistent Oropharyngeal SARS-CoV-2 Wuhan/D614G Strain Viral Shedding. <i>Journal of Biomedical Research & Environmental Sciences</i> , 2021, 2, 1253-1266.	0.1	0
851	Epigallocatechin Gallate (EGCG), a Green Tea Polyphenol, Reduces Coronavirus Replication in a Mouse Model. <i>Viruses</i> , 2021, 13, 2533.	1.5	31
853	Genetic Diversity and Molecular Epidemiology of Circulating Respiratory Syncytial Virus in Central Taiwan, 2008–2017. <i>Viruses</i> , 2022, 14, 32.	1.5	7
854	COVID-19 and the Differences in Physiological Background Between Children and Adults and Their Clinical Consequences. <i>Physiological Research</i> , 2021, 70, S209-S225.	0.4	12
855	A new tool to probe SARS-CoV-2 variants. <i>Science</i> , 2021, 374, 1557-1558.	6.0	3
857	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
858	Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab626.	0.4	6
859	The Development of mRNA Vaccines for Infectious Diseases: Recent Updates. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5271-5285.	1.1	16
860	Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. <i>Cancer Discovery</i> , 2022, 12, 303-330.	7.7	24
861	Phage Display-Derived Peptide for the Specific Binding of SARS-CoV-2. <i>ACS Omega</i> , 2022, 7, 3203-3211.	1.6	21
863	Changes in Receptor Binding Domain of the Covid-19 during Pandemic; a Review Study. <i>Pizh-Salamat</i> , 2021, 7, 75-86.	0.2	0

#	ARTICLE	IF	CITATIONS
864	Viral surface geometry shapes influenza and coronavirus spike evolution through antibody pressure. <i>PLoS Computational Biology</i> , 2021, 17, e1009664.	1.5	4
868	Microarray-Based Detection of Antibodies against SARS-CoV-2 Proteins, Common Respiratory Viruses and Type I Interferons. <i>Viruses</i> , 2021, 13, 2553.	1.5	15
869	Contact-Tracing Outcomes Among Household Contacts of Fully Vaccinated Coronavirus Disease 2019 (COVID-19) Patients: San Francisco, California, 29 Januaryâ€“2 July 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, e267-e275.	2.9	12
870	Allosteric Modulation of Small Molecule Drugs on ACE2 Conformational Change upon Binding to SARS-CoV-2 Spike Protein. , 2021, , .		5
871	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. <i>Journal of Microbiology and Biotechnology</i> , 2021, 31, 1601-1614.	0.9	8
874	Impact of SARS-CoV-2 Mutations on Global Travel and the Increasing Number of Re-Infections: A Risk-Assessment Perspective. <i>The Open Covid Journal</i> , 2021, 1, 196-204.	0.4	2
875	Modeling serological testing to inform relaxation of social distancing for COVID-19 control. <i>Nature Communications</i> , 2021, 12, 7063.	5.8	11
877	D3AI-CoV: a deep learning platform for predicting drug targets and for virtual screening against COVID-19. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	13
878	Omicron, SARS CoV2 Variant. <i>International Journal of Medical and Dental Sciences</i> , 0, , 2024-2025.	0.1	1
879	Scope of SARS-CoV-2 variants, mutations, and vaccine technologies. <i>The Egyptian Journal of Internal Medicine</i> , 2022, 34, 34.	0.3	5
880	Evaluation of Mutation in Spike Gene of Covid-19 in Iranian Patients. <i>Annals of Military and Health Sciences Research</i> , 2022, 20, .	0.1	0
881	Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo. <i>Cell Research</i> , 2022, 32, 589-592.	5.7	5
883	SARS-CoV-2 mutations acquired during serial passage in human cell lines are consistent with several of those found in recent natural SARS-CoV-2 variants. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1925-1934.	1.9	16
885	Structures of Omicron spike complexes and implications for neutralizing antibody development. <i>Cell Reports</i> , 2022, 39, 110770.	2.9	47
888	Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor. <i>ACS Infectious Diseases</i> , 2022, 8, 1022-1030.	1.8	13
889	Amomum tsao-ko essential oil, a novel anti-COVID-19 Omicron spike protein natural products: A computational study. <i>Arabian Journal of Chemistry</i> , 2022, 15, 103916.	2.3	4
890	4â€™-fluorouridine and its derivatives as potential COVID-19 oral drugs: a review. <i>F1000Research</i> , 0, 11, 410.	0.8	3
891	DeepSARS: simultaneous diagnostic detection and genomic surveillance of SARS-CoV-2. <i>BMC Genomics</i> , 2022, 23, 289.	1.2	5

#	ARTICLE	IF	CITATIONS
892	Comparative genomics, evolutionary epidemiology, and RBD-hACE2 receptor binding pattern in B.1.1.7 (Alpha) and B.1.617.2 (Delta) related to their pandemic response in UK and India. <i>Infection, Genetics and Evolution</i> , 2022, 101, 105282.	1.0	7
894	Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	6
895	Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. <i>Viruses</i> , 2022, 14, 827.	1.5	14
896	Breakthrough gastrointestinal COVID and intra-host evolution consequent to combination monoclonal antibody prophylaxis. <i>Journal of Infectious Diseases</i> , 2022, , .	1.9	0
897	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	10
898	Cyclosporin A Reveals Potent Antiviral Effects in Preclinical Models of SARS-CoV-2 Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 964-968.	2.5	5
901	Coding-Complete Sequence of a SARS-CoV-2 Strain from an Omicron (B.1.1.529+BA.1) Variant Detected in Morocco. <i>Microbiology Resource Announcements</i> , 2022, , e0006322.	0.3	0
903	Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)? <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1077-1082.	2.5	4
904	COVID-19 Vaccines: Current and Future Perspectives. <i>Vaccines</i> , 2022, 10, 608.	2.1	26
905	The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines. <i>Vaccines</i> , 2022, 10, 591.	2.1	27
908	Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques. <i>PLoS Pathogens</i> , 2022, 18, e1010155.	2.1	6
909	Control of common viral epidemics but not of SARS-CoV-2 through the application of hygiene and distancing measures. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105163.	1.6	6
910	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3020-3031.	0.8	26
911	Annotating Spike Protein Polymorphic Amino Acids of Variants of SARS-CoV-2, Including Omicron. <i>Biochemistry Research International</i> , 2022, 2022, 1-7.	1.5	3
912	Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 1871-1887.	1.1	23
914	Repurposing of Four Drugs as Anti-SARS-CoV-2 Agents and Their Interactions with Protein Targets. <i>Scientia Pharmaceutica</i> , 2022, 90, 24.	0.7	7
915	Comparative analysis of SARS-CoV-2 quasispecies in the upper and lower respiratory tract shows an ongoing evolution in the spike cleavage site. <i>Virus Research</i> , 2022, 315, 198786.	1.1	5
916	Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology. <i>Journal of Molecular Cell Biology</i> , 2022, 14, .	1.5	4

#	ARTICLE	IF	CITATIONS
917	Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection. JCI Insight, 2022, 7, .	2.3	15
918	Structural and functional impact by SARS-CoV-2 Omicron spike mutations. Cell Reports, 2022, 39, 110729.	2.9	102
919	Robust Mutation Profiling of SARS-CoV-2 Variants from Multiple Raw Illumina Sequencing Data with Cloud Workflow. Genes, 2022, 13, 686.	1.0	7
920	How Do Point Mutations Enhancing the Basic Character of the RBDs of SARS-CoV-2 Variants Affect Their Transmissibility and Infectivity Capacities?. Viruses, 2022, 14, 783.	1.5	9
922	Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2. Journal of Clinical Virology, 2022, 150-151, 105161.	1.6	8
923	Molecular insights into the differential dynamics of SARS-CoV-2 variants of concern. Journal of Molecular Graphics and Modelling, 2022, 114, 108194.	1.3	21
924	SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets. Inflammation, 2022, 45, 1430-1449.	1.7	16
925	Designing and characterization of a SARS-CoV-2 immunogen with receptor binding motif grafted on a protein scaffold: An epitope-focused vaccine approach. International Journal of Biological Macromolecules, 2022, 209, 1359-1367.	3.6	3
926	Use of wastewater surveillance for early detection of Alpha and Epsilon SARS-CoV-2 variants of concern and estimation of overall COVID-19 infection burden. Science of the Total Environment, 2022, 835, 155410.	3.9	34
927	Identification of potential bioactive natural compounds from Indonesian medicinal plants against 3-chymotrypsin-like protease (3CL ^{pro}) of SARS-CoV-2: molecular docking, ADME/T, molecular dynamic simulations, and DFT analysis. Journal of Biomolecular Structure and Dynamics, 2023, 41, 4467-4484.	2.0	10
928	The Evolution and Biology of SARS-CoV-2 Variants. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a041390.	2.9	110
929	Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy. MBio, 2022, 13, e0036422.	1.8	17
930	Bacillus Calmette-Guérin-induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice. JCI Insight, 2022, 7, .	2.3	29
931	Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies. Molecular Biomedicine, 2022, 3, 12.	1.7	12
932	An in-silico study of the mutation-associated effects on the spike protein of SARS-CoV-2, Omicron variant. PLoS ONE, 2022, 17, e0266844.	1.1	18
933	Interest in Infectious Diseases specialty among Japanese medical students amidst the COVID-19 pandemic: A web-based, cross-sectional study. PLoS ONE, 2022, 17, e0267587.	1.1	4
934	Fabrication of a Lateral Flow Assay for Rapid In-Field Detection of COVID-19 Antibodies Using Additive Manufacturing Printing Technologies. International Journal of Bioprinting, 2021, 7, 399.	1.7	8
935	Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity.. Science Translational Medicine, 2021, , eabj6824.	5.8	11

#	ARTICLE	IF	CITATIONS
936	Rapid Genotyping of Sars-Cov-2 Variants with a Duplex-Targeting Lateral Flow Strip by Crispr-Cas 12a/13a in Pam Independent Manner. SSRN Electronic Journal, 0, , .	0.4	0
937	SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. Computational and Structural Biotechnology Journal, 2022, 20, 2042-2056.	1.9	8
938	Targeting SARS-CoV-2 Infection Through CAR-T Like Bispecific T Cell Engagers Incorporating ACE2. SSRN Electronic Journal, 0, , .	0.4	0
941	SARS-CoV-2: An Overview of the Genetic Profile and Vaccine Effectiveness of the Five Variants of Concern. Pathogens, 2022, 11, 516.	1.2	10
942	In Silico Analysis Predicts a Limited Impact of SARS-CoV-2 Variants on CD8 T Cell Recognition. Frontiers in Immunology, 2022, 13, 891524.	2.2	0
945	Delta Variant of SARS-CoV-2 Replacement in Brazil: A National Epidemiologic Surveillance Program. Viruses, 2022, 14, 847.	1.5	11
946	SARS-CoV-2 Virus-like Particles Produced by a Single Recombinant Baculovirus Generate Anti-S Antibody and Protect against Variant Challenge. Viruses, 2022, 14, 914.	1.5	10
947	Detection of Major SARS-CoV-2 Variants of Concern in Clinical Samples via CRISPR-Cas12a-Mediated Mutation-Specific Assay. ACS Synthetic Biology, 2022, 11, 1811-1823.	1.9	9
948	Molecular Dynamics Studies on the Structural Stability Prediction of SARS-CoV-2 Variants Including Multiple Mutants. International Journal of Molecular Sciences, 2022, 23, 4956.	1.8	5
949	Ubiquitous Micro-Modular Homologies among Genomes from Viruses to Bacteria to Human Mitochondrial DNA: Platforms for Recombination during Evolution?. Viruses, 2022, 14, 885.	1.5	0
950	Neurologic Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Hospitalized Patients During the First Year of the COVID-19 Pandemic. , 2022, 4, e0686.		11
951	A Short Series of Case Reports of COVID-19 in Immunocompromised Patients. Viruses, 2022, 14, 934.	1.5	4
952	The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. Vaccines, 2022, 10, 712.	2.1	4
953	Epidemiological Features of COVID-19 in Northwest Russia in 2021. Viruses, 2022, 14, 931.	1.5	7
956	SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduction and Targeted Therapy, 2022, 7, 141.	7.1	315
957	Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19. Frontiers in Drug Discovery, 2022, 2, .	1.1	5
958	Dual-Positive MPO- and PR3-ANCA-Associated Vasculitis Following SARS-CoV-2 mRNA Booster Vaccination: A Case Report and Systematic Review. Vaccines, 2022, 10, 653.	2.1	21
959	Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants. Biomedicines, 2022, 10, 996.	1.4	3

#	ARTICLE	IF	CITATIONS
960	Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 138.	7.1	140
961	Binding Interactions between Receptor-Binding Domain of Spike Protein and Human Angiotensin Converting Enzyme-2 in Omicron Variant. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 3915-3921.	2.1	49
962	Hypericum perforatum and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2. <i>Pharmaceuticals</i> , 2022, 15, 530.	1.7	22
963	Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron. <i>Frontiers in Immunology</i> , 2022, 13, 863831.	2.2	10
964	Probing the Immune System Dynamics of the COVID-19 Disease for Vaccine Designing and Drug Repurposing Using Bioinformatics Tools. <i>Immuno</i> , 2022, 2, 344-371.	0.6	2
965	A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant. <i>PLoS Pathogens</i> , 2022, 18, e1010465.	2.1	8
966	An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron. <i>Nature Microbiology</i> , 2022, 7, 716-725.	5.9	62
967	Identifying SARS-CoV-2 Variants of Concern through Saliva-Based RT-qPCR by Targeting Recurrent Mutation Sites. <i>Microbiology Spectrum</i> , 2022, 10, e0079722.	1.2	3
969	Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2068883.	1.4	44
970	Convergent Evolution of Multiple Mutations Improves the Viral Fitness of SARS-CoV-2 Variants by Balancing Positive and Negative Selection. <i>Biochemistry</i> , 2022, 61, 963-980.	1.2	12
971	Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing. <i>Molecular Diversity</i> , 2023, 27, 463-475.	2.1	25
972	Impact of SARS-CoV-2 Mu variant on vaccine effectiveness: A comparative genomics study at the peak of the third wave in Bogota, Colombia. <i>Journal of Medical Virology</i> , 2022, , .	2.5	4
973	COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. <i>Cureus</i> , 2022, , .	0.2	3
974	Multicenter international assessment of a SARS-CoV-2 RT-LAMP test for point of care clinical application. <i>PLoS ONE</i> , 2022, 17, e0268340.	1.1	15
975	Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host. <i>Nature Communications</i> , 2022, 13, 2560.	5.8	64
976	Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals. <i>Nature Medicine</i> , 2022, 28, 1476-1485.	15.2	24
977	SARS-CoV-2 variants – Evolution, spike protein, and vaccines. <i>Biomedical Journal</i> , 2022, 45, 573-579.	1.4	26
978	EPIDEMIOLOGICAL PROFILE OF COVID-19 CASES NOTIFIED IN THE HEALTH SECRETARY OF ARAGUARI CITY, MG, BRAZIL. <i>International Journal for Innovation Education and Research</i> , 2022, 10, 178-189.	0.0	0

#	ARTICLE	IF	CITATIONS
979	Towards Control and Oversight of SARS-CoV-2 Diagnosis and Monitoring through Multiplexed Quantitative Electroanalytical Immune Response Biosensors.. <i>Angewandte Chemie</i> , 0, , .	1.6	2
980	Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months. <i>Frontiers in Immunology</i> , 2022, 13, 879036.	2.2	13
981	SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	28
982	Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 â€“ A Comprehensive Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 841009.	2.2	0
983	Towards Control and Oversight of SARS-CoV-2 Diagnosis and Monitoring through Multiplexed Quantitative Electroanalytical Immune Response Biosensors. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	12
984	Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant. <i>MedComm</i> , 2022, 3, e143.	3.1	3
985	Data analysis and prediction of the COVID-19 outbreak in the first and second waves for top 5 affected countries in the world. <i>Nonlinear Dynamics</i> , 2022, 109, 77-90.	2.7	5
986	SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells. <i>Journal of Virology</i> , 2022, 96, e0059422.	1.5	21
987	Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts. <i>Microbiology Spectrum</i> , 2022, 10, e0079122.	1.2	19
988	3D Bioprinted Neural-Like Tissue as a Platform to Study Neurotropism of Mouse-Adapted SARS-CoV-2. <i>Advanced Biology</i> , 2022, 6, e2200002.	1.4	4
989	Potent neutralization by monoclonal human IgM against SARS-CoV-2 is impaired by class switch. <i>EMBO Reports</i> , 2022, , e53956.	2.0	8
990	Genetic and Structural Analysis of SARS-CoV-2 Spike Protein for Universal Epitope Selection. <i>Molecular Biology and Evolution</i> , 2022, 39, .	3.5	7
991	The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	4
992	Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2022, 386, 2084-2096.	13.9	118
993	Imported SARS-CoV-2 Variants of Concern Drove Spread of Infections across Kenya during the Second Year of the Pandemic. <i>Covid</i> , 2022, 2, 586-598.	0.7	9
994	Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	10
995	Obesity and Impaired Metabolic Health Increase Risk of COVID-19-Related Mortality in Young and Middle-Aged Adults to the Level Observed in Older People: The LEOSS Registry. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	17
996	The International Virus Bioinformatics Meeting 2022. <i>Viruses</i> , 2022, 14, 973.	1.5	3

#	ARTICLE	IF	CITATIONS
997	Immunoinformatic approach for the construction of multi-epitopes vaccine against omicron COVID-19 variant. <i>Virology</i> , 2022, 572, 28-43.	1.1	11
998	Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: Mutational impacts, concerns, and the possible solutions. <i>Annals of Medicine and Surgery</i> , 2022, 78, 103737.	0.5	33
999	An in silico approach unveils the potential of antiviral compounds in preclinical and clinical trials as SARS-CoV-2 omicron inhibitors. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 103297.	1.8	11
1000	In silico prediction and experimental evaluation of potential siRNAs against SARS-CoV-2 inhibition in Vero E6 cells. <i>Journal of King Saud University - Science</i> , 2022, 34, 102049.	1.6	7
1001	Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins. <i>Antiviral Research</i> , 2022, 203, 105332.	1.9	2
1002	A multi-strain epidemic model for COVID-19 with infected and asymptomatic cases: Application to French data. <i>Journal of Theoretical Biology</i> , 2022, 545, 111117.	0.8	26
1003	Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study. <i>Computers in Biology and Medicine</i> , 2022, 146, 105552.	3.9	16
1004	SARS-CoV-2 Infection and Possible Neonatal Neurological Outcomes: A Literature Review. <i>Viruses</i> , 2022, 14, 1037.	1.5	4
1005	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
1006	The emergence of SARS-CoV-2 variants of concern in Australia by haplotype coalescence reveals a continental link to COVID-19 seasonality. <i>Methods in Microbiology</i> , 2022, , 233-268.	0.4	2
1007	NGS data vectorization, clustering, and finding key codons in SARS-CoV-2 variations. <i>BMC Bioinformatics</i> , 2022, 23, 187.	1.2	2
1008	Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 159.	7.1	21
1009	Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, .	1.8	6
1010	SARS-CoV-2 variant trends in Ireland: Wastewater-based epidemiology and clinical surveillance. <i>Science of the Total Environment</i> , 2022, 838, 155828.	3.9	25
1011	In silico analysis of mutations near S1/S2 cleavage site in SARS-CoV-2 spike protein reveals increased propensity of glycosylation in Omicron strain. <i>Journal of Medical Virology</i> , 2022, 94, 4181-4192.	2.5	10
1012	Complex Mutation Pattern of Omicron BA.2: Evading Antibodies without Losing Receptor Interactions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5534.	1.8	10
1013	Mechanistic Models of COVID-19: Insights into Disease Progression, Vaccines, and Therapeutics. <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106606.	1.1	13
1014	Increased Abundance of <i>Achromobacter xylosoxidans</i> and <i>Bacillus cereus</i> in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome. <i>Microbiology Spectrum</i> , 2022, 10, e0231121.	1.2	16

#	ARTICLE	IF	CITATIONS
1015	Structure-Based Development of SARS-CoV-2 Spike Interactors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5601.	1.8	3
1016	Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003991.	3.9	75
1017	Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro. <i>Nature Communications</i> , 2022, 13, 2766.	5.8	20
1018	Molecular evolution and structural analyses of the spike glycoprotein from Brazilian SARS-CoV-2 genomes: the impact of selected mutations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 3110-3128.	2.0	1
1019	Pandemic responsiveness: Evidence from social distancing and lockdown policy during COVID-19. <i>PLoS ONE</i> , 2022, 17, e0267611.	1.1	13
1026	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?. <i>Expert Review of Vaccines</i> , 2022, 21, 1071-1086.	2.0	3
1028	High prevalence of an alpha variant lineage with a premature stop codon in ORF7a in Iraq, winter 2020â€“2021. <i>PLoS ONE</i> , 2022, 17, e0267295.	1.1	8
1030	Deep phylogenetic-based clustering analysis uncovers new and shared mutations in SARS-CoV-2 variants as a result of directional and convergent evolution. <i>PLoS ONE</i> , 2022, 17, e0268389.	1.1	7
1031	Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	9
1032	Evolution and bioinformatic analysis of the whole genome sequences of SARs-COV-2. <i>Wetchasan Songkla Nakarin</i> , 2022, 2, 85-98.	0.1	0
1033	Exploring the Spike-hACE 2 Residueâ€“Residue Interaction in Human Coronaviruses SARS-CoV-2, SARS-CoV, and HCoV-NL63. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 2857-2868.	2.5	6
1035	The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Concern. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	43
1036	Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants. <i>Pharmaceutics</i> , 2022, 14, 1101.	2.0	15
1037	Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	53
1039	Viral hijacking mechanism in humans through proteinâ€“protein interactions. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, , .	1.0	1
1040	Determinants of Spike Infectivity, Processing and Neutralization in SARS-CoV-2 Omicron Subvariants BA.1 and BA.2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1041	The seasonal behaviour of COVID-19 and its galectin-like culprit of the viral spike. <i>Methods in Microbiology</i> , 2022, , 27-81.	0.4	3
1042	Conserved Structures in the Viral Macrodomein of Rubella Virus Confers Protection Against SARS-CoV-2-Induced Pulmonary Pathology. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1043	Current molecular diagnostics assays for SARS-CoV-2 and emerging variants. <i>Methods in Microbiology</i> , 2022, , 83-121.	0.4	2
1044	Simplified Cas13-based assays for the fast identification of SARS-CoV-2 and its variants. <i>Nature Biomedical Engineering</i> , 2022, 6, 932-943.	11.6	76
1045	The ORF8 Protein of SARS-CoV-2 Modulates the Spike Protein and Its Implications in Viral Transmission. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	14
1046	Where is the next SARS-CoV-2 variant of concern?. <i>Lancet, The</i> , 2022, 399, 1938-1939.	6.3	16
1048	SARS-CoV-2 Within-Host and in vitro Genomic Variability and Sub-Genomic RNA Levels Indicate Differences in Viral Expression Between Clinical Cohorts and in vitro Culture. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	4
1049	Geographical distribution of <sc>SARS-CoV-2</sc> amino acids mutations and the concomitant evolution of seven distinct clades in non-human hosts. <i>Zoonoses and Public Health</i> , 2022, 69, 816-825.	0.9	4
1050	Prediction of the effects of the top 10 nonsynonymous variants from 30229 SARS-CoV-2 strains on their proteins. <i>F1000Research</i> , 0, 11, 9.	0.8	3
1051	Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 7561-7580.	2.9	65
1052	Antigenic structure of the human coronavirus OC43 spike reveals exposed and occluded neutralizing epitopes. <i>Nature Communications</i> , 2022, 13, .	5.8	12
1053	Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1056	An Insight Based on Computational Analysis of the Interaction between the Receptor-Binding Domain of the Omicron Variants and Human Angiotensin-Converting Enzyme 2. <i>Biology</i> , 2022, 11, 797.	1.3	10
1057	VOC-alarm: mutation-based prediction of SARS-CoV-2 variants of concern. <i>Bioinformatics</i> , 2022, 38, 3549-3556.	1.8	4
1058	Real-time allelic assays of SARS-CoV-2 variants to enhance sewage surveillance. <i>Water Research</i> , 2022, 220, 118686.	5.3	17
1059	Changing Dynamics of SARS-CoV-2: A Global Challenge. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 5546.	1.3	3
1061	An early warning system for emerging SARS-CoV-2 variants. <i>Nature Medicine</i> , 2022, 28, 1110-1115.	15.2	47
1062	Detection of SARS-CoV-2 Variants of Concern with Tiling Amplicon Sequencing from Wastewater. <i>ACS ES&T Water</i> , 2022, 2, 2185-2193.	2.3	5
1064	Biochemical Characterization of SARS-CoV-2 Spike RBD Mutations and Their Impact on ACE2 Receptor Binding. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	3
1066	Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	5

#	ARTICLE	IF	CITATIONS
1067	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis. <i>Lancet Microbe</i> , The, 2022, 3, e493-e502.	3.4	22
1068	Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	24
1070	Recent insights into SARS-CoV-2 omicron variant. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	29
1071	Mutations of the SARS-CoV-2 Spike Glycoprotein Detected in Cats and Their Effect on Its Structure and Function. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, .	1.8	4
1072	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	5.1	50
1073	Rise of the SARS-CoV-2 Variants: can proteomics be the silver bullet?. <i>Expert Review of Proteomics</i> , 2022, 19, 197-212.	1.3	2
1074	Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. <i>Science Immunology</i> , 2022, 7, .	5.6	144
1075	Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. <i>Immunological Reviews</i> , 2022, 310, 6-26.	2.8	138
1076	COVID-19 vaccine design using reverse and structural vaccinology, ontology-based literature mining and machine learning. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	4
1077	Mapping of SARS-CoV-2 spike protein evolution during the first and second waves of COVID-19 infections in India. <i>Future Virology</i> , 2022, 17, 557-575.	0.9	2
1078	Characterization of the Cross-Species Transmission Potential for Porcine Deltacoronaviruses Expressing Sparrow Coronavirus Spike Protein in Commercial Poultry. <i>Viruses</i> , 2022, 14, 1225.	1.5	2
1080	Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. <i>Nature Immunology</i> , 2022, 23, 960-970.	7.0	39
1082	Structural Characterization of a Neutralizing Nanobody With Broad Activity Against SARS-CoV-2 Variants. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	5
1084	COVID-19 Vaccine Booster Significantly Decreases the Risk of Intensive Care Unit Hospitalization in Heart Failure Patients During the Omicron Variant Wave: A Population-Based Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1086	The Spike Protein of SARS-CoV-2 Is Adapting Because of Selective Pressures. <i>Vaccines</i> , 2022, 10, 864.	2.1	17
1087	Human pathogenic RNA viruses establish noncompeting lineages by occupying independent niches. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	9
1088	Antibody Level Predicts the Clinical Course of Breakthrough Infection of COVID-19 Caused by Delta and Omicron Variants: A Prospective Cross-Sectional Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	22
1089	Mutational analysis of SARS-CoV-2 variants of concern reveals key tradeoffs between receptor affinity and antibody escape. <i>PLoS Computational Biology</i> , 2022, 18, e1010160.	1.5	14

#	ARTICLE	IF	CITATIONS
1090	Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	4
1093	Effectiveness of Mathulungadi Nasyam in the prophylaxis of COVID19 infection â€“ Retrospective analysis of Clinical Data. <i>Journal of Ayurveda and Integrative Medicine</i> , 2022, , 100600.	0.9	0
1094	Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants. <i>Viruses</i> , 2022, 14, 1332.	1.5	12
1095	Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review. <i>Vaccines</i> , 2022, 10, 909.	2.1	6
1097	Age and sex effects on DNA methylation sites linked to genes implicated in severe COVID-19 and SARS-CoV-2 host cell entry. <i>PLoS ONE</i> , 2022, 17, e0269105.	1.1	2
1098	Broadly Neutralizing Antibodies to SARS-CoV-2 Provide Novel Insights Into the Neutralization of Variants and Other Human Coronaviruses. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	12
1099	The Cellular Characterization of SARS-CoV-2 Spike Protein in Virus-Infected Cells Using the Receptor Binding Domain Binding Specific Human Monoclonal Antibodies. <i>Journal of Virology</i> , 0, , .	1.5	0
1100	The past, current and future epidemiological dynamic of SARS-CoV-2. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	24
1102	Brief dispersion of a putative B.1.1.28-derived SARS-CoV-2 lineage harboring additional N234P and E471Q spike protein mutations in individuals crossing the Argentina-Brazil border. <i>Travel Medicine and Infectious Disease</i> , 2022, 49, 102390.	1.5	3
1104	SARS-CoV-2 Spike mutations modify the interaction between virus Spike and human ACE2 receptors. <i>Biochemical and Biophysical Research Communications</i> , 2022, 620, 8-14.	1.0	3
1106	Interaction of 5-[4â€“(N-Methyl-1,3-benzimidazol-2-yl)phenyl]-10,15,20-tri-(N-methyl-3â€“(pyridyl)porphyrin Triiodide with SARS-CoV-2 Spike Protein. <i>Russian Journal of General Chemistry</i> , 2022, 92, 1005-1010.	0.3	1
1108	Interpretable modeling of genotypeâ€“phenotype landscapes with state-of-the-art predictive power. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	14
1109	Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity. <i>Vaccine</i> , 2022, 40, 4440-4452.	1.7	17
1110	Insertion-and-Deletion Mutations between the Genomes of SARS-CoV, SARS-CoV-2, and Bat Coronavirus RaTG13. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	11
1111	SARS-CoV-2: Two Years in the Pandemic: What Have We Observed from Genome Sequencing Results in Lithuania?. <i>Microorganisms</i> , 2022, 10, 1229.	1.6	0
1113	Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3. <i>Immunity</i> , 2022, 55, 1501-1514.e3.	6.6	59
1114	Effect of Norelgestromin and Ethinylestradiol in Transdermal Patches on the Clinical Outcomes and Biochemical Parameters of COVID-19 Patients: A Clinical Trial Pilot Study. <i>Pharmaceuticals</i> , 2022, 15, 757.	1.7	5
1116	CVIEW: A network based tool for enhanced alignment visualization. <i>PLoS ONE</i> , 2022, 17, e0259726.	1.1	1

#	ARTICLE	IF	CITATIONS
1117	Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19. <i>Viruses</i> , 2022, 14, 1349.	1.5	7
1119	Smartphone-Based SARS-CoV-2 and Variants Detection System using Colorimetric DNAzyme Reaction Triggered by Loop-Mediated Isothermal Amplification (LAMP) with Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). <i>ACS Nano</i> , 2022, 16, 11300-11314.	7.3	48
1120	Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines. <i>Journal of Virology</i> , 0, , .	1.5	3
1121	Using outbreak data to estimate the dynamic COVID-19 landscape in Eastern Africa. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	2
1122	Drivers of adaptive evolution during chronic SARS-CoV-2 infections. <i>Nature Medicine</i> , 2022, 28, 1501-1508.	15.2	81
1123	OMICRON: Virology, immunopathogenesis, and laboratory diagnosis. <i>Journal of Gene Medicine</i> , 2022, 24, .	1.4	33
1124	D,L-Lysine-Acetylsalicylate + Glycine (LASAG) Reduces SARS-CoV-2 Replication and Shows an Additive Effect with Remdesivir. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6880.	1.8	1
1125	Lessons from SARS-CoV-2 and its variants (Review). <i>Molecular Medicine Reports</i> , 2022, 26, .	1.1	5
1126	The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta variants: A computational approach. <i>Microbial Pathogenesis</i> , 2022, 169, 105619.	1.3	4
1127	Therapeutics to tackle Omicron outbreak. <i>Immunotherapy</i> , 2022, 14, 833-838.	1.0	22
1128	Insights from a computational analysis of the SARS-CoV-2 Omicron variant: Host-pathogen interaction, pathogenicity, and possible drug therapeutics. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	7
1129	Analysis of the competition among viral strains using a temporal interaction-driven contagion model. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
1130	Clinical and Genetic Characteristics of Coronaviruses with Particular Emphasis on SARS-CoV-2 Virus. <i>Polish Journal of Microbiology</i> , 2022, 71, 141-159.	0.6	0
1132	A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program. <i>Future Virology</i> , 0, , .	0.9	4
1133	Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 72, 128867.	1.0	5
1134	A time-motion study of the COVID-19 vaccination process in an urban primary health center of Odisha, India. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
1135	Superimmunity by pan-sarbecovirus nanobodies. <i>Cell Reports</i> , 2022, 39, 111004.	2.9	13
1136	Microbiome Analysis for Wastewater Surveillance during COVID-19. <i>MBio</i> , 2022, 13, .	1.8	40

#	ARTICLE	IF	CITATIONS
1137	The Impact of COVID-19 Pandemic on Seafood Safety and Human Health. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	6
1140	Jigsaw puzzle of SARS-CoV-2 RBD evolution and immune escape. , 2022, 19, 848-851.		9
1142	From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1704-1714.	2.5	15
1143	Sequential HCoV-HKU1 and SARS-CoV-2 Infections, a Case Report. <i>Journal of Medical Microbiology and Infectious Diseases</i> , 2022, 10, 93-97.	0.1	0
1144	Clinical Severity of SARS-CoV-2 Omicron Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and Winter Season 2021â€“2022. <i>Viruses</i> , 2022, 14, 1297.	1.5	41
1145	First report on genome wide association study in western Indian population reveals host genetic factors for COVID-19 severity and outcome. <i>Genomics</i> , 2022, 114, 110399.	1.3	3
1146	Structural basis of Omicron immune evasion: A comparative computational study. <i>Computers in Biology and Medicine</i> , 2022, 147, 105758.	3.9	6
1147	Epitope identification of SARS-CoV-2 structural proteins using in silico approaches to obtain a conserved rational immunogenic peptide. <i>Immunoinformatics</i> , 2022, 7, 100015.	1.2	1
1148	Bioluminescent and Fluorescent Reporter-Expressing Recombinant SARS-CoV-2. <i>Methods in Molecular Biology</i> , 2022, , 235-248.	0.4	3
1149	Broadly Neutralizing Antibodies Against Omicron Variants of SARS-CoV-2 Derived from mRNA-Lipid Nanoparticle-Immunized Mice. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1150	Covid-19 and Parkinson's disease: Nursing care, vaccination and impact on advanced therapies. <i>International Review of Neurobiology</i> , 2022, , 173-196.	0.9	5
1152	An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entry. <i>Emerging Microbes and Infections</i> , 2022, 11, 1920-1935.	3.0	7
1153	Genome sequence diversity of SARS-CoV-2 obtained from clinical samples in Uzbekistan. <i>PLoS ONE</i> , 2022, 17, e0270314.	1.1	4
1154	Conserved 3â€™ UTR of Severe Acute Respiratory Syndrome Coronavirus 2: Potential Therapeutic Targets. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
1155	Differential Dynamics of Humoral and Cell-Mediated Immunity with Three Doses of BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers in Japan: A Prospective Cohort Study. <i>Vaccines</i> , 2022, 10, 1050.	2.1	3
1156	Chest CT Findings in Hospitalized Patients with SARS-CoV-2: Delta versus Omicron Variants. <i>Radiology</i> , 2023, 306, 252-260.	3.6	33
1157	Projecting the SARS-CoV-2 transition from pandemicity to endemicity: Epidemiological and immunological considerations. <i>PLoS Pathogens</i> , 2022, 18, e1010591.	2.1	20
1158	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59

#	ARTICLE	IF	CITATIONS
1159	Spike Protein Cleavage-Activation in the Context of the SARS-CoV-2 P681R Mutation: an Analysis from Its First Appearance in Lineage A.23.1 Identified in Uganda. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	20
1160	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. <i>Journal of Clinical Oncology</i> , 2022, 40, 3808-3816.	0.8	19
1161	Catwalk: identifying closely related sequences in large microbial sequence databases. <i>Microbial Genomics</i> , 2022, 8, .	1.0	0
1162	Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant. <i>Communications Medicine</i> , 2022, 2, .	1.9	11
1163	Comparison of CT findings of coronavirus disease 2019 (COVID-19) pneumonia caused by different major variants. <i>Japanese Journal of Radiology</i> , 2022, 40, 1246-1256.	1.0	5
1164	Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	9
1166	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	28
1167	A broad and potent neutralization epitope in SARS-related coronaviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	34
1168	Ab-CoV: a curated database for binding affinity and neutralization profiles of coronavirus-related antibodies. <i>Bioinformatics</i> , 2022, 38, 4051-4052.	1.8	1
1169	COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme. <i>Journal of Clinical Microbiology</i> , 2022, 60, .	1.8	18
1170	SARS-CoV-2 Seroprevalence: Demographic and Behavioral Factors Associated With Seropositivity Among College Students in a University Setting. <i>Journal of Adolescent Health</i> , 2022, 71, 559-569.	1.2	3
1171	Metabolite, protein, and tissue dysfunction associated with COVID-19 disease severity. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
1172	Dynamics of the interaction between the receptor-binding domain of SARS-CoV-2 Omicron (B.1.1.529) variant and human angiotensin-converting enzyme 2. <i>PeerJ</i> , 0, 10, e13680.	0.9	1
1173	Current state of COVID-19 in pregnancy. <i>Gynecology</i> , 2022, 24, 206-211.	0.1	0
1174	Development, analysis, and preclinical evaluation of inactivated vaccine candidate for prevention of Covid-19 disease. <i>International Journal of Transgender Health</i> , 2022, 15, 771-793.	1.1	1
1175	Pseudoscience and fraudulent products for COVID-19 management. <i>Environmental Science and Pollution Research</i> , 2022, 29, 62887-62912.	2.7	15
1176	Raman Fingerprints of the SARS-CoV-2 Delta Variant and Mechanisms of Its Instantaneous Inactivation by Silicon Nitride Bioceramics. <i>ACS Infectious Diseases</i> , 2022, 8, 1563-1581.	1.8	7
1178	Viral variant-resolved wastewater surveillance of SARS-CoV-2 at national scale. <i>Nature Biotechnology</i> , 2022, 40, 1814-1822.	9.4	82

#	ARTICLE	IF	CITATIONS
1179	â€œMutation blacklistâ€ and â€œmutation whitelistâ€ of SARS-CoV-2. <i>Journal of Biosafety and Biosecurity</i> , 2022, 4, 114-120.	1.4	4
1180	The Mutational Landscape of SARS-CoV-2 Variants of Concern Recovered From Egyptian Patients in 2021. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
1182	In vitro evolution predicts emerging SARS-CoV-2 mutations with high affinity for ACE2 and cross-species binding. <i>PLoS Pathogens</i> , 2022, 18, e1010733.	2.1	28
1183	Identifying Markers of Emerging SARS-CoV-2 Variants in Patients With Secondary Immunodeficiency. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	6
1184	Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies. <i>Nature Communications</i> , 2022, 13, .	5.8	14
1185	Two years of COVID-19: Challenges, opportunities and the way forward. <i>Indian Journal of Microbiology Research</i> , 2022, 9, 114-118.	0.0	0
1186	Virtual Screening of Repurposed Drugs as Potential Spike Protein Inhibitors of Different SARS-CoV-2 Variants: Molecular Docking Study. <i>Current Issues in Molecular Biology</i> , 2022, 44, 3018-3029.	1.0	6
1187	Phylogenetic analysis and comparative genomics of SARS-CoV-2 from survivor and non-survivor COVID-19 patients in Cordoba, Argentina. <i>BMC Genomics</i> , 2022, 23, .	1.2	2
1188	Buckling up against COVID-19 after CAR T-cell therapy. <i>Blood</i> , 2022, 140, 85-87.	0.6	2
1189	Wastewater surveillance allows early detection of SARS-CoV-2 omicron in North Rhine-Westphalia, Germany. <i>Science of the Total Environment</i> , 2022, 846, 157375.	3.9	13
1190	The T Cell Epitope Landscape of SARS-CoV-2 Variants of Concern. <i>Vaccines</i> , 2022, 10, 1123.	2.1	4
1191	SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. <i>Cell Host and Microbe</i> , 2022, 30, 1231-1241.e6.	5.1	55
1192	Efficient compression of SARS-CoV-2 genome data using Nucleotide Archival Format (NAF). <i>Patterns</i> , 2022, , 100562.	3.1	1
1193	The complex evolutionary dynamics of SARSâ€CoVâ€2, a big challenge to control the pandemic of COVIDâ€19. <i>Journal of Medical Virology</i> , 2022, 94, 5082-5085.	2.5	2
1194	The role of multi-omics in the diagnosis of COVID-19 and the prediction of new therapeutic targets. <i>Virulence</i> , 2022, 13, 1101-1110.	1.8	7
1196	Clinical grade <sc>ACE2</sc> as a universal agent to block <sc>SARSâ€CoV</sc> â€2 variants. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	35
1197	A booster dose of Deltaâ€%Ã—â€%Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	42
1198	Impact of the temperature on the interactions between common variants of the SARS-CoV-2 receptor binding domain and the human ACE2. <i>Scientific Reports</i> , 2022, 12, .	1.6	7

#	ARTICLE	IF	CITATIONS
1199	Long-COVID in immunocompromised children. <i>European Journal of Pediatrics</i> , 2022, 181, 3501-3509.	1.3	12
1200	Suppression of SARS-CoV-2 Replication with Stabilized and Click-Chemistry Modified siRNAs. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	6
1202	Insertions and Deletions (Indels): A Missing Piece of the Protein Engineering Jigsaw. <i>Biochemistry</i> , 2023, 62, 148-157.	1.2	13
1204	A herd immunity approach to the COVID-19 pandemic?. <i>Health and Technology</i> , 0, , .	2.1	2
1205	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	6
1206	Exposure modality influences viral kinetics but not respiratory outcome of COVID-19 in multiple nonhuman primate species. <i>PLoS Pathogens</i> , 2022, 18, e1010618.	2.1	5
1207	Specific CD4+ T Cell Responses to Ancestral SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to Beta Variant. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1208	Continent-wide evolutionary trends of emerging SARS-CoV-2 variants: dynamic profiles from Alpha to Omicron. <i>GeroScience</i> , 2022, 44, 2371-2392.	2.1	9
1209	Neutralization of ARCoV-induced sera against SARS-CoV-2 variants. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
1210	New discovery of high-affinity SARS-CoV-2 spike S2 protein binding peptide selected by PhIP-Seq. <i>Virologica Sinica</i> , 2022, 37, 758-761.	1.2	0
1211	Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults. <i>Nature Communications</i> , 2022, 13, .	5.8	43
1212	Toehold-controlled ligation and transcription for accurate COVID-19 genotyping. <i>Analytical Biochemistry</i> , 2022, 654, 114803.	1.1	1
1213	Relatively rapid evolution rates of SARS-CoV-2 spike gene at the primary stage of massive vaccination. <i>Biosafety and Health</i> , 2022, 4, 228-233.	1.2	6
1214	Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. <i>Nature Microbiology</i> , 2022, 7, 1180-1188.	5.9	39
1215	Novel Lateral Flow-Based Assay for Simple and Visual Detection of SARS-CoV-2 Mutations. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	1
1216	Suppression of SARS-CoV-2 Replication with Stabilized and Click-Chemistry Modified siRNAs. <i>Angewandte Chemie</i> , 0, , .	1.6	0
1217	Respuesta inmune humoral a cuatro vacunas contra el SARS-CoV-2 en profesionales de la salud. <i>Horizonte Mdico</i> , 2022, 22, e1937.	0.1	0
1218	Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein. <i>Drug Discovery Today</i> , 2022, 27, 103312.	3.2	13

#	ARTICLE	IF	CITATIONS
1219	Adverse Impacts of Temporomandibular Disorders Symptoms and Tooth Loss on Psychological States and Oral Health-Related Quality of Life During the COVID-19 Pandemic Lockdown. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
1220	Mutations in SARS-CoV-2 are on the increase against the acquired immunity. <i>PLoS ONE</i> , 2022, 17, e0271305.	1.1	17
1221	Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope. <i>Cell</i> , 2022, 185, 2936-2951.e19.	13.5	47
1223	Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities. <i>Science Advances</i> , 2022, 8, .	4.7	27
1224	Lack of Difference in Tocilizumab Efficacy in the Treatment of Severe COVID-19 Caused by Different SARS-CoV-2 Variants. <i>Journal of Personalized Medicine</i> , 2022, 12, 1103.	1.1	3
1225	Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein. <i>Antibody Therapeutics</i> , 2022, 5, 177-191.	1.2	6
1226	Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission. <i>Nature</i> , 2022, 609, 101-108.	13.7	200
1229	Rapid displacement of SARS-CoV-2 variant Delta by Omicron revealed by allele-specific PCR in wastewater. <i>Water Research</i> , 2022, 221, 118809.	5.3	30
1230	Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. <i>EBioMedicine</i> , 2022, 82, 104158.	2.7	128
1231	In-silico screening and in-vitro assay show the antiviral effect of Indomethacin against SARS-CoV-2. <i>Computers in Biology and Medicine</i> , 2022, 147, 105788.	3.9	10
1232	A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera. <i>Antiviral Research</i> , 2022, 204, 105370.	1.9	16
1233	MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies. <i>Life Sciences</i> , 2022, 305, 120761.	2.0	23
1234	A severe presentation of breakthrough infection caused by the Omicron variant with radiological findings of COVID-19 pneumonia in an elderly woman. <i>Radiology Case Reports</i> , 2022, 17, 3326-3330.	0.2	2
1235	Coronaviruses. , 2023, , 277-306.		0
1237	Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic. <i>Cancers</i> , 2022, 14, 3598.	1.7	7
1238	Histopathological and Immunological Findings in the Common Marmoset Following Exposure to Aerosolized SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1580.	1.5	2
1239	Knowledge, perception, and fear among the global population towards newly evoked variant Omicron (B.1.1.529). <i>PLoS ONE</i> , 2022, 17, e0270761.	1.1	4
1240	Insight into Genetic Characteristics of Identified SARS-CoV-2 Variants in Egypt from March 2020 to May 2021. <i>Pathogens</i> , 2022, 11, 834.	1.2	9

#	ARTICLE	IF	CITATIONS
1241	Potential association factors for developing effective peptide-based cancer vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1242	Genomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
1244	Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant. <i>Infection and Drug Resistance</i> , 0, Volume 15, 4013-4027.	1.1	4
1245	Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York. <i>EBioMedicine</i> , 2022, 82, 104141.	2.7	11
1246	SARS-CoV-2 and Emerging Foodborne Pathogens: Intriguing Commonalities and Obvious Differences. <i>Pathogens</i> , 2022, 11, 837.	1.2	0
1247	SARS-CoV-2â€™s Variants of Concern: A Brief Characterization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	31
1248	A strategy to optimize the peptide-based inhibitors against different mutants of the spike protein of SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 6191-6202.	2.0	2
1249	Characterization of binding interactions of SARS-CoV-2 spike protein and DNA-peptide nanostructures. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
1250	Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2. <i>Cell Host and Microbe</i> , 2022, 30, 1255-1268.e5.	5.1	45
1251	Design and finite element modeling of two-dimensional nanomechanical biosensors for SARS-CoV-2 detection. <i>Diamond and Related Materials</i> , 2022, 128, 109263.	1.8	1
1252	Omicron and vaccine booster dose â€™ an update. <i>Indian Journal of Community Health</i> , 2022, 34, 167-169.	0.1	1
1253	Carbohydrate prolectin-M, a galectin-3 antagonist, blocks SARS-CoV-2 activity. <i>International Journal of Health Sciences</i> , 0, , 6671-6683.	0.0	0
1254	(+)-Usnic acid and its salts, inhibitors of SARS-CoV-2, identified by using in silico methods and in vitro assay. <i>Scientific Reports</i> , 2022, 12, .	1.6	12
1255	Diagnostic Tools for Rapid Screening and Detection of SARS-CoV-2 Infection. <i>Vaccines</i> , 2022, 10, 1200.	2.1	9
1256	The First Identification in Italy of SARS-CoV-2 Omicron BA.4 Harboring KSF141_del: A Genomic Comparison with Omicron Sub-Variants. <i>Biomedicines</i> , 2022, 10, 1839.	1.4	3
1257	Perspective Chapter: Bioinformatics Study of the Evolution of SARS-CoV-2 Spike Protein. <i>Infectious Diseases</i> , 0, , .	4.0	0
1259	Clinical and Virological Features of Patients Hospitalized with Different Types of COVID-19 Vaccination in Mexico City. <i>Vaccines</i> , 2022, 10, 1181.	2.1	2
1260	Progress in Electrochemical Biosensing of SARS-CoV-2 Virus for COVID-19 Management. <i>Chemosensors</i> , 2022, 10, 287.	1.8	21

#	ARTICLE	IF	CITATIONS
1261	Dynamics of Viral Infection and Evolution of SARS-CoV-2 Variants in the Calabria Area of Southern Italy. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	10
1263	Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview. <i>Journal of Diabetes and Metabolic Disorders</i> , 2022, 21, 1763-1783.	0.8	4
1264	Contrasting Distribution of SARS-CoV-2 Lineages across Multiple Rounds of Pandemic Waves in West Bengal, the Gateway of East and North-East States of India. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	1
1265	Covariance predicts conserved protein residue interactions important for the emergence and continued evolution of SARS-CoV-2 as a human pathogen. <i>PLoS ONE</i> , 2022, 17, e0270276.	1.1	1
1266	Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1267	Removal of clinically relevant SARS-CoV-2 variants by an affinity resin containing <i>Galanthus nivalis</i> agglutinin. <i>PLoS ONE</i> , 2022, 17, e0272377.	1.1	4
1268	Replacement of the Alpha variant of SARS-CoV-2 by the Delta variant in Lebanon between April and June 2021. <i>Microbial Genomics</i> , 2022, 8, .	1.0	8
1269	Recurrent SARS-CoV-2 mutations in immunodeficient patients. <i>Virus Evolution</i> , 2022, 8, .	2.2	53
1270	Common Indications and Techniques in Prenatal MRI. , 0, , .		1
1272	Early Isolates of SARS-CoV-2 Result in Different Pathogenesis in the Transduced Mouse Model of COVID-19. <i>Viruses</i> , 2022, 14, 1769.	1.5	1
1273	A bibliometric analysis of the 100 most cited articles describing SARS-CoV-2 variants. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
1274	Immunological and Pathological Peculiarity of Severe Acute Respiratory Syndrome 2 Beta Variant. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	2
1275	Affinity of anti-spike antibodies to three major SARS-CoV-2 variants in recipients of three major vaccines. <i>Communications Medicine</i> , 2022, 2, .	1.9	3
1276	The SARS-CoV-2 Variants and their Impacts. <i>Journal of Pure and Applied Microbiology</i> , 2022, 16, 1409-1424.	0.3	3
1277	De novo emergence of SARS-CoV-2 spike mutations in immunosuppressed patients. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	9
1278	Surface charge changes in spike RBD mutations of SARS-CoV-2 and its variant strains alter the virus evasiveness via HSPGs: A review and mechanistic hypothesis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	7
1279	COVID-19 and vaccination: myths vs science. <i>Expert Review of Vaccines</i> , 2022, 21, 1603-1620.	2.0	23
1280	Virtual screening reveals liquiritigenin as a broad-spectrum inhibitor of SARS-CoV-2 variants of concern: an <i>in silico</i> study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 6709-6727.	2.0	2

#	ARTICLE	IF	CITATIONS
1281	COVID-19 and pregnancy: clinical outcomes; mechanisms, and vaccine efficacy. <i>Translational Research</i> , 2023, 251, 84-95.	2.2	14
1282	Human coronaviruses disassemble processing bodies. <i>PLoS Pathogens</i> , 2022, 18, e1010724.	2.1	9
1284	Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. <i>Cell Host and Microbe</i> , 2022, 30, 1242-1254.e6.	5.1	27
1285	Review of concerned SARS-CoV-2 variants like Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529), as well as novel methods for reducing and inactivating SARS-CoV-2 mutants in wastewater treatment facilities. <i>Journal of Hazardous Materials Advances</i> , 2022, 7, 100140.	1.2	10
1286	Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1287	A spatial vaccination strategy to reduce the risk of vaccine-resistant variants. <i>PLoS Computational Biology</i> , 2022, 18, e1010391.	1.5	8
1288	PEDOT:PSS in Solution Form Exhibits Strong Potential in Inhibiting SARS-CoV-2 Infection of the Host Cells by Targeting Viruses and Also the Host Cells. <i>Biomacromolecules</i> , 2022, 23, 3535-3548.	2.6	4
1289	Effects of boosted mRNA and adenoviralâ€¢vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination. <i>Journal of Medical Virology</i> , 2022, 94, 5713-5722.	2.5	23
1290	Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease. <i>Communications Biology</i> , 2022, 5, .	2.0	15
1292	Interactions between heparin and SARS-CoV-2 spike glycoprotein RBD from omicron and other variants. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	11
1293	A Comparative Study of the Plasma Chemokine Profile in COVID-19 Patients Infected with Different SARS-CoV-2 Variants. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9058.	1.8	14
1294	Differentiation of SARS-CoV-2 Variants Using RT-qPCRs by Targeting Recurrent Mutation Sites: A Diagnostic Laboratory Experience from Multi-Center Regional Study, August 2020â€¢December 2021, Poland. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9416.	1.8	8
1295	Epidemiologic characteristics of SARS-CoV-2 in Wuhan, other regions of China, and globally based on data gathered from January 2020 to February 2021. <i>Medicine (United States)</i> , 2022, 101, e30019.	0.4	3
1296	Structural bases for the higher adherence to ACE2 conferred by the SARS-CoV-2 spike Q498Y substitution. <i>Acta Crystallographica Section D: Structural Biology</i> , 2022, 78, 1156-1170.	1.1	2
1297	B.1.1.7 (Alpha) variant is the most antigenic compared to Wuhan strain, B.1.351, B.1.1.28/triple mutant and B.1.429 variants. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
1300	Identification and semisynthesis of (â€¢)-anisomelic acid as oral agent against SARS-CoV-2 in mice. <i>National Science Review</i> , 2022, 9, .	4.6	1
1302	Improved SARS-CoV-2 sequencing surveillance allows the identification of new variants and signatures in infected patients. <i>Genome Medicine</i> , 2022, 14, .	3.6	12
1303	In Vitro Evaluation and Mitigation of Niclosamideâ€¢Liabilities as a COVID-19 Treatment. <i>Vaccines</i> , 2022, 10, 1284.	2.1	3

#	ARTICLE	IF	CITATIONS
1304	Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1565-1576.	4.6	55
1305	IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	15
1306	Manifestation of SARS-CoV-2 Infections in Mink Related to Host-, Virus- and Farm-Associated Factors, The Netherlands 2020. <i>Viruses</i> , 2022, 14, 1754.	1.5	8
1308	Impact of SARS-CoV-2 RBD Mutations on the Production of a Recombinant RBD Fusion Protein in Mammalian Cells. <i>Biomolecules</i> , 2022, 12, 1170.	1.8	2
1310	Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer. <i>British Journal of Cancer</i> , 2022, 127, 1787-1792.	2.9	3
1311	Structural analysis of Spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations. <i>Future Virology</i> , 2022, 17, 723-732.	0.9	7
1312	The Omicron variant of concern: The genomics, diagnostics, and clinical characteristics in children. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	19
1313	Evolution of Stronger SARS-CoV-2 Variants as Revealed Through the Lens of Molecular Dynamics Simulations. <i>Protein Journal</i> , 2022, 41, 444-456.	0.7	4
1317	Infections with the SARS-CoV-2 Delta variant exhibit fourfold increased viral loads in the upper airways compared to Alpha or non-variants of concern. <i>Scientific Reports</i> , 2022, 12, .	1.6	26
1318	Lineage BA.2 Dominated the Omicron SARS-CoV-2 Epidemic Wave in the Philippines. <i>Virus Evolution</i> , 0, , .	2.2	2
1319	Production of single-cycle infectious SARS-CoV-2 through a trans-complemented replicon. <i>Journal of Medical Virology</i> , 2022, 94, 6078-6090.	2.5	4
1320	COVID-19 vaccine design and vaccination strategy for emerging variants. <i>Expert Review of Vaccines</i> , 2022, 21, 1359-1361.	2.0	10
1321	Clinical characteristics of 310 SARS-CoV-2 Omicron variant patients and comparison with Delta and Beta variant patients in China. <i>Virologica Sinica</i> , 2022, 37, 704-715.	1.2	15
1322	Tracing the origin of Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2): A systematic review and narrative synthesis. <i>Journal of Medical Virology</i> , 0, , .	2.5	3
1324	Design and Immunoinformatic Assessment of Candidate Multivalent mRNA Vaccine Construct against Immune Escape Variants of SARS-CoV-2. <i>Polymers</i> , 2022, 14, 3263.	2.0	3
1325	Unsupervised clustering of SARS-CoV-2 using deep convolutional autoencoder. <i>Journal of Engineering and Applied Science</i> , 2022, 69, .	0.8	6
1326	Single-Nanoparticle-Based Digital SERS Sensing Platform for the Accurate Quantitative Detection of SARS-CoV-2. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 38459-38470.	4.0	13
1327	SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization. <i>Nature Communications</i> , 2022, 13, .	5.8	34

#	ARTICLE	IF	CITATIONS
1328	Strain wars 5: Gibbs energies of binding of BA.1 through BA.4 variants of SARS-CoV-2. <i>Microbial Risk Analysis</i> , 2022, 22, 100231.	1.3	11
1329	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. <i>Nature Communications</i> , 2022, 13, .	5.8	27
1330	Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections. <i>Nature Communications</i> , 2022, 13, .	5.8	54
1331	Observation of SARS-CoV-2 genome characteristics and clinical manifestations within eight family clusters from GH and GK clades in Jakarta, Indonesia. <i>F1000Research</i> , 0, 11, 886.	0.8	0
1332	How Did the COVID-19 Pandemic Affect Population Mobility in Taiwan?. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10559.	1.2	5
1333	Plant-based bioactive molecules for targeting of endoribonuclease using steered molecular dynamic simulation approach: a highly conserved therapeutic target against variants of SARS-CoV-2. <i>Molecular Simulation</i> , 2023, 49, 1267-1279.	0.9	9
1334	The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development. <i>Vaccines</i> , 2022, 10, 1346.	2.1	4
1336	Structural and Phylogenetic Analysis of SARS-CoV-2 Spike Glycoprotein from the Most Widespread Variants. <i>Life</i> , 2022, 12, 1245.	1.1	7
1337	Scope of repurposed drugs against the potential targets of the latest variants of SARS-CoV-2. <i>Structural Chemistry</i> , 2022, 33, 1585-1608.	1.0	6
1338	Core fucose-specific <i>Pholiota squarrosa</i> lectin (PhoSL) as a potent broad-spectrum inhibitor of SARS-CoV-2 infection. <i>FEBS Journal</i> , 2023, 290, 412-427.	2.2	4
1339	SCORE: SARS-CoV-2 Omicron Variant RBD-Binding DNA Aptamer for Multiplexed Rapid Detection and Pseudovirus Neutralization. <i>Analytical Chemistry</i> , 2022, 94, 12683-12690.	3.2	12
1340	Differential effect of SARS-CoV-2 infection on stress granule formation in Vero and Calu-3 cells. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	11
1341	SARS-CoV-2 Papain-Like Protease: Structure, Function and Inhibition. <i>ChemBioChem</i> , 2022, 23, .	1.3	26
1342	SARS-CoV-2 Viroporins: A Multi-Omics Insight from Nucleotides to Amino Acids. <i>Applied Microbiology</i> , 2022, 2, 572-593.	0.7	1
1343	The Flexible, Extended Coil of the PDZ-Binding Motif of the Three Deadly Human Coronavirus E Proteins Plays a Role in Pathogenicity. <i>Viruses</i> , 2022, 14, 1707.	1.5	3
1344	Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 5678-5690.	2.5	16
1345	Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection. <i>Cell Reports Medicine</i> , 2022, 3, 100735.	3.3	29
1346	Considering epitopes conservity in targeting SARS-CoV-2 mutations in variants: a novel immunoinformatics approach to vaccine design. <i>Scientific Reports</i> , 2022, 12, .	1.6	6

#	ARTICLE	IF	CITATIONS
1347	A study protocol to prepare an RBD protein for vaccine against COVID-19. <i>F1000Research</i> , 0, 10, 943.	0.8	0
1348	Temporal lineage replacements and dominance of imported variants of concern during the COVID-19 pandemic in Kenya. <i>Communications Medicine</i> , 2022, 2, .	1.9	4
1349	SARS-CoV-2 immunity and vaccine strategies in people with HIV. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	12
1350	Sequencing and mutations analysis of the first recorded SARS-CoV-2 Omicron variant during the fourth wave of pandemic in Iraq. <i>Brazilian Journal of Infectious Diseases</i> , 2022, 26, 102677.	0.3	2
1351	Accuracy of Allplex SARS-CoV-2 assay amplification curve analysis for the detection of SARS-CoV-2 variant Alpha. <i>Future Microbiology</i> , 2022, 17, 1125-1131.	1.0	3
1352	An extracellular matrix biosensing mimetic for evaluating cathepsin as a host target for COVID-19. <i>Analytica Chimica Acta</i> , 2022, 1225, 340267.	2.6	0
1353	Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern. <i>IScience</i> , 2022, 25, 104935.	1.9	8
1354	Selective reversed-phase high-performance liquid chromatography method for the determination of intact SARS-CoV-2 spike protein. <i>Journal of Chromatography A</i> , 2022, 1680, 463424.	1.8	2
1355	Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. <i>International Journal of Biological Macromolecules</i> , 2022, 219, 980-997.	3.6	28
1356	Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant. <i>Journal of Clinical Virology</i> , 2022, 155, 105253.	1.6	6
1357	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. <i>International Immunopharmacology</i> , 2022, 111, 109128.	1.7	9
1358	The next frontier in vaccine design: blending immune correlates of protection into rational vaccine design. <i>Current Opinion in Immunology</i> , 2022, 78, 102234.	2.4	4
1359	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522.	2.5	56
1360	Decoding molecular factors shaping human angiotensin converting enzyme 2 receptor usage by spike glycoprotein in lineage B beta-coronaviruses. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166514.	1.8	2
1361	Delta SARS-CoV-2 inactivation and bactericidal performance of cotton wipes decorated with TiO ₂ /Ag nanoparticles like Brazilian heavy-fruited <i>Myrciaria cauliflora</i> . <i>Materials Today Communications</i> , 2022, 33, 104288.	0.9	3
1362	Exploiting reverse vaccinology approach for the design of a multiepitope subunit vaccine against the major SARS-CoV-2 variants. <i>Computational Biology and Chemistry</i> , 2022, 101, 107754.	1.1	7
1363	Large interfacial relocation in RBD-ACE2 complex may explain fast-spreading property of Omicron. <i>Journal of Molecular Structure</i> , 2022, 1270, 133842.	1.8	0
1364	Electrochemical paper-based antigen sensing platform using plant-derived monoclonal antibody for detecting SARS-CoV-2. <i>Talanta</i> , 2023, 251, 123783.	2.9	18

#	ARTICLE	IF	CITATIONS
1365	Biosynthetic proteins targeting the SARS-CoV-2 spike as anti-virals. <i>PLoS Pathogens</i> , 2022, 18, e1010799.	2.1	2
1366	SARS-CoV-2 and COVID-19: A Narrative Review. , 0, 79, .		9
1367	Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. <i>Nature Chemical Biology</i> , 2022, 18, 1270-1276.	3.9	8
1368	Regional importation and asymmetric within-country spread of SARS-CoV-2 variants of concern in the Netherlands. <i>ELife</i> , 0, 11, .	2.8	12
1369	COVID-19 diverse outcomes: Aggravated reinfection, type I interferons and antibodies. <i>Medical Hypotheses</i> , 2022, 167, 110943.	0.8	1
1370	Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1422-1423.	4.6	22
1371	Molecular dynamics simulations highlight the altered binding landscape at the spike-ACE2 interface between the Delta and Omicron variants compared to the SARS-CoV-2 original strain. <i>Computers in Biology and Medicine</i> , 2022, 149, 106035.	3.9	14
1372	Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis. <i>Respiratory Medicine</i> , 2022, 202, 106986.	1.3	6
1373	Genomic and epidemiologic surveillance of SARS-CoV-2 in Southern Brazil and identification of a new Omicron-L452R sublineage. <i>Virus Research</i> , 2022, 321, 198907.	1.1	8
1374	Sustainable policy: Don't get infected and don't infect others. <i>Journal of Hazardous Materials Advances</i> , 2022, 8, 100165.	1.2	4
1375	Genomic surveillance: Circulating lineages and genomic variation of SARS-CoV-2 in early pandemic in Cear� state, Northeast Brazil. <i>Virus Research</i> , 2022, 321, 198908.	1.1	2
1376	A 21L/BA.2-21K/BA.1 ��MixOmicron��SARS-CoV-2 hybrid undetected by qPCR that screen for variant in routine diagnosis. <i>Infection, Genetics and Evolution</i> , 2022, 105, 105360.	1.0	5
1377	Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes. <i>Biochemical and Biophysical Research Communications</i> , 2022, 629, 54-60.	1.0	22
1378	Development of multiplex S-gene-targeted RT-PCR for rapid identification of SARS-CoV-2 variants by extended S-gene target failure. <i>Clinica Chimica Acta</i> , 2022, 536, 6-11.	0.5	4
1379	Omicron variant: Current insights and future directions. <i>Microbiological Research</i> , 2022, 265, 127204.	2.5	32
1380	Beyond COVID-19: Do biothermodynamic properties allow predicting the future evolution of SARS-CoV-2 variants?. <i>Microbial Risk Analysis</i> , 2022, 22, 100232.	1.3	13
1381	Evolution of Long-Term Hybrid Immunity in Healthcare Workers after Different Covid-19 Vaccination Regimens: A Longitudinal Observational Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
1382	Emergence of COVID-19 Variants and Its Global Impact. , 2022, , 183-201.		1

#	ARTICLE	IF	CITATIONS
1383	Analysis of SARS-CoV-2 Mutations in the Context of Epitope Affinity for HLA Class I and Class II Most Frequent in Russia Alleles. <i>Re:GEN Open</i> , 2022, 2, 75-84.	0.7	0
1384	Nanoluciferase-based cell fusion assay for rapid and high-throughput assessment of SARS-CoV-2-neutralizing antibodies in patient samples. <i>Methods in Enzymology</i> , 2022, , 351-381.	0.4	2
1385	Distinct core glycan and <i>O</i> -glycoform utilization of SARS-CoV-2 Omicron variant Spike protein RBD revealed by top-down mass spectrometry. <i>Chemical Science</i> , 2022, 13, 10944-10949.	3.7	13
1386	RBD spatial orientation of the spike protein and its binding to ACE2: insight into the high infectivity of the SARS-CoV-2 Delta variant from MD simulations. <i>Physical Chemistry Chemical Physics</i> , 0, , .	1.3	2
1387	Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines. <i>International Journal of Biological Sciences</i> , 2022, 18, 4781-4791.	2.6	5
1388	Using Molecular Visualisation Techniques to Explain the Molecular Biology of SARS-CoV-2 Spike Protein Mutations to a General Audience. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 129-152.	0.8	1
1389	Dynamic Single-Cell RNA Sequencing Reveals that Intravenous BCG Vaccination Curtails SARS-CoV-2 Induced Disease Severity and Lung Inflammation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1390	Global Coronavirus Pandemic Crisis. <i>Springer Texts in Business and Economics</i> , 2022, , 89-128.	0.2	0
1391	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
1392	The diverse role of heparan sulfate and other GAGs in SARS-CoV-2 infections and therapeutics. <i>Carbohydrate Polymers</i> , 2023, 299, 120167.	5.1	8
1394	Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1396	Fatal Pneumonia Caused by Omicron Subvariant BA.2 of Severe Acute Respiratory Syndrome Coronavirus 2 with the Pulmonary Tuberculosis. <i>Korean Journal of Legal Medicine</i> , 2022, 46, 79-84.	0.1	1
1397	Early Detection of SARS-CoV-2 Omicron BA.4 and BA.5 in German Wastewater. <i>Viruses</i> , 2022, 14, 1876.	1.5	12
1398	Applications of Molecular Dynamics Simulation in Protein Study. <i>Membranes</i> , 2022, 12, 844.	1.4	18
1399	An Ultrasensitive, One-Pot RNA Detection Method Based on Rationally Engineered Cas9 Nickase-Assisted Isothermal Amplification Reaction. <i>Analytical Chemistry</i> , 2022, 94, 12461-12471.	3.2	7
1400	Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2. <i>Journal of Microbiology and Biotechnology</i> , 2022, 32, 1073-1085.	0.9	2
1401	Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice. <i>ACS Omega</i> , 2022, 7, 31935-31944.	1.6	11
1402	Genomic epidemiology and emergence of SARS-CoV-2 variants of concern in the United Arab Emirates. <i>Scientific Reports</i> , 2022, 12, .	1.6	4

#	ARTICLE	IF	CITATIONS
1403	The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19. <i>Annals of Internal Medicine</i> , 2022, 175, 1401-1410.	2.0	32
1404	Simultaneous measurement of the antibody responses against SARS-CoV-2 and its multiple variants by a phage display mediated immuno-multiplex quantitative PCR-based assay. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	3
1405	Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction from a Chemical Space of Privileged Protein Binders. <i>Pharmaceuticals</i> , 2022, 15, 1084.	1.7	5
1406	Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain. <i>Cell</i> , 2022, 185, 4008-4022.e14.	13.5	55
1407	Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1408	Using multiple sampling strategies to estimate SARS-CoV-2 epidemiological parameters from genomic sequencing data. <i>Nature Communications</i> , 2022, 13, .	5.8	10
1409	The evaluation of an automated <sc>point-of-care</sc> SARS-CoV-2 antigen test compared to <sc>RT-qPCR</sc> SARS-CoV-2 assay and comparison of its sensitivity in Delta and Omicron variant samples. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 1033-1039.	1.5	2
1410	The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness. <i>Scientific Reports</i> , 2022, 12, .	1.6	41
1411	Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	18
1413	Complementary and Alternative Medicine in COVID-19 Infection, an Old Weapon Against a New Enemy, , 0, , .		0
1414	Impacto de la variante de interÃs Mu en la pandemia de COVID-19 en Colombia. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2022, 54, .	0.0	0
1415	Comparison of clinical characteristics among patients infected with alpha vs. delta SARS-CoV-2 variants. <i>Wiener Klinische Wochenschrift</i> , 0, , .	1.0	0
1416	A Spotlight on Novel Coronavirus (COVID -19) with Various Types of Strains. <i>International Journal of Life Science and Pharma Research</i> , 0, , .	0.1	0
1417	When the Dust Has Settled: Calculation of Binding Affinities from First Principles for SARS-CoV-2 Variants with Quantitative Accuracy. <i>Journal of Chemical Theory and Computation</i> , 2022, 18, 5890-5900.	2.3	15
1418	Boosting the detection performance of severe acute respiratory syndrome coronavirus 2 test through a sensitive optical biosensor with new superior antibody. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	2
1419	A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1421	Drug repurposing and sequence analysis in S-glycoprotein variants reveals critical signature patterns and destabilization of receptor-binding domain in omicron variant. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 7931-7948.	2.0	0
1422	SARS-CoV-2 Spatiotemporal Genomic and Molecular Analysis of the First Wave of the COVID-19 Pandemic in Maca, the Brazilian Capital of Oil. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11497.	1.8	0

#	ARTICLE	IF	CITATIONS
1423	Binding of Glycans to the SARS CoVâ€2 Spike Protein, an Open Question: NMR Data on Binding Site Localization, Affinity, and Selectivity. <i>Chemistry - A European Journal</i> , 2022, 28, .	1.7	3
1425	Development of chemiluminescent labâ€onâ€fiber immunosensors for rapid pointâ€ofâ€care testing of antiâ€SARSâ€CoVâ€2 antibodies and evaluation of longitudinal immune response kinetics following threeâ€dose inactivation virus vaccination. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
1426	The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines. <i>IScience</i> , 2022, 25, 105016.	1.9	2
1427	Mutations in SARS-CoV-2 nucleocapsid in variants of concern impair the sensitivity of SARS-CoV-2 detection by rapid antigen tests. <i>Frontiers in Virology</i> , 0, 2, .	0.7	3
1429	Tracing the trajectories of SARS-CoV-2 variants of concern between December 2020 and September 2021 in the Canary Islands (Spain). <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	3
1431	SARS-CoV-2 Variant Surveillance in Genomic Medicine Era. <i>Infectious Diseases</i> , 0, , .	4.0	0
1432	Panâ€coronavirus fusion inhibitors to combat COVIDâ€19 and other emerging coronavirus infectious diseases. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	10
1433	The importance of LDH/Albumin, LDH/Lymphocyte, and LDH/Platelet ratios in the evaluation of COVID-19 B.1.1.7 variant. <i>Biyokimya Dergisi</i> , 2022, .	0.1	0
1434	SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. <i>Vaccines</i> , 2022, 10, 1538.	2.1	12
1435	Molecular characterization of a new SARS-CoV-2 recombinant cluster XAG identified in Brazil. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	6
1436	SARS-CoV-2 infects adipose tissue in a fat depot- and viral lineage-dependent manner. <i>Nature Communications</i> , 2022, 13, .	5.8	27
1437	A study protocol to prepare an RBD protein for vaccine against COVID-19. <i>F1000Research</i> , 0, 10, 943.	0.8	0
1438	Probing the mutational landscape of the SARS-CoV-2 spike protein via quantum mechanical modeling of crystallographic structures. , 2022, 1, .		3
1440	SARS-CoV-2 Variants Identification: Overview of Molecular Existing Methods. <i>Pathogens</i> , 2022, 11, 1058.	1.2	20
1443	Tracking mutational semantics of SARS-CoV-2 genomes. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1444	Proteomicsâ€based mass spectrometry profiling of SARSâ€CoVâ€2 infection from human nasopharyngeal samples. <i>Mass Spectrometry Reviews</i> , 2024, 43, 193-229.	2.8	2
1445	Single-Cell Infection of Influenza A Virus Using Drop-Based Microfluidics. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	5
1446	Designing multi-epitope based peptide vaccine targeting spike protein SARS-CoV-2 B1.1.529 (Omicron) variant using computational approaches. <i>Structural Chemistry</i> , 2022, 33, 2243-2260.	1.0	6

#	ARTICLE	IF	CITATIONS
1447	Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
1448	Translation landscape of SARS-CoV-2 noncanonical subgenomic RNAs. <i>Virologica Sinica</i> , 2022, 37, 813-822.	1.2	4
1449	MVsim is a toolset for quantifying and designing multivalent interactions. <i>Nature Communications</i> , 2022, 13, .	5.8	1
1450	Anti-SARS-CoV-2 and anticoagulant properties of <i>Pentacta pygmaea</i> fucosylated chondroitin sulfate depend on high molecular weight structures. <i>Glycobiology</i> , 2023, 33, 75-85.	1.3	10
1451	Single-Cell Gene Expression Analysis Revealed Immune Cell Signatures of Delta COVID-19. <i>Cells</i> , 2022, 11, 2950.	1.8	1
1453	Analysis of COVID-19 in India using a vaccine epidemic model incorporating vaccine effectiveness and herd immunity. <i>European Physical Journal Plus</i> , 2022, 137, .	1.2	5
1454	Biophysical and Biochemical Characterization of the Receptor Binding Domain of SARS-CoV-2 Variants. <i>Protein Journal</i> , 2022, 41, 457-467.	0.7	0
1455	In-silico investigation of systematic missense mutations of middle east respiratory coronavirus spike protein. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	2
1456	Molecular Characterization of Whole-Genome SARS-CoV-2 from the First Suspected Cases of the XE Variant in the Lazio Region, Italy. <i>Diagnostics</i> , 2022, 12, 2219.	1.3	0
1457	COVID-19 immunopathology: From acute diseases to chronic sequelae. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	24
1458	Molecular Analyses of Clinical Isolates and Recombinant SARS-CoV-2 Carrying B.1 and B.1.617.2 Spike Mutations Suggest a Potential Role of Non-Spike Mutations in Infection Kinetics. <i>Viruses</i> , 2022, 14, 2017.	1.5	3
1459	On the Origins of Omicron's Unique Spike Gene Insertion. <i>Vaccines</i> , 2022, 10, 1509.	2.1	10
1461	Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	23
1462	Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates. <i>Virologica Sinica</i> , 2022, 37, 804-812.	1.2	4
1463	Preventing SARS-CoV-2 Infection Using Anti-spike Nanobody-IFN- γ Conjugated Exosomes. <i>Pharmaceutical Research</i> , 0, , .	1.7	2
1464	Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective. <i>Vaccines</i> , 2022, 10, 1612.	2.1	14
1465	SARS-CoV-2 variants Alpha, Beta, Delta and Omicron show a slower host cell interferon response compared to an early pandemic variant. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1466	SARS-CoV-2 vaccines: A double-edged sword throughout rapid evolution of COVID-19. <i>Cell Biology International</i> , 2022, 46, 2009-2017.	1.4	3

#	ARTICLE	IF	CITATIONS
1467	Clinical outcomes in individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152). <i>IJID Regions</i> , 2022, 5, 104-110.	0.5	4
1469	Intrahost SARS-CoV-2 k-mer Identification Method (iSKIM) for Rapid Detection of Mutations of Concern Reveals Emergence of Global Mutation Patterns. <i>Viruses</i> , 2022, 14, 2128.	1.5	0
1470	Epistatic Variations in the Omicron Receptor Binding Domain Can Enhance Host Recognition: An <i>i>In Silico</i> Assessment and Prediction. <i>Journal of Physical Chemistry Letters</i>, 2022, 13, 8808-8815.</i>	2.1	2
1471	Vaccine-Induced T-Cell and Antibody Responses at 12 Months after Full Vaccination Differ with Respect to Omicron Recognition. <i>Vaccines</i> , 2022, 10, 1563.	2.1	4
1474	Assessing COVID-19 vaccination strategies in varied demographics using an individual-based model. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	5
1475	Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination. <i>Emerging Microbes and Infections</i> , 2022, 11, 2474-2484.	3.0	3
1476	Delta variant: Partially sensitive to vaccination, but still worth global attention. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 227-235.	1.0	2
1478	Agile design and development of a high throughput cobas SARS-CoV-2 RT-PCR diagnostic test. <i>Heliyon</i> , 2022, 8, e10591.	1.4	0
1480	Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants. <i>Vaccines</i> , 2022, 10, 1596.	2.1	1
1481	SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope. <i>Nature Microbiology</i> , 2022, 7, 1635-1649.	5.9	25
1482	Reagentless Quantum-Rate-Based Electrochemical Signal of Graphene for Detecting SARS-CoV-2 Infection Using Nasal Swab Specimens. <i>ACS Sensors</i> , 2022, 7, 2645-2653.	4.0	9
1483	Clinical comparison of omicron and delta variants in older COVID-19 patients and the effect of vaccination status. <i>Journal of Health Sciences and Medicine</i> , 2022, 5, 1421-1427.	0.0	1
1484	Real-world effectiveness and protection of SARS-CoV-2 vaccine among patients hospitalized for COVID-19 in Xiâ€™an, China, December 8, 2021, to January 20, 2022: A retrospective study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1485	Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern. <i>IScience</i> , 2022, 25, 105193.	1.9	7
1486	The Role of Disordered Regions in Orchestrating the Properties of Multidomain Proteins: The SARS-CoV-2 Nucleocapsid Protein and Its Interaction with Enoxaparin. <i>Biomolecules</i> , 2022, 12, 1302.	1.8	4
1487	Effect of Delta and Omicron Mutations on the RBD-SD1 Domain of the Spike Protein in SARS-CoV-2 and the Omicron Mutations on RBD-ACE2 Interface Complex. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10091.	1.8	8
1489	Subtyping of major SARS-CoV-2 variants reveals different transmission dynamics based on 10 million genomes. , 0, , .		3
1490	The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2. <i>Journal of the Royal Society Interface</i> , 2022, 19, .	1.5	3

#	ARTICLE	IF	CITATIONS
1491	Validation of reduced S-gene target performance and failure for rapid surveillance of SARS-CoV-2 variants. PLoS ONE, 2022, 17, e0275150.	1.1	11
1492	Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world. Frontiers in Immunology, 0, 13, .	2.2	21
1493	Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals. Scientific Reports, 2022, 12, .	1.6	8
1495	An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization. International Journal of Pharmaceutics, 2022, 627, 122256.	2.6	8
1496	How to correct relative voxel scale factors for calculations of vector-difference Fourier maps in cryo-EM. Journal of Structural Biology, 2022, 214, 107902.	1.3	3
1497	Adaptation of Proof SARS-CoV-2 Vaccine Design. Advanced Functional Materials, 2022, 32, .	7.8	7
1498	The paradigm of immune escape by SARS-CoV-2 variants and strategies for repositioning subverted mAbs against escaped VOCs. Molecular Therapy, 2022, 30, 3101-3105.	3.7	4
1499	Exploring nanoselenium to tackle mutated SARS-CoV-2 for efficient COVID-19 management. Frontiers in Nanotechnology, 0, 4, .	2.4	8
1500	A novel vaccine based on SARS-CoV-2 CD4+ and CD8+ T cell conserved epitopes from variants Alpha to Omicron. Scientific Reports, 2022, 12, .	1.6	8
1501	A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses. Molecular Therapy - Methods and Clinical Development, 2022, 27, 309-323.	1.8	14
1503	SARS-CoV-2 Omicron variant emerged under immune selection. Nature Microbiology, 2022, 7, 1756-1761.	5.9	21
1505	Acriflavine and proflavine hemisulfate as potential antivirals by targeting Mpro. Bioorganic Chemistry, 2022, 129, 106185.	2.0	4
1507	IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern. Nature Communications, 2022, 13, .	5.8	5
1508	Critical pediatric neurological illness associated with COVID-19 (Omicron BA.2.3.7 variant) infection in Taiwan: immunological assessment and viral genome analysis in tertiary medical center. International Journal of Infectious Diseases, 2022, 124, 45-48.	1.5	21
1509	Ganoderma microsporium immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion. Biomedicine and Pharmacotherapy, 2022, 155, 113766.	2.5	6
1510	Non-uniform aspects of the SARS-CoV-2 intraspecies evolution reopen question of its origin. International Journal of Biological Macromolecules, 2022, 222, 972-993.	3.6	2
1511	Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen. European Journal of Medicinal Chemistry, 2022, 244, 114803.	2.6	12
1512	Concise two-step chemical synthesis of molnupiravir. RSC Advances, 2022, 12, 30120-30124.	1.7	4

#	ARTICLE	IF	CITATIONS
1513	Heterologous <scp>SARSâ€CoV</scp>â€2 <scp>IgA</scp> neutralising antibody responses in convalescent plasma. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	5
1514	Targeting <scp>SARSâ€CoV</scp>â€2 infection through <scp>CARâ€T</scp>â€like bispecific T cell engagers incorporating <scp>ACE2</scp>. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	6
1515	Environmental Impacts on COVID-19: Mechanisms of Increased Susceptibility. <i>Annals of Global Health</i> , 2022, 88, .	0.8	4
1516	Clinical and biological consequences of respiratory syncytial virus genetic diversity. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612211280.	1.1	6
1517	Importancia de la vigilancia genÃ³mica de SARS-CoV-2 en los tiempos de las vacunas contra la COVID-19. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2022, 54, .	0.0	0
1518	First Detection of the SARS-CoV-2 Omicron BA.5/22B in Monaco. <i>Microorganisms</i> , 2022, 10, 1952.	1.6	2
1519	RPA-ligation-qPCR combined method for genotyping the SARS-CoV-2 key mutation E484Q. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 1924-1927.	0.9	1
1520	Biological effects of COVID-19 on lung cancer: Can we drive our decisions. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
1521	Characteristics and management of multiple sclerosis patients during the Omicron era: is there a concern about the MS course in the face of the new variant of COVID-19?. <i>Neurological Sciences</i> , 2023, 44, 659-665.	0.9	5
1523	Physician Perspectives on Telemedicine in Radiation Oncology. <i>Advances in Radiation Oncology</i> , 2023, 8, 101005.	0.6	2
1524	Clinical characteristics of 1139 mild cases of the SARSâ€CoVâ€2 Omicron variant infected patients in Shanghai. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	16
1525	Continued Complexity of Mutations in Omicron Sublineages. <i>Biomedicines</i> , 2022, 10, 2593.	1.4	5
1526	Designed Ankyrin Repeat Proteins: A New Class of Viral Entry Inhibitors. <i>Viruses</i> , 2022, 14, 2242.	1.5	7
1527	Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1528	Genomic Analysis of SARS-CoV-2 Alpha, Beta and Delta Variants of Concern Uncovers Signatures of Neutral and Non-Neutral Evolution. <i>Viruses</i> , 2022, 14, 2375.	1.5	4
1529	Molnupiravir Outpatient Treatment for Adults with COVID-19 in a Real-World Settingâ€”A Single Center Experience. <i>Journal of Clinical Medicine</i> , 2022, 11, 6464.	1.0	6
1530	Mapping Potential Vaccine Candidates Predicted by Vaxijen for Different Viral Pathogens between 2017â€2021â€”A Scoping Review. <i>Vaccines</i> , 2022, 10, 1785.	2.1	5
1531	Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination. <i>Vaccines</i> , 2022, 10, 1784.	2.1	1

#	ARTICLE	IF	CITATIONS
1532	De novo selected hACE2 mimics that integrate hotspot peptides with aptameric scaffolds for binding tolerance of SARS-CoV-2 variants. <i>Science Advances</i> , 2022, 8, .	4.7	9
1533	Atomistic insights into the binding of SARS-CoV-2 spike receptor binding domain with the human ACE2 receptor: The importance of residue 493. <i>Journal of Molecular Graphics and Modelling</i> , 2023, 118, 108360.	1.3	5
1534	A rational strategy for the maintenance of antiviral immunity to new SARS-CoV-2 strains. <i>Journal of Clinical Practice</i> , 2022, 13, 43-55.	0.2	3
1535	SARS-CoV-2: Searching for the Missing Variants. <i>Viruses</i> , 2022, 14, 2364.	1.5	1
1536	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
1537	Protection from COVID-19 with a VSV-based vaccine expressing the spike and nucleocapsid proteins. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1538	COVID-19 vaccine booster significantly decreases the risk of intensive care unit hospitalization in heart failure patients during the Omicron variant wave: A population-based study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
1539	Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, .	5.8	7
1540	Membrane attachment and fusion of HIV-1, influenza A, and SARS-CoV-2: resolving the mechanisms with biophysical methods. <i>Biophysical Reviews</i> , 2022, 14, 1109-1140.	1.5	15
1541	Effect on the conformations of the spike protein of SARS-CoV-2 due to mutation. <i>Biotechnology and Applied Biochemistry</i> , 2023, 70, 979-991.	1.4	2
1542	From oncoproteins to spike proteins: the evaluation of intramolecular stability using hydrophobic force field. <i>Journal of Computer-Aided Molecular Design</i> , 2022, 36, 797-804.	1.3	3
1543	SARS-CoV-2 Variant-Specific Infectivity and Immune Profiles Are Detectable in a Humanized Lung Mouse Model. <i>Viruses</i> , 2022, 14, 2272.	1.5	3
1544	SARS-CoV-2 down-regulates ACE2 through lysosomal degradation. <i>Molecular Biology of the Cell</i> , 2022, 33, .	0.9	19
1545	Quantum Chemical Computation of Omicron Mutations Near Cleavage Sites of the Spike Protein. <i>Microorganisms</i> , 2022, 10, 1999.	1.6	4
1546	Risk Stratification Based on a Pattern of Immunometabolic Host Factors Is Superior to Body Mass Index-Based Prediction of COVID-19-Associated Respiratory Failure. <i>Nutrients</i> , 2022, 14, 4280.	1.7	3
1547	Early detection of emerging SARS-CoV-2 variants of interest for experimental evaluation. <i>Frontiers in Bioinformatics</i> , 0, 2, .	1.0	6
1548	Molecular epidemiology of SARS-CoV-2 in healthcare workers and identification of viral genomic correlates of transmissibility and vaccine break through infection: A retrospective observational study from a cancer hospital in eastern India. <i>Indian Journal of Medical Microbiology</i> , 2022, .	0.3	0
1549	Local monitoring of SARS-CoV-2 variants in two large California counties in 2021. <i>Scientific Reports</i> , 2022, 12, .	1.6	0

#	ARTICLE	IF	CITATIONS
1550	Systematic benchmarking of nanopore Q20+ kit in SARS-CoV-2 whole genome sequencing. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	11
1551	SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. <i>Nature Reviews Microbiology</i> , 2023, 21, 112-124.	13.6	128
1552	Omicron BA.2.75 Subvariant of SARS-CoV-2 Is Expected to Have the Greatest Infectivity Compared with the Competing BA.2 and BA.5, Due to Most Negative Gibbs Energy of Binding. <i>BioTech</i> , 2022, 11, 45.	1.3	16
1553	Proteomic Approach for Comparative Analysis of the Spike Protein of SARS-CoV-2 Omicron (B.1.1.529) Variant and Other Pango Lineages. <i>Proteomes</i> , 2022, 10, 34.	1.7	1
1554	Are inhaled mRNA vaccines safe and effective? A review of preclinical studies. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 1471-1485.	2.4	11
1555	The Advantage of Using Immunoinformatic Tools on Vaccine Design and Development for Coronavirus. <i>Vaccines</i> , 2022, 10, 1844.	2.1	3
1556	Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine. <i>Cell Host and Microbe</i> , 2022, 30, 1732-1744.e7.	5.1	7
1558	Structural basis for mouse receptor recognition by SARS-CoV-2 omicron variant. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	26
1559	Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). <i>Viruses</i> , 2022, 14, 2419.	1.5	1
1560	Multi-Omics Reveals Mechanisms of Partial Modulation of COVID-19 Dysregulation by Glucocorticoid Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12079.	1.8	11
1562	Genotype-to-Protein Map and Collective Adaptation in a Viral Population. <i>Biophysica</i> , 2022, 2, 381-399.	0.6	2
1563	Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant. <i>Vaccines</i> , 2022, 10, 1728.	2.1	5
1564	Choosing a cellular model to study SARS-CoV-2. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	22
1565	Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1568	Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum. <i>Virologica Sinica</i> , 2022, 37, 831-841.	1.2	2
1569	Cyclophilin A-mediated mitigation of coronavirus <sc>SARS-CoV</sc>. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	8
1571	Evolutionary trajectory of receptor binding specificity and promiscuity of the spike protein of <sc>SARS-CoV</sc>. <i>Protein Science</i> , 2022, 31, .	3.1	1
1572	A Vaccine with Multiple Receptor-Binding Domain Subunit Mutations Induces Broad-Spectrum Immune Response against SARS-CoV-2 Variants of Concern. <i>Vaccines</i> , 2022, 10, 1653.	2.1	1

#	ARTICLE	IF	CITATIONS
1573	Stability and expression of SARS-CoV-2 spike-protein mutations. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 1269-1280.	1.4	4
1574	Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19. <i>Vaccines</i> , 2022, 10, 1762.	2.1	7
1575	Performance evaluation of Novaplex SARS-CoV-2 variants assay kit series for SARS-CoV-2 detection using single nucleotide polymorphisms. <i>Access Microbiology</i> , 2022, 4, .	0.2	0
1576	Clustered Regularly Interspaced short palindromic repeatsâ€Based Microfluidic System in Infectious Diseases Diagnosis: Current Status, Challenges, and Perspectives. <i>Advanced Science</i> , 2022, 9, .	5.6	12
1577	Epidemic spreading under mutually independent intra- and inter-host pathogen evolution. <i>Nature Communications</i> , 2022, 13, .	5.8	12
1578	SARSâ€CoVâ€2 evolves to reduce but not abolish neutralizing action. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6
1579	The lymphatic system and COVID-19 vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1580	State-of-the-art Tools to Elucidate the Therapeutic Potential of TAT-peptide (TP) Conjugated Repurposing Drug Against SARS-CoV-2 Spike Glycoproteins. <i>Current Pharmaceutical Design</i> , 2022, 28, 3706-3719.	0.9	2
1581	A comparative study of spike protein of SARS-CoV-2 and its variant Omicron (B.1.1.529) on some immune characteristics. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
1582	Genetic diversity and evolutionary convergence of cryptic SARS- CoV-2 lineages detected via wastewater sequencing. <i>PLoS Pathogens</i> , 2022, 18, e1010636.	2.1	32
1583	Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. <i>Cell Host and Microbe</i> , 2022, 30, 1540-1555.e15.	5.1	96
1584	The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between Mpro and antiviral drugs (nirmatrelvir and ritonavir). <i>Advances in Medical Sciences</i> , 2023, 68, 1-9.	0.9	4
1585	S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	39
1586	SARS-CoV-2 spike opening dynamics and energetics reveal the individual roles of glycans and their collective impact. <i>Communications Biology</i> , 2022, 5, .	2.0	37
1587	Management of hospital beds and ventilators in the Gauteng province, South Africa, during the COVID-19 pandemic. <i>PLOS Global Public Health</i> , 2022, 2, e0001113.	0.5	3
1588	RASCL: Rapid Assessment of Selection in CLades through molecular sequence analysis. <i>PLoS ONE</i> , 2022, 17, e0275623.	1.1	2
1589	Prognostic value of initial electrocardiography in predicting long-term all-cause mortality in COVID-19. <i>Journal of Electrocardiology</i> , 2022, 75, 1-9.	0.4	4
1590	A multi-population-based genomic analysis uncovers unique haplotype variants and crucial mutant genes in SARS-CoV-2. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 149.	1.5	0

#	ARTICLE	IF	CITATIONS
1591	Epidemiological and molecular description of nosocomial outbreak of COVID-19 Alpha (B.1.1.7) variant in Saudi Arabia. <i>Journal of Infection and Public Health</i> , 2022, 15, 1279-1286.	1.9	0
1592	A systematic review of current status and challenges of vaccinating children against SARS-CoV-2. <i>Journal of Infection and Public Health</i> , 2022, 15, 1212-1224.	1.9	2
1593	City-wide wastewater genomic surveillance through the successive emergence of SARS-CoV-2 Alpha and Delta variants. <i>Water Research</i> , 2022, 226, 119306.	5.3	13
1594	Cartography of SARS-CoV-2 variants based on the susceptibility to therapeutic monoclonal antibodies. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
1595	Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant. <i>Emerging Infectious Diseases</i> , 2022, 28, 2278-2288.	2.0	17
1596	The rapid emergence of multiple sublineages of Omicron (B.1.1.529) variant: Dynamic profiling via molecular phylogenetics and mutational landscape studies. <i>Journal of Infection and Public Health</i> , 2022, 15, 1234-1258.	1.9	14
1597	High-Throughput Molecular Dynamics-Based Alchemical Free Energy Calculations for Predicting the Binding Free Energy Change Associated with the Selected Omicron Mutations in the Spike Receptor-Binding Domain of SARS-CoV-2. <i>Biomedicines</i> , 2022, 10, 2779.	1.4	2
1598	Ribavirin aerosol in hospitalized adults with respiratory distress and COVID-19: An open-label trial. <i>Clinical and Translational Science</i> , 0, , .	1.5	1
1599	Development and characterization of a new monoclonal antibody against SARS-CoV-2 NSP12 (RdRp). <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
1600	Nasal irrigation efficiently attenuates SARS-CoV-2 Omicron infection, transmission and lung injury in the Syrian hamster model. <i>IScience</i> , 2022, 25, 105475.	1.9	8
1601	Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination. <i>IScience</i> , 2022, 25, 105379.	1.9	4
1602	COVID-DSNet: A novel deep convolutional neural network for detection of coronavirus (SARS-CoV-2) cases from CT and Chest X-Ray images. <i>Artificial Intelligence in Medicine</i> , 2022, 134, 102427.	3.8	16
1603	D3AI-Spike: A deep learning platform for predicting binding affinity between SARS-CoV-2 spike receptor binding domain with multiple amino acid mutations and human angiotensin-converting enzyme 2. <i>Computers in Biology and Medicine</i> , 2022, 151, 106212.	3.9	5
1604	Genomic evolution of SARS-CoV-2 in Reunion Island. <i>Infection, Genetics and Evolution</i> , 2022, 106, 105381.	1.0	1
1605	Astersaponin I from <i>Aster koraiensis</i> is a natural viral fusion blocker that inhibits the infection of SARS-CoV-2 variants and syncytium formation. <i>Antiviral Research</i> , 2022, 208, 105428.	1.9	4
1606	Rapid Emergence of the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Korea. <i>Annals of Laboratory Medicine</i> , 2023, 43, 211-213.	1.2	5
1607	Comparative study of clinical features and vaccination status in Omicron and non-Omicron infected patients during the third wave in Mumbai, India. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 6135.	0.3	3
1608	Integrated microdroplet array platform with temperature controller and micro-stirring for ultra-fast SARS-CoV-2 detection. <i>Biosensors and Bioelectronics</i> , 2023, 220, 114903.	5.3	2

#	ARTICLE	IF	CITATIONS
1609	Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 113977.	2.5	66
1610	Structures of SARS-CoV-2 spike protein alert noteworthy sites for the potential approaching variants. <i>Virologica Sinica</i> , 2022, 37, 938-941.	1.2	1
1611	On the peptide binding affinity changes in population-specific HLA repertoires to the SARS-CoV-2 variants Delta and Omicron. <i>Journal of Autoimmunity</i> , 2022, , 102952.	3.0	5
1612	Global disparities in SARS-CoV-2 genomic surveillance. <i>Nature Communications</i> , 2022, 13, .	5.8	90
1614	Health literacy on COVID-19 and COVID-19 vaccinations in Indonesia. <i>F1000Research</i> , 0, 11, 1296.	0.8	0
1615	The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14057.	1.8	4
1616	Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants. <i>Communications Biology</i> , 2022, 5, .	2.0	8
1617	Antigenic mapping reveals sites of vulnerability on SARS-CoV-2 spike protein. <i>Communications Biology</i> , 2022, 5, .	2.0	2
1618	Antigenic escape is accelerated by the presence of immunocompromised hosts. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2022, 289, .	1.2	3
1619	Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters. <i>Nature Communications</i> , 2022, 13, .	5.8	11
1620	SARS-CoV-2 variants: Impact on biological and clinical outcome. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
1622	The Impact of Demographic, Clinical Characteristics and the Various COVID-19 Variant Types on All-Cause Mortality: A Case-Series Retrospective Study. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 100.	1.0	2
1623	SARS-CoV-2 neutralizing antibody response in vaccinated and non-vaccinated hospital healthcare workers with or without history of infection. <i>Microbes and Infection</i> , 2022, , 105077.	1.0	2
1624	Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study. <i>Vaccines</i> , 2022, 10, 1931.	2.1	1
1625	Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond. <i>IScience</i> , 2022, 25, 105507.	1.9	10
1626	Non-Neutralizing Epitopes Shade Neutralizing Epitopes against Omicron in a Multiple Epitope-Based Vaccine. <i>ACS Infectious Diseases</i> , 2022, 8, 2586-2593.	1.8	2
1628	Detection of the SARS-CoV-2 Omicron Variant in COVID-19 Patients from South Tangerang Using SNP-Probes S371L and K417N. <i>Journal of Pure and Applied Microbiology</i> , 0, , .	0.3	0
1629	The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. <i>Vaccines</i> , 2022, 10, 1926.	2.1	29

#	ARTICLE	IF	CITATIONS
1630	Understanding Molecular Actors of SARS-CoV-2 Virulence to Tackle COVID-19 Outbreak. <i>Cells</i> , 2022, 11, 3597.	1.8	0
1631	A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein. <i>Cell Research</i> , 2022, 32, 1068-1085.	5.7	27
1632	XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection. <i>Nature Communications</i> , 2022, 13, .	5.8	7
1633	Influence of viral genome properties on polymerase fidelity. <i>Trends in Genetics</i> , 2022, , .	2.9	0
1634	Subgenomic RNAs and Their Encoded Proteins Contribute to the Rapid Duplication of SARS-CoV-2 and COVID-19 Progression. <i>Biomolecules</i> , 2022, 12, 1680.	1.8	0
1635	Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir. <i>Viruses</i> , 2022, 14, 2540.	1.5	33
1637	Structural effects of spike protein D614G mutation in SARS-CoV-2. <i>Biophysical Journal</i> , 2023, 122, 2910-2920.	0.2	11
1638	Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India. <i>Indian Journal of Medical Microbiology</i> , 2022, , .	0.3	0
1639	ACE2 N-glycosylation modulates interactions with SARS-CoV-2 spike protein in a site-specific manner. <i>Communications Biology</i> , 2022, 5, .	2.0	13
1640	A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1641	Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual. <i>Virus Evolution</i> , 2023, 9, .	2.2	9
1643	Pathogenesis and Preventive Tactics of Immune-Mediated Non-Pulmonary COVID-19 in Children and Beyond. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14157.	1.8	3
1644	Accurate Diagnosis of COVID-19 from Self-Collectable Biospecimens Using Synthetic Apolipoprotein H Peptide-Coated Nanoparticle Assay. <i>Analytical Chemistry</i> , 2022, 94, 17186-17194.	3.2	0
1646	Characterization and analysis of linear epitopes corresponding to SARS-CoV-2 outbreak in Jilin Province, China. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	4
1647	Long-term filter efficiency of mobile air purifiers in schools. <i>Aerosol Science and Technology</i> , 2023, 57, 134-152.	1.5	0
1648	Atlas of interactions between SARS-CoV-2 macromolecules and host proteins. , 2023, 2, 100068.		6
1649	An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay. <i>Vaccine</i> , 2023, 41, 109-118.	1.7	17
1650	Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. <i>Journal of Infection and Public Health</i> , 2023, 16, 4-14.	1.9	105

#	ARTICLE	IF	CITATIONS
1651	Conformational stability of SARS-CoV-2 glycoprotein spike variants. <i>IScience</i> , 2023, 26, 105696.	1.9	5
1652	Probability Calculation of Upcoming Waves of COVID-19 in Poland. <i>WSB Journal of Business and Finance</i> , 2022, 56, 17-24.	0.0	0
1653	Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD. <i>IScience</i> , 2023, 26, 105783.	1.9	4
1654	Nanobody derived using a peptide epitope from the spike protein receptor-binding motif inhibits entry of SARS-CoV-2 variants. <i>Journal of Biological Chemistry</i> , 2023, 299, 102732.	1.6	3
1655	How to build disaster-resilient cities and societies for making people happy. <i>Building and Environment</i> , 2023, 228, 109845.	3.0	6
1656	Modeling variants of the COVID-19 virus in Hawai'i and the responses to forecasting. <i>AIMS Mathematics</i> , 2023, 8, 4487-4523.	0.7	1
1657	SARS-CoV-2 RdRp uses NDPs as a substrate and is able to incorporate NHC into RNA from diphosphate form molnupiravir. <i>International Journal of Biological Macromolecules</i> , 2023, 226, 946-955.	3.6	2
1658	Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination. <i>IScience</i> , 2023, 26, 105753.	1.9	4
1659	Host microRNAs exhibit differential propensity to interact with SARS-CoV-2 and variants of concern. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166612.	1.8	2
1660	COVID-19 and ocular complications: A review of ocular manifestations, diagnostic tools, and prevention strategies. <i>Advances in Ophthalmology Practice and Research</i> , 2023, 3, 33-38.	0.3	5
1661	SARS-CoV-2 multi-variant rapid detector based on graphene transistor functionalized with an engineered dimeric ACE2 receptor. <i>Nano Today</i> , 2023, 48, 101729.	6.2	14
1662	Comorbidities prolonged viral shedding of patients infected with SARS-CoV-2 omicron variant in Shanghai: A multi-center, retrospective, observational study. <i>Journal of Infection and Public Health</i> , 2023, 16, 182-189.	1.9	9
1663	Structural patterns of SARS-CoV-2 variants of concern (alpha, beta, gamma, delta) spike protein are influenced by variant-specific amino acid mutations: A computational study with implications on viral evolution. <i>Journal of Theoretical Biology</i> , 2023, 558, 111376.	0.8	2
1664	Self-directed molecular diagnostics (SdMDx) system for COVID-19 via one-pot processing. <i>Sensors and Actuators B: Chemical</i> , 2023, 378, 133193.	4.0	0
1665	Network analysis of the autophagy biochemical network in relation to various autophagy-targeted proteins found among SARS-CoV-2 variants of concern. <i>Journal of Molecular Graphics and Modelling</i> , 2023, 119, 108396.	1.3	0
1666	Modelling SARS-CoV-2 spike-protein mutation effects on ACE2 binding. <i>Journal of Molecular Graphics and Modelling</i> , 2023, 119, 108379.	1.3	4
1667	Discovery of novel thioquinazoline-N-aryl-acetamide/N-arylaceto-hydrazide hybrids as anti-SARS-CoV-2 agents: Synthesis, in vitro biological evaluation, and molecular docking studies. <i>Journal of Molecular Structure</i> , 2023, 1276, 134690.	1.8	5
1668	Biomarker Changes in Pediatric Patients With COVID-19: A Retrospective Study from a Single Center Database. <i>In Vivo</i> , 2022, 36, 2813-2822.	0.6	5

#	ARTICLE	IF	CITATIONS
1669	FDA Should Re-evaluate All mRNA Vaccines and Revoke Their Use Authorizations (The Short Version).. International Journal of Coronaviruses, 2022, 4, 16-66.	0.8	0
1670	Expression of Concern: Potential Risks and Unknown Effects of mRNA Vaccines on Population Health (6th Rev). Damages Are Being Materialized. International Journal of Coronaviruses, 2022, 4, 7-43.	0.8	0
1671	Optimization of Vaccination Clinics to Improve Staffing Decisions for COVID-19: A Time-Motion Study. Vaccines, 2022, 10, 2045.	2.1	0
1672	Electrostatic Interactions Are the Primary Determinant of the Binding Affinity of SARS-CoV-2 Spike RBD to ACE2: A Computational Case Study of Omicron Variants. International Journal of Molecular Sciences, 2022, 23, 14796.	1.8	14
1673	Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review. Medicina (Lithuania), 2022, 58, 1733.	0.8	2
1674	Structural Insight into the Resistance of the SARS-CoV-2 Omicron BA.4 and BA.5 Variants to Cilgavimab. Viruses, 2022, 14, 2677.	1.5	8
1675	Structural Profiles of SARS-CoV-2 Variants in India. Current Microbiology, 2023, 80, .	1.0	4
1676	SARS-CoV-2 epitopes inform future vaccination strategies. Frontiers in Immunology, 0, 13, .	2.2	3
1677	In Silico Screening of Prospective MHC Class I and II Restricted T-Cell Based Epitopes of the Spike Protein of SARS-CoV-2 for Designing of a Peptide Vaccine for COVID-19. Covid, 2022, 2, 1731-1747.	0.7	1
1678	Characteristics of the severe acute respiratory syndrome coronavirus 2 omicron BA.2 subvariant in Jilin, China from March to May 2022. Journal of Translational Internal Medicine, 2023, 10, 349-358.	1.0	3
1679	Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning. Science Advances, 2022, 8, .	4.7	16
1680	Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice. Viruses, 2022, 14, 2584.	1.5	6
1682	Using nanomaterials to address SARS-CoV-2 variants through development of vaccines and therapeutics. Frontiers in Materials, 0, 9, .	1.2	0
1683	Pre-processing SARS-CoV-2 Sequence Data for Application of Machine Learning Techniques for Visualization and Clustering of Virus Characteristics. , 2022, , .		0
1684	Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies. Science China Life Sciences, 2023, 66, 658-678.	2.3	3
1685	Nasal vaccines: solutions for respiratory infectious diseases. Trends in Molecular Medicine, 2023, 29, 124-140.	3.5	10
1686	Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. Frontiers in Microbiology, 0, 13, .	1.5	5
1688	Vaccination with the Omicron spike RBD boosts broadly neutralizing antibody levels and confers sustained protection even after acquiring immunity to the original antigen. International Immunology, 2023, 35, 197-207.	1.8	4

#	ARTICLE	IF	CITATIONS
1689	Comparison of machine learning methods with logistic regression analysis in creating predictive models for risk of critical in-hospital events in COVID-19 patients on hospital admission. BMC Medical Informatics and Decision Making, 2022, 22, .	1.5	7
1690	SARS-CoV-2 Variants Identification; A Fast and Affordable Strategy Based on Partial S-Gene Targeted PCR Sequencing. Viruses, 2022, 14, 2588.	1.5	1
1691	Longitudinal single-cell analysis of SARS-CoV-2-reactive B cells uncovers persistence of early-formed, antigen-specific clones. JCI Insight, 2023, 8, .	2.3	6
1693	Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave. Frontiers in Medicine, 0, 9, .	1.2	2
1694	Immune evasion of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); molecular approaches. Molecular Immunology, 2023, 156, 10-19.	1.0	3
1695	SARS-CoV-2 Antibody Effectiveness Is Influenced by Non-Epitope Mutation/Binding-Induced Denaturation of the Epitope 3D Architecture. Pathogens, 2022, 11, 1437.	1.2	2
1696	Oral manifestations associated with Novel Coronavirus Disease - 2019 (COVID-19): A questionnaire based hypothetical study. F1000Research, 0, 11, 1443.	0.8	0
1697	Nucleic acid testing of SARS-CoV-2: A review of current methods, challenges, and prospects. Frontiers in Microbiology, 0, 13, .	1.5	7
1698	Effect of Double Mutation (L452R and E484Q) on the Binding Affinity of Monoclonal Antibodies (mAbs) against the RBD-A Target for Vaccine Development. Vaccines, 2023, 11, 23.	2.1	4
1700	Health literacy on COVID-19 and COVID-19 vaccinations in Indonesia. F1000Research, 0, 11, 1296.	0.8	3
1705	Rapid Conductometric Detection of SARS-CoV-2 Proteins and Its Variants Using Molecularly Imprinted Polymer Nanoparticles. Advanced Materials Technologies, 0, , 2200965.	3.0	0
1707	The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts. International Journal of Infectious Diseases, 2022, , .	1.5	5
1708	The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. Nature Reviews Immunology, 2023, 23, 304-316.	10.6	56
1710	Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. Nature Communications, 2022, 13, .	5.8	17
1711	Clinical characteristics and severity of beta and delta variants of SARS-CoV-2 and the effect of vaccine on delta variants. Heliyon, 2022, 8, e12594.	1.4	1
1712	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. Journal of Taibah University Medical Sciences, 2023, 18, 600-638.	0.5	1
1713	Sensitivity of Detection and Variant Typing of SARS-CoV-2 in European Laboratories. Journal of Clinical Microbiology, 2022, 60, .	1.8	4
1714	Variations within the Glycan Shield of SARS-CoV-2 Impact Viral Spike Dynamics. Journal of Molecular Biology, 2023, 435, 167928.	2.0	24

#	ARTICLE	IF	CITATIONS
1715	Smart Nanostructured Materials for SARS-CoV-2 and Variants Prevention, Biosensing and Vaccination. Biosensors, 2022, 12, 1129.	2.3	0
1716	Evaluation of antibody response to SARS-CoV-2 variants after 2 doses of mRNA COVID-19 vaccine in a correctional facility. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	3
1720	Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression. Vaccines, 2022, 10, 2180.	2.1	16
1721	Cardiovascular, Pulmonary, and Neuropsychiatric Short- and Long-Term Complications of COVID-19. Cells, 2022, 11, 3882.	1.8	7
1722	Gastrointestinal microbiota: A predictor of COVID-19 severity?. World Journal of Gastroenterology, 0, 28, 6328-6344.	1.4	12
1723	Potential therapeutic applications of extracellular vesicles in the immunopathogenesis of COVID-19. Pathology Research and Practice, 2023, 241, 154280.	1.0	6
1724	Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein. Scientific Reports, 2022, 12, .	1.6	11
1725	Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature, 0, , .	13.7	187
1726	Molecular Epidemiology of the Norwegian SARS-CoV-2 Delta Lineage AY.63. Viruses, 2022, 14, 2734.	1.5	1
1727	A hypothesis on designing strategy of effective RdRp inhibitors for the treatment of SARS-CoV-2. 3 Biotech, 2023, 13, .	1.1	2
1728	Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4+ T cell recognition. Nature Immunology, 2022, 23, 1726-1734.	7.0	11
1730	Quasispecies Analysis of SARS-CoV-2 of 15 Different Lineages during the First Year of the Pandemic Prompts Scratching under the Surface of Consensus Genome Sequences. International Journal of Molecular Sciences, 2022, 23, 15658.	1.8	3
1731	Rapid Evaluation of the Xpert® Xpress CoV-2 plus and Xpert® Xpress CoV-2/Flu/RSV plus Tests. Diagnostics, 2023, 13, 34.	1.3	5
1734	Analysis of research hotspots in COVID-19 genomics based on citespace software: Bibliometric analysis. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	4
1736	Conformational Dynamics of the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. Biomedicines, 2022, 10, 3233.	1.4	0
1737	Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nature Reviews Immunology, 2023, 23, 381-396.	10.6	61
1738	Harnessing Stress Granule Formation by Small Molecules to Inhibit the Cellular Replication of SARS-CoV-2. Springer Theses, 2023, , 79-100.	0.0	0
1739	Development and Characterization of Phage-Display-Derived Novel Human Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2. Biomedicines, 2022, 10, 3274.	1.4	5

#	ARTICLE	IF	CITATIONS
1740	Therapeutic potential of compounds targeting SARS-CoV-2 helicase. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	3
1742	Isolation and characterization of a SARS-CoV-2 variant with a Q677H mutation in the spike protein. <i>Archives of Virology</i> , 2023, 168, .	0.9	1
1743	Emergence of a unique SARS-CoV-2 Delta sub-cluster harboring a constellation of co-appearing non-spike mutations. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
1744	The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages. <i>Virologica Sinica</i> , 2022, 37, 786-795.	1.2	12
1745	Insights from computational studies on the potential of natural compounds as inhibitors against SARS-CoV-2 spike omicron variant. <i>SAR and QSAR in Environmental Research</i> , 2022, 33, 953-968.	1.0	6
1746	Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 16902-16917.	2.9	15
1747	Towards evolutionary predictions: Current promises and challenges. <i>Evolutionary Applications</i> , 2023, 16, 3-21.	1.5	19
1748	Key mutations in the spike protein of SARS-CoV-2 affecting neutralization resistance and viral internalization. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	15
1749	Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes. <i>Vaccines</i> , 2022, 10, 2063.	2.1	1
1750	Potential targets of severe acute respiratory syndrome coronavirus 2 of clinical drug fluvoxamine: Docking and molecular dynamics studies to elucidate viral action. <i>Cell Biochemistry and Function</i> , 2023, 41, 98-111.	1.4	5
1751	Development, testing and validation of a SARS-CoV-2 multiplex panel for detection of the five major variants of concern on a portable PCR platform. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
1752	SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far. <i>Life</i> , 2022, 12, 2087.	1.1	4
1753	Genomic landscape of alpha-variant of SARS-CoV-2 circulated in Pakistan. <i>PLoS ONE</i> , 2022, 17, e0276171.	1.1	5
1754	Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	4
1755	Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 818-831.	1.5	13
1756	Multiple Mutations Associated with Emergent Variants Can Be Detected as Low-Frequency Mutations in Early SARS-CoV-2 Pandemic Clinical Samples. <i>Viruses</i> , 2022, 14, 2775.	1.5	3
1757	Salmonella-mediated oral delivery of multiple-target vaccine constructs with conserved and variable regions of SARS-CoV-2 protect against the Delta and Omicron variants in hamster. <i>Microbes and Infection</i> , 2023, 25, 105101.	1.0	3
1758	Assessment of Immunogenic and Antigenic Properties of Recombinant Nucleocapsid Proteins of Five SARS-CoV-2 Variants in a Mouse Model. <i>Viruses</i> , 2023, 15, 230.	1.5	4

#	ARTICLE	IF	CITATIONS
1759	INVESTIGATION OF ANTI-SARS COV-2 ACTIVITY OF SOME TETRAHYDRO CURCUMIN DERIVATIVES: AN IN SILICO STUDY. <i>International Journal of Applied Pharmaceutics</i> , 0, , 333-339.	0.3	2
1761	Receptor-binding domain of SARS-CoV-2 is a functional β -integrin agonist. <i>Journal of Biological Chemistry</i> , 2023, 299, 102922.	1.6	11
1762	A bivalent subunit vaccine efficiently produced in <i>Pichia pastoris</i> against SARS-CoV-2 and emerging variants. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	2
1763	The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19. <i>Journal of Inflammation Research</i> , 0, Volume 16, 145-160.	1.6	5
1764	Impacts of delta and omicron variants on inactivated SARS-CoV-2 vaccine-induced T cell responses in patients with autoimmune diseases and healthy controls. <i>Clinical and Translational Medicine</i> , 2023, 13, .	1.7	2
1765	High-throughput, targeted MHC class I immunopeptidomics using a functional genetics screening platform. <i>Nature Biotechnology</i> , 2023, 41, 980-992.	9.4	8
1766	The benefits and costs of U.S. employer COVID-19 vaccine mandates. <i>Risk Analysis</i> , 2023, 43, 2053-2068.	1.5	1
1767	Bioinformatical Design and Performance Evaluation of a Nucleocapsid- and an RBD-Based Particle Enhanced Turbidimetric Immunoassay (PETIA) to Quantify the Wild Type and Variants of Concern-Derived Immunoreactivity of SARS-CoV-2. <i>Biomedicines</i> , 2023, 11, 160.	1.4	1
1768	Self-Adjuvanting Protein Vaccine Conjugated with a Novel Synthetic TLR4 Agonist on Virus-Like Liposome Induces Potent Immunity against SARS-CoV-2. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 1467-1483.	2.9	3
1769	RNA recording in single bacterial cells using reprogrammed tracrRNAs. <i>Nature Biotechnology</i> , 2023, 41, 1107-1116.	9.4	6
1770	Valproate-coenzyme A conjugate blocks opening of receptor binding domains in the spike trimer of SARS-CoV-2 through an allosteric mechanism. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 1066-1076.	1.9	4
1771	Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies. <i>Pathogens</i> , 2023, 12, 109.	1.2	2
1772	Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1773	Insight into free energy and dynamic cross-correlations of residue for binding affinity of antibody and receptor binding domain SARS-CoV-2. <i>Heliyon</i> , 2023, 9, e12667.	1.4	0
1775	COVID-19 vaccine and booster hesitation around the world: A literature review. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	17
1776	Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?. <i>Bioelectronic Medicine</i> , 2023, 9, .	1.0	5
1777	Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants. <i>Cell Reports</i> , 2023, 42, 111995.	2.9	12
1778	A strategy for evaluating potential antiviral resistance to small molecule drugs and application to SARS-CoV-2. <i>Scientific Reports</i> , 2023, 13, .	1.6	6

#	ARTICLE	IF	CITATIONS
1779	Cross-variant proof predictive vaccine design based on SARS-CoV-2 spike protein using immunoinformatics approach. Beni-Suef University Journal of Basic and Applied Sciences, 2023, 12, .	0.8	1
1780	The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS-CoV-2 variant. Journal of Medical Virology, 2023, 95, .	2.5	3
1781	Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau. Frontiers in Public Health, 0, 10, .	1.3	4
1782	Rapid detection of SARS-CoV-2: The gradual boom of lateral flow immunoassay. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	11
1784	Structural analysis of receptor engagement and antigenic drift within the BA.2 spike protein. Cell Reports, 2023, 42, 111964.	2.9	9
1785	Viral Fitness, Population Complexity, Host Interactions, and Resistance to Antiviral Agents. Current Topics in Microbiology and Immunology, 2023, , 197-235.	0.7	0
1786	Investigation on the interaction mechanism of different SARS-CoV-2 spike variants with hACE2: insights from molecular dynamics simulations. Physical Chemistry Chemical Physics, 2023, 25, 2304-2319.	1.3	3
1787	A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model. Journal of Virology, 0, , .	1.5	2
1788	Humoral immunity for durable control of SARS-CoV-2 and its variants. Inflammation and Regeneration, 2023, 43, .	1.5	6
1789	Characterization and phylogenetic analysis of Iranian SARS-CoV-2 genomes: A phylogenomic study. Health Science Reports, 2023, 6, .	0.6	1
1790	Intermediate Levels of Pre-Existing Protective Antibody Allow Priming of Protective T Cell Immunity against Influenza. Journal of Immunology, 2023, 210, 628-639.	0.4	1
1791	COVID-19 infection rates and mitigation strategies in orthodontic practices. BMC Oral Health, 2023, 23, .	0.8	2
1792	Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2. Biomedical Journal, 2023, 46, 70-80.	1.4	8
1794	SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nature Reviews Microbiology, 0, , .	13.6	160
1795	SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19. Nature Communications, 2023, 14, .	5.8	18
1796	Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients. Heliyon, 2023, 9, e12704.	1.4	2
1797	A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19). Antibodies, 2023, 12, 5.	1.2	15
1798	Validation and Establishment of the SARS-CoV-2 Lentivirus Surrogate Neutralization Assay as a Prescreening Tool for the Plaque Reduction Neutralization Test. Microbiology Spectrum, 2023, 11, .	1.2	6

#	ARTICLE	IF	CITATIONS
1800	Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	32
1801	Mathematical Modeling of COVID-19 Dynamics under Two Vaccination Doses and Delay Effects. <i>Mathematics</i> , 2023, 11, 369.	1.1	11
1802	Genomic Analysis of Non-B Nucleic Acids Structures in SARS-CoV-2: Potential Key Roles for These Structures in Mutability, Translation, and Replication?. <i>Genes</i> , 2023, 14, 157.	1.0	2
1803	Applications of nanobodies in the prevention, detection, and treatment of the evolving SARS-CoV-2. <i>Biochemical Pharmacology</i> , 2023, 208, 115401.	2.0	5
1804	A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2. <i>Nano Today</i> , 2023, 48, 101730.	6.2	10
1805	Functional studies of HLA and its role in SARS-CoV-2: Stimulating T cell response and vaccine development. <i>Life Sciences</i> , 2023, 315, 121374.	2.0	3
1806	Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2023, 37, e00780.	2.1	3
1807	Computational Analysis of Receptor-Binding Domains of SARS-CoV-2 to Reveal the Mechanism of Immune Escape. , 2022, , .		0
1808	Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. <i>Npj Vaccines</i> , 2022, 7, .	2.9	19
1809	Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. <i>Medical Microbiology and Immunology</i> , 2023, 212, 103-122.	2.6	18
1810	Highly efficacious and safe neutralizing DNA aptamer of SARS-CoV-2 as an emerging therapy for COVID-19 disease. <i>Virology Journal</i> , 2022, 19, .	1.4	3
1811	Incursions by severe acute respiratory syndrome coronavirus-2 on the host anti-viral immunity during mild, moderate, and severe coronavirus disease 2019 disease. <i>Exploration of Medicine</i> , 0, , 794-811.	1.5	1
1812	Characterization of SARS-CoV-2 omicron variants from Iran and evaluation of the effect of mutations on the spike, nucleocapsid, ORF8, and ORF9b proteins function. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 11415-11430.	2.0	2
1813	Biology of the SARS-CoV-2 Coronavirus. <i>Biochemistry (Moscow)</i> , 2022, 87, 1662-1678.	0.7	2
1814	Transmission cluster characteristics of global, regional, and lineage-specific SARS-CoV-2 phylogenies. , 2022, , .		1
1815	Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques. <i>JCI Insight</i> , 2023, 8, .	2.3	11
1816	Entropic Overcompensation of the N501Y Mutation on SARS-CoV-2 S Binding to ACE2. <i>Journal of Chemical Information and Modeling</i> , 2023, 63, 633-642.	2.5	0
1817	RNA Interference Approach Is a Good Strategy against SARS-CoV-2. <i>Viruses</i> , 2023, 15, 100.	1.5	2

#	ARTICLE	IF	CITATIONS
1818	Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants. <i>Vaccines</i> , 2023, 11, 42.	2.1	5
1819	Immunological Studies to Understand Hybrid/Recombinant Variants of SARS-CoV-2. <i>Vaccines</i> , 2023, 11, 45.	2.1	4
1820	Clinical and epidemiological aspects of Delta and Gamma SARS-CoV-2 variant of concern from the western Brazilian Amazon. <i>Memorias Do Instituto Oswaldo Cruz</i> , 0, 117, .	0.8	4
1821	Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection. <i>Cell Reports Medicine</i> , 2023, 4, 100943.	3.3	31
1824	A Molecular and Epidemiological Investigation of a Large SARS-CoV-2 Outbreak in a Long-Term Care Facility in Luxembourg, 2021. <i>Geriatrics (Switzerland)</i> , 2023, 8, 19.	0.6	1
1825	The role of T _H 1 cell immunity in COVID-19. , 2023, , 129-140.		0
1826	Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study. <i>PLoS Medicine</i> , 2023, 20, e1004086.	3.9	24
1827	Ocular Symptoms Associated with COVID-19 Are Correlated with the Expression Profile of Mouse SARS-CoV-2 Binding Sites. <i>Viruses</i> , 2023, 15, 354.	1.5	0
1828	A covalent opsonization approach to enhance synthetic immunity against viral escape variants. <i>Cell Reports Physical Science</i> , 2023, , 101258.	2.8	1
1829	Tracking of Mutational Signature of SARS-CoV-2 Omicron on Distinct Continents and Little Difference was Found. <i>Viruses</i> , 2023, 15, 321.	1.5	0
1830	Dynamics of Different Classes and Subclasses of Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants after Coronavirus Disease 2019 and CoronaVac Vaccination in Thailand. <i>MSphere</i> , 2023, 8, .	1.3	2
1832	Early detection of variants of concern via funnel plots of regional reproduction numbers. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
1834	Is N-acetylcysteine effective in treating patients with coronavirus disease 2019? A meta-analysis. <i>Journal of the Chinese Medical Association</i> , 2023, 86, 274-281.	0.6	4
1835	Revealing the Molecular Interactions between Human ACE2 and the Receptor Binding Domain of the SARS-CoV-2 Wild-Type, Alpha and Delta Variants. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2517.	1.8	1
1836	Investigation on Phytoactive Constituent of <i>Clerodendrum paniculatum</i> as Therapeutic Agent against Viral Diseases. <i>ChemistrySelect</i> , 2023, 8, .	0.7	0
1837	White-tailed deer (<i>Odocoileus virginianus</i>) may serve as a wildlife reservoir for nearly extinct SARS-CoV-2 variants of concern. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	37
1838	Evolution of SARS-CoV-2-specific CD4+ T cell epitopes. <i>Immunogenetics</i> , 2023, 75, 283-293.	1.2	2
1840	Detection of a SARS-CoV-2 Beta-like variant in coastal Kenya after more than a year of disappearance. <i>Wellcome Open Research</i> , 0, 8, 34.	0.9	1

#	ARTICLE	IF	CITATIONS
1842	Evolutionary dynamics of respiratory syncytial virus in Buenos Aires: Viral diversity, migration, and subgroup replacement. <i>Virus Evolution</i> , 2023, 9, .	2.2	1
1843	Coronavirus Pandemics. , 2023, , 143-222.		0
1844	Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection. , 2023, , 237-262.		0
1845	Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1847	The conjugacy of the use of synbiotic Maxilac® with the severity and duration of the course of COVID-19 in outpatient treatment. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2023, , 86-93.	0.1	0
1848	Applications of genetic engineering in COVID-19. , 2023, , 219-237.		0
1849	Com probe implemented STexS II greatly enhances specificity in SARS-CoV-2 variant detection. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
1850	Electrostatic Surface Potential as a Key Parameter in Virus Transmission and Evolution: How to Manage Future Virus Pandemics in the Post-COVID-19 Era. <i>Viruses</i> , 2023, 15, 284.	1.5	10
1852	Minimal Antigenic Evolution after a Decade of Norovirus GII.4 Sydney_2012 Circulation in Humans. <i>Journal of Virology</i> , 2023, 97, .	1.5	8
1853	Trivalent SARS-CoV-2 S1 Subunit Protein Vaccination Induces Broad Humoral Responses in BALB/c Mice. <i>Vaccines</i> , 2023, 11, 314.	2.1	7
1854	Comparative Characterization of Diverse DNA Aptamers for Recognition of Spike Proteins of Multiple SARS-CoV-2 Variants. <i>Analysis & Sensing</i> , 2023, 3, .	1.1	0
1855	Genomic Analysis of S protein in SARS-CoV-2 samples from Washington D.C. <i>Journal of Student Research</i> , 2022, 11, .	0.0	0
1856	Molecular Docking Studies of Coronavirinae Spike Proteins with Different Vertebrate Receptors (ACE2, APN, DPP4). <i>Springer Proceedings in Materials</i> , 2023, , 103-109.	0.1	0
1857	Children's SARS-CoV-2 Infection and Their Vaccination. <i>Vaccines</i> , 2023, 11, 418.	2.1	3
1858	How public health authorities can use pathogen genomics in health protection practice: a consensus-building Delphi study conducted in the United Kingdom. <i>Microbial Genomics</i> , 2023, 9, .	1.0	1
1860	An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines. <i>Progress in Biophysics and Molecular Biology</i> , 2023, 178, 32-49.	1.4	16
1863	Extending the Library of 4-Hydroxycoumarin Derivatives with Potential Pharmacological Activity by a Catalytic-Free and Purification-Free Method. <i>ChemistrySelect</i> , 2023, 8, .	0.7	0
1864	A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy. <i>Vaccine</i> , 2023, 41, 2101-2112.	1.7	6

#	ARTICLE	IF	CITATIONS
1865	Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort. <i>Vaccine</i> , 2023, 41, 2234-2242.	1.7	7
1866	SARS-CoV-2 before and after Omicron: two different viruses and two different diseases?. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	9
1868	Single-epitope T cell-based vaccine protects against SARS-CoV-2 infection in a preclinical animal model. <i>JCI Insight</i> , 2023, 8, .	2.3	2
1869	19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern. <i>IScience</i> , 2023, 26, 106562.	1.9	1
1870	Bidirectional and persistent immunomodulation of Astragalus polysaccharide as an adjuvant of influenza and recombinant SARS-CoV-2 vaccine. <i>International Journal of Biological Macromolecules</i> , 2023, 234, 123635.	3.6	6
1871	Blood Biomarkers from the Emergency Department Disclose Severe Omicron COVID-19-Associated Outcomes. <i>Microorganisms</i> , 2023, 11, 925.	1.6	1
1872	Adaptive Evolution of the Spike Protein in Coronaviruses. <i>Molecular Biology and Evolution</i> , 2023, 40, .	3.5	6
1873	SARS-CoV-2 Omicron Variant in Medicinal Chemistry Research. <i>Current Topics in Medicinal Chemistry</i> , 2023, 23, .	1.0	1
1874	Evaluation of a multiplexed oligonucleotide ligation assay for SARS-CoV-2 variant identification. <i>Journal of Clinical Virology</i> , 2023, 162, 105444.	1.6	0
1875	Is BF.7 more infectious than other Omicron subtypes: Insights from structural and simulation studies of BF.7 spike RBD variant. <i>International Journal of Biological Macromolecules</i> , 2023, 238, 124154.	3.6	4
1876	Co-occurrence of BA.1 and BA.2 at the start of Singapore's Omicron wave revealed by Community and University Campus wastewater surveillance. <i>Science of the Total Environment</i> , 2023, 875, 162611.	3.9	9
1877	Synthesis, molecular docking, and binding Gibbs free energy calculation of \hat{I}^2 -nitrostyrene derivatives: Potential inhibitors of SARS-CoV-2 3CL protease. <i>Journal of Molecular Structure</i> , 2023, 1284, 135409.	1.8	4
1878	Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114367.	2.5	33
1879	Design, synthesis, and computational studies of novel imidazo[1,2-a]pyrimidine derivatives as potential dual inhibitors of hACE2 and spike protein for blocking SARS-CoV-2 cell entry. <i>Journal of Molecular Structure</i> , 2023, 1285, 135525.	1.8	3
1880	Vaccines Alone Cannot Slow the Evolution of SARS-CoV-2. <i>Vaccines</i> , 2023, 11, 853.	2.1	4
1881	The impact of mutation sets in receptor-binding domain of SARS-CoV-2 variants on stability of the RBD-ACE2 complex. <i>Future Virology</i> , 2023, 18, 225-242.	0.9	3
1882	DeGlyPHER: Highly sensitive site-specific analysis of N-linked glycans on proteins. <i>Methods in Enzymology</i> , 2023, , 137-185.	0.4	2
1884	Comparative Analysis of Library Preparation Approaches for SARS-CoV-2 Genome Sequencing on the Illumina MiSeq Platform. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2374.	1.8	0

#	ARTICLE	IF	CITATIONS
1885	Sequence analysis of SARS-CoV-2 Delta variant isolated from Makassar, South Sulawesi, Indonesia. <i>Heliyon</i> , 2023, 9, e13382.	1.4	3
1886	Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2. <i>Brain, Behavior, & Immunity - Health</i> , 2023, 28, 100600.	1.3	4
1887	Optimal control of the coronavirus pandemic with both pharmaceutical and non-pharmaceutical interventions. <i>International Journal of Dynamics and Control</i> , 0, , .	1.5	1
1888	Quantitative profiling of N-glycosylation of SARS-CoV-2 spike protein variants. <i>Glycobiology</i> , 2023, 33, 188-202.	1.3	7
1889	The Spread of SARS-CoV-2 Omicron Variant in CALABRIA: A Spatio-Temporal Report of Viral Genome Evolution. <i>Viruses</i> , 2023, 15, 408.	1.5	6
1890	Coordinated evolution at amino acid sites of SARS-CoV-2 spike. <i>ELife</i> , 0, 12, .	2.8	9
1891	Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	16
1892	Tixagevimab and Cilgavimab (Evusheldâ„¸) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study. <i>Vaccines</i> , 2023, 11, 350.	2.1	6
1893	Host Response of Syrian Hamster to SARS-CoV-2 Infection including Differences with Humans and between Sexes. <i>Viruses</i> , 2023, 15, 428.	1.5	6
1894	Co-infection associated with SARS-CoV-2 and their management. <i>Future Science OA</i> , 2022, 8, .	0.9	5
1895	Urological complications of COVID-19: a systematic review. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2023, 49, 24-40.	0.7	3
1896	LRR15 mediates an accessory interaction with the SARS-CoV-2 spike protein. <i>PLoS Biology</i> , 2023, 21, e3001959.	2.6	8
1897	The Role of Cyclodextrins in COVID-19 Therapyâ€”A Literature Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2974.	1.8	8
1898	Escalating spread of SARS-CoV-2 infection after school reopening among students in hotspot districts of Oromia Region in Ethiopia: Longitudinal study. <i>PLoS ONE</i> , 2023, 18, e0280801.	1.1	1
1899	Molecular Evolution of SARS-CoV-2 during the COVID-19 Pandemic. <i>Genes</i> , 2023, 14, 407.	1.0	10
1900	Arrayed Imaging Reflectometry monitoring of anti-viral antibody production throughout vaccination and breakthrough Covid-19. <i>PLoS ONE</i> , 2023, 18, e0277846.	1.1	1
1902	Genomic and phenotypic analyses suggest moderate fitness differences among Zika virus lineages. <i>PLoS Neglected Tropical Diseases</i> , 2023, 17, e0011055.	1.3	2
1903	Targeted photodynamic neutralization of SARS-CoV-2 mediated by singlet oxygen. <i>Photochemical and Photobiological Sciences</i> , 2023, 22, 1323-1340.	1.6	2

#	ARTICLE	IF	CITATIONS
1904	Experimental and clinical data analysis for identification of COVID-19 resistant ACE2 mutations. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
1905	Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease. <i>Journal of Biological Chemistry</i> , 2023, 299, 103004.	1.6	31
1906	Immunoinformatics Study: Multi-Epitope Based Vaccine Design from SARS-CoV-2 Spike Glycoprotein. <i>Vaccines</i> , 2023, 11, 399.	2.1	1
1907	Towards Quantum-Chemical Level Calculations of SARS-CoV-2 Spike Protein Variants of Concern by First Principles Density Functional Theory. <i>Biomedicines</i> , 2023, 11, 517.	1.4	4
1908	Competition of SARS-CoV-2 variants on the pandemic transmission dynamics. <i>Chaos, Solitons and Fractals</i> , 2023, 169, 113193.	2.5	6
1909	CRISPR-based nucleic acid diagnostics for pathogens. <i>TrAC - Trends in Analytical Chemistry</i> , 2023, 160, 116980.	5.8	7
1910	Dual-Domain Reporter Approach for Multiplex Identification of Major SARS-CoV-2 Variants of Concern in a Microarray-Based Assay. <i>Biosensors</i> , 2023, 13, 269.	2.3	1
1912	Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron. <i>Viruses</i> , 2023, 15, 530.	1.5	1
1913	Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens. <i>Med</i> , 2023, 4, 191-215.e9.	2.2	16
1914	SARS-CoV-2 Variant-Specific mRNA Vaccine: Pros and Cons. <i>Viral Immunology</i> , 0, , .	0.6	0
1915	COVID-19: Prevention, Detection, and Treatment by Using Carbon Nanotubes-Based Materials. <i>ChemistrySelect</i> , 2023, 8, .	0.7	0
1916	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. <i>Immunity</i> , 2023, 56, 669-686.e7.	6.6	43
1917	Uptake of severe acute respiratory syndrome coronavirus 2 spike protein mediated by angiotensin converting enzyme 2 and ganglioside in human cerebrovascular cells. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	2
1918	Origin and evolution of SARS-CoV-2. <i>European Physical Journal Plus</i> , 2023, 138, .	1.2	16
1919	Computational analysis of the sequence-structure relation in SARS-CoV-2 spike protein using protein contact networks. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
1920	Lung T cell response in COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
1922	Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants. <i>Metabolites</i> , 2023, 13, 309.	1.3	13
1923	Using weather factors and google data to predict COVID-19 transmission in Melbourne, Australia: A time-series predictive model. <i>Heliyon</i> , 2023, 9, e13782.	1.4	4

#	ARTICLE	IF	CITATIONS
1926	Computational framework to understand the clinical stages of COVID-19 and visualization of time course for various treatment strategies. <i>Biotechnology and Bioengineering</i> , 0, , .	1.7	1
1927	Memory B-cell diversity: From early generation to tissue residency and reactivation. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	1
1928	Host-Pathogen Interactions Influencing Zoonotic Spillover Potential and Transmission in Humans. <i>Viruses</i> , 2023, 15, 599.	1.5	6
1929	Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID. <i>Cells</i> , 2023, 12, 688.	1.8	21
1930	Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review. <i>Journal of Blood Medicine</i> , 0, Volume 14, 159-187.	0.7	2
1931	The effect of the third dose of the BNT162b2 vaccine on anti-SARS-CoV-2 spike antibody levels in healthcare workers with and without COVID-19 infection. <i>Annals of Medicine</i> , 2023, 55, 722-732.	1.5	0
1932	SARS-CoV-2 infection of airway organoids reveals conserved use of Tetraspanin-8 by Ancestral, Delta, and Omicron variants. <i>Stem Cell Reports</i> , 2023, 18, 636-653.	2.3	3
1933	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	1.4	28
1934	Development and validation of a rapid and easy-to-perform point-of-care lateral flow immunoassay (LFIA) for the detection of SARS-CoV-2 spike protein. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
1935	Mutation-driven parallel evolution in emergence of ACE2-utilizing sarbecoviruses. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	1
1936	LC-MS/MS-Based Proteomics Approach for the Identification of Candidate Serum Biomarkers in Patients with Narcolepsy Type 1. <i>Biomolecules</i> , 2023, 13, 420.	1.8	4
1937	In silico prediction of potential inhibitors for SARS-CoV-2 Omicron variant using molecular docking and dynamics simulation-based drug repurposing. <i>Journal of Molecular Modeling</i> , 2023, 29, .	0.8	2
1938	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4401.	1.8	4
1940	Detecting punctuated evolution in SARS-CoV-2 over the first year of the pandemic. <i>Frontiers in Virology</i> , 0, 3, .	0.7	0
1941	Microfluidic Devices with Electrochemical Detection Towards Covid-19 Detection. , 2023, , 21-39.		0
1942	Network-based drug repurposing for the treatment of COVID-19 patients in different clinical stages. <i>Heliyon</i> , 2023, 9, e14059.	1.4	3
1943	Machine Learning Guided Design of High-Affinity ACE2 Decoys for SARS-CoV-2 Neutralization. <i>Journal of Physical Chemistry B</i> , 2023, 127, 1995-2001.	1.2	4
1944	Development of broadly reactive antibody therapeutics for SARS-CoV-2. <i>Drug Delivery System</i> , 2022, 37, 388-394.	0.0	0

#	ARTICLE	IF	CITATIONS
1945	Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants. <i>Nature Communications</i> , 2023, 14, .	5.8	6
1946	SARS-CoV-2 pandemics: An update of CRISPR in diagnosis and host-virus interaction studies. <i>Biomedical Journal</i> , 2023, 46, 100587.	1.4	4
1947	Emergent Omicron BR.2.1 sublineage of SARS-CoV-2 in New South Wales, Australia: a subvariant with high fitness but without increased disease severity. <i>International Journal of Infectious Diseases</i> , 2023, 130, 38-41.	1.5	0
1948	Emergence of BS.1 and BS.1.1, highly mutated new SARS-CoV-2 Omicron variants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
1949	Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2023, 15, 624.	1.5	4
1950	A structural perspective on the evolution of viral/cellular macromolecular complexes within the arenaviridae family of viruses. <i>Current Opinion in Structural Biology</i> , 2023, 79, 102561.	2.6	2
1951	Delta (B1.617.2) variant of SARS-CoV-2 induces severe neurotropic patterns in K18-hACE2 mice. <i>Scientific Reports</i> , 2023, 13, .	1.6	6
1952	Diagnostic, Prognostic and Mechanistic Biomarkers of COVID-19 Identified by Mass Spectrometric Metabolomics. <i>Metabolites</i> , 2023, 13, 342.	1.3	3
1953	Single-domain antibody for binding the conserved epitope in the SARS-CoV-2 spike protein receptor-binding domain. <i>Bulletin of Russian State Medical University</i> , 2023, , .	0.3	0
1956	Development of a screening platform to discover natural products active against SARS-CoV-2 infection using lung organoid models. <i>Biomaterials Research</i> , 2023, 27, .	3.2	9
1957	Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 3664-3702.	2.9	12
1958	The SARS-CoV-2 Omicron Variant and its Multiple Sublineages: Transmissibility, Vaccine Development, Antiviral Drugs, Monoclonal Antibodies, and Strategies for Infection Control - a Review. <i>ChemistrySelect</i> , 2023, 8, .	0.7	4
1959	Genetic variety of ORF3a shapes SARS-CoV-2 fitness through modulation of lipid droplet. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	8
1960	SARS-CoV-2 Delta (B.1.617.2) variant replicates and induces syncytia formation in human induced pluripotent stem cell-derived macrophages. <i>PeerJ</i> , 0, 11, e14918.	0.9	0
1961	CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern. <i>TrAC - Trends in Analytical Chemistry</i> , 2023, 161, 117000.	5.8	11
1962	Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1963	Epitope mapping of SARS-CoV-2 spike protein differentiates the antibody binding activity in vaccinated and infected individuals. <i>Frontiers in Virology</i> , 0, 3, .	0.7	0
1964	Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infection. <i>Microbiome</i> , 2023, 11, .	4.9	8

#	ARTICLE	IF	CITATIONS
1965	Variants of SARS-CoV-2: Influences on the Vaccinesâ€™ Effectiveness and Possible Strategies to Overcome Their Consequences. <i>Medicina (Lithuania)</i> , 2023, 59, 507.	0.8	5
1966	Two sides of the same coin: the N-terminal and the receptor-binding domains of SARS-CoV-2 Spike. <i>Future Virology</i> , 2023, 18, 75-78.	0.9	3
1967	Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	5
1969	Investigating antigenic features of the SARS-CoV-2 isolated in Russian Federation in 2021â€“2022 by hyperimmune mouse serum neutralisation. <i>Russian Journal of Infection and Immunity</i> , 2023, 13, 37-45.	0.2	1
1970	Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1971	Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG). <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.4	1
1972	Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1973	Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	9
1976	Comorbidities in the COVID-19 Pandemic: Scopus-Based Bibliometric Analysis. <i>Journal of Korean Medical Science</i> , 2023, 38, .	1.1	2
1977	An Adjuvanted Inactivated SARS-CoV-2 Microparticulate Vaccine Delivered Using Microneedles Induces a Robust Immune Response in Vaccinated Mice. <i>Pharmaceutics</i> , 2023, 15, 895.	2.0	6
1978	Therapeutic potential of salicylamide derivatives for combating viral infections. <i>Medicinal Research Reviews</i> , 2023, 43, 897-931.	5.0	2
1979	THE PROBLEM OF INCIDENCE OF ACUTE INTESTINAL INFECTIONS IN CHILDREN DURING WARTIME IN UKRAINE. , 2023, 23, 205-210.	0.1	0
1980	ZnO-Based Electrochemical Immunosensor to Assess Vaccine-Induced Antibody-Mediated Immunity against Wild-Type and Gamma SARS-CoV-2 Strains. <i>Biosensors</i> , 2023, 13, 371.	2.3	3
1981	Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia, 2020â€“2022. <i>Genes</i> , 2023, 14, 705.	1.0	2
1984	Seasonal effects decouple SARS-CoV-2 haplotypes worldwide. <i>F1000Research</i> , 0, 12, 267.	0.8	4
1985	Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein. <i>Nature Communications</i> , 2023, 14, .	5.8	21
1986	Extracellular vesicles in COVID-19 prognosis, treatment, and vaccination: an update. <i>Applied Microbiology and Biotechnology</i> , 2023, 107, 2131-2141.	1.7	4
1987	Comparative Analysis of Clinical and CT Findings in Patients with SARS-CoV-2 Original Strain, Delta and Omicron Variants. <i>Biomedicines</i> , 2023, 11, 901.	1.4	5

#	ARTICLE	IF	CITATIONS
1989	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
1990	Conformational Behavior of SARS-Cov-2 Spike Protein Variants: Evolutionary Jumps in Sequence Reverberate in Structural Dynamic Differences. <i>Journal of Chemical Theory and Computation</i> , 2023, 19, 2120-2134.	2.3	2
1991	Deep Structural Analysis of Myriads of Omicron Sub-Variants Revealed Hotspot for Vaccine Escape Immunity. <i>Vaccines</i> , 2023, 11, 668.	2.1	3
1992	Molecular Analysis of SARS-CoV-2 Spike Protein-Induced Endothelial Cell Permeability and vWF Secretion. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5664.	1.8	3
1996	Highly Selective Aptamer-Molecularly Imprinted Polymer Hybrids for Recognition of SARS-CoV-2 Spike Protein Variants. <i>Global Challenges</i> , 2023, 7, .	1.8	0
1998	adaPop: Bayesian inference of dependent population dynamics in coalescent models. <i>PLoS Computational Biology</i> , 2023, 19, e1010897.	1.5	0
1999	SARS-CoV-2 M ^{pro} Protease Variants of Concern Display Altered Viral Substrate and Cell Host Target Galectin-8 Processing but Retain Sensitivity toward Antivirals. <i>ACS Central Science</i> , 2023, 9, 696-708.	5.3	14
2000	Editorial: Molecular and cellular mechanisms involved in inflammation, metabolism and oxidative stress induced by coronaviruses. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	0
2001	Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
2003	Nanotechnology laying new foundations for combating COVID-19 pandemic. , 2023, , 459-506.		0
2004	Analytical performance evaluation of Lumipulse [®] SARS-CoV-2 antigen assay in 392 asymptomatic patients. <i>Journal of Clinical Laboratory Analysis</i> , 0, , .	0.9	2
2005	Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir. <i>PLoS Pathogens</i> , 2023, 19, e1011231.	2.1	2
2006	Abiotic Synthetic Antibody Inhibitor with Broad-Spectrum Neutralization and Antiviral Efficacy against Escaping SARS-CoV-2 Variants. <i>ACS Nano</i> , 2023, 17, 7017-7034.	7.3	1
2007	Protection from SARS-CoV-2 Variants by MVAs expressing matched or mismatched S administered intranasally to mice. <i>Npj Vaccines</i> , 2023, 8, .	2.9	1
2009	Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review. <i>Cureus</i> , 2023, , .	0.2	1
2010	Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. <i>Viruses</i> , 2023, 15, 856.	1.5	10
2011	Longitudinal Neutralizing and Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants Following Messenger RNA Coronavirus Disease 2019 Vaccination. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	0
2012	Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1. <i>Life Science Alliance</i> , 2023, 6, e202201745.	1.3	8

#	ARTICLE	IF	CITATIONS
2014	Virus-Specific Stem Cell Memory CD8+ T Cells May Indicate a Long-Term Protection against Evolving SARS-CoV-2. <i>Diagnostics</i> , 2023, 13, 1280.	1.3	0
2015	Designing and fabrication of electrochemical nano-biosensor for the fast detection of SARS-CoV-2-RNA. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
2016	Different Variants of SARS-CoV-2: A Comprehensive Review on Mutation Patterns and Pathogenicity. <i>Coronaviruses</i> , 2023, 4, .	0.2	1
2017	Effects of vaccines on clinical characteristics of convalescent adult patients infected with SARS-CoV-2 Omicron variant: A retrospective study. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	0
2018	Rational strategies for enhancing mAb binding to SARS-CoV-2 variants through CDR diversification and antibody-escape prediction. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
2019	Genetic Diversity and Spatiotemporal Distribution of SARS-CoV-2 Alpha Variant in India. <i>Covid</i> , 2023, 3, 472-479.	0.7	0
2020	Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses. <i>IScience</i> , 2023, 26, 106540.	1.9	2
2021	Genotyping SARS-CoV-2 Variants Using Ratiometric Nucleic Acid Barcode Panels. <i>Analytical Chemistry</i> , 2023, 95, 5877-5885.	3.2	0
2022	Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant. <i>MBio</i> , 2023, 14, .	1.8	9
2023	Subclass-switched anti-spike IgG3 oligoclonal cocktails strongly enhance Fc-mediated opsonization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	6
2024	Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants. <i>Cell Discovery</i> , 2023, 9, .	3.1	2
2026	High levels of pro-inflammatory SARS-CoV-2-specific biomarkers revealed by in vitro whole blood cytokine release assay (CRA) in recovered and long-COVID-19 patients. <i>PLoS ONE</i> , 2023, 18, e0283983.	1.1	7
2027	A comparison of five Illumina, Ion Torrent, and nanopore sequencing technology-based approaches for whole genome sequencing of SARS-CoV-2. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2023, 42, 701-713.	1.3	6
2028	Cryo-EM structures and binding of mouse and human ACE2 to SARS-CoV-2 variants of concern indicate that mutations enabling immune escape could expand host range. <i>PLoS Pathogens</i> , 2023, 19, e1011206.	2.1	8
2029	The evolution of SARS-CoV-2. <i>Nature Reviews Microbiology</i> , 2023, 21, 361-379.	13.6	239
2030	Immunology of COVID-19. , 2024, , 52-71.		0
2031	SARS-CoV-2 RBD Conjugated to Polyglucin, Spermidine, and dsRNA Elicits a Strong Immune Response in Mice. <i>Vaccines</i> , 2023, 11, 808.	2.1	1
2032	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0

#	ARTICLE	IF	CITATIONS
2033	An optimized circular polymerase extension reaction-based method for functional analysis of SARS-CoV-2. <i>Virology Journal</i> , 2023, 20, .	1.4	3
2034	Covid-19 infection: Successful global spread, challenges to public health surveillance, and lessons learnt. <i>Journal of Public Health and Epidemiology</i> , 2023, 15, 50-54.	0.1	0
2035	Selective SARS-CoV2 BA.2 escape of antibody Fc/Fc-receptor interactions. <i>IScience</i> , 2023, 26, 106582.	1.9	2
2036	SARS-CoV-2 evolved variants optimize binding to cellular glycolyx. <i>Cell Reports Physical Science</i> , 2023, 4, 101346.	2.8	12
2037	Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines. <i>Virology Journal</i> , 2023, 20, .	1.4	1
2038	Suramin binds and inhibits infection of SARS-CoV-2 through both spike protein-heparan sulfate and ACE2 receptor interactions. <i>Communications Biology</i> , 2023, 6, .	2.0	4
2040	Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. <i>Communications Biology</i> , 2023, 6, .	2.0	0
2041	DNA immunization with in silico predicted T-cell epitopes protects against lethal SARS-CoV-2 infection in K18-hACE2 mice. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
2042	Sars-escape network for escape prediction of SARS-COV-2. <i>Briefings in Bioinformatics</i> , 0, , .	3.2	0
2043	Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. <i>Viruses</i> , 2023, 15, 944.	1.5	19
2044	Sanitize the Man, Sanitize the Car: COVID-19 Disease Control in Botswana. <i>Journal of Developing Societies</i> , 0, , 097340822311588.	0.5	0
2045	Perceptions about COVID-19 preventive measures among Ghanaian women. <i>PLoS ONE</i> , 2023, 18, e0284362.	1.1	1
2046	Phytochemicals of <i>Withania somnifera</i> as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. <i>Microorganisms</i> , 2023, 11, 1000.	1.6	2
2047	Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies. <i>World Journal of Gastroenterology</i> , 0, 29, 2064-2077.	1.4	4
2048	C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Contrasting Results of PANAMO and FORCE. <i>Critical Care Medicine</i> , 2023, 51, e129-e130.	0.4	2
2049	A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response. <i>Vaccines</i> , 2023, 11, 832.	2.1	1
2050	Analysis of SARS-CoV-2 variants from patient specimens in Nevada from October 2020 to August 2021. <i>Infection, Genetics and Evolution</i> , 2023, 111, 105434.	1.0	1
2052	Genomic Surveillance of SARS-CoV-2 Variants in the Dominican Republic and Emergence of a Local Lineage. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 5503.	1.2	2

#	ARTICLE	IF	CITATIONS
2053	SARS-CoV-2 BW lineage, a fast-growing Omicron variant from southeast Mexico bearing relevant escape mutations. <i>Infection</i> , 2023, 51, 1549-1555.	2.3	3
2054	Does the SARS-CoV-2 spike really have an Achilles heel?. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	0
2055	The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data. <i>Viruses</i> , 2023, 15, 976.	1.5	7
2056	Case report: Severe pneumonia and pneumomediastinum in a previously robust adolescent caused by Omicron BA.5.2. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	1
2057	Variant-specific introduction and dispersal dynamics of SARS-CoV-2 in New York City “ from Alpha to Omicron. <i>PLoS Pathogens</i> , 2023, 19, e1011348.	2.1	3
2058	Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice. <i>Heliyon</i> , 2023, 9, e15587.	1.4	1
2059	Next-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein. <i>Zoonoses</i> , 2023, 3, .	0.5	1
2060	Evaluating the effect of SARS-CoV-2 spike mutations with a linear doubly robust learner. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	0
2061	Immunodominant SARS-CoV-2-specific CD4 ⁺ and CD8 ⁺ T cell responses elicited by inactivated vaccines in healthy adults. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
2062	Virulence Profiles of Wild-Type, P.1 and Delta SARS-CoV-2 Variants in K18-hACE2 Transgenic Mice. <i>Viruses</i> , 2023, 15, 999.	1.5	3
2063	Dynamical changes of SARS-CoV-2 spike variants in the highly immunogenic regions impact the viral antibodies escaping. <i>Proteins: Structure, Function and Bioinformatics</i> , 2023, 91, 1116-1129.	1.5	2
2065	Development of SARS-CoV-2 Vaccine: Challenges and Prospects. <i>Diseases (Basel, Switzerland)</i> , 2023, 11, 64.	1.0	1
2082	From Genomes to Variant Interpretations Through Protein Structures. <i>SpringerBriefs in Applied Sciences and Technology</i> , 2023, , 41-50.	0.2	0
2084	Superspreading and Heterogeneity in Epidemics. , 2023, , 473-507.		0
2089	Factor Related to Anxiety Among Parents of Children Under Five Years of Age During COVID-19 Pandemic. , 2023, , 879-886.		0
2135	Omicron variant evolved: Signs, symptoms and complications. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
2137	A critical appraisal of the toxicological aspects of COVID-19 and its vaccines. , 2024, , 1-11.		0
2157	The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology, and Variants of Concern. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 3-26.	0.8	0

#	ARTICLE	IF	CITATIONS
2167	Nucleic Acid in Diagnostics. , 2023, , 213-269.		0
2184	Surveillance of SARS-CoV-2 in Wastewater at the Population Level: Insights into the Implementation of Non-invasive Targeted Monitoring in Singapore and the USA. Handbook of Environmental Chemistry, 2023, , .	0.2	1
2202	Proteomic Investigation of COVID-19 Severity During the Tsunamic Second Wave in Mumbai. Advances in Experimental Medicine and Biology, 2023, , 175-195.	0.8	0
2209	Implications of antibiotics and antimicrobial resistance development during COVID-19. , 2023, , 375-395.		0
2217	Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review. Neurology and Therapy, 0, , .	1.4	1
2249	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
2282	Chronicing the 3-year evolution of the COVID-19 pandemic: analysis of disease management, characteristics of major variants, and impacts on pathogenicity. Clinical and Experimental Medicine, 0, , .	1.9	0
2290	Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation. Chemical Society Reviews, 2023, 52, 6497-6553.	18.7	1
2291	CAMEROON: Epidemiological Insights, Public Health Response, and Potential Psycho-Socio-Economic Impacts of COVID-19 Pandemic in Doualaâ€”A Population-Based Study. Urban Health and Wellbeing, 2023, , 29-48.	0.3	0
2338	Case report: Presentations and cytokine profiles of inflammatory non-pulmonary COVID-19 and related diseases in children. Frontiers in Pediatrics, 0, 11, .	0.9	0
2339	SARS-CoV-2 evolution in the Omicron era. Nature Microbiology, 2023, 8, 1952-1959.	5.9	18
2394	Relevance of Multi-Omics Approach for Future Pandemic Preparedness and Response. , 2023, , 53-64.		0
2395	Need for Quicker Systems for Development and Evaluation of Vaccines and Drugs. , 2023, , 105-120.		0
2415	The Interplay of Clustering and Evolution in the Emergence of Epidemics on Networks. , 2023, , .		1
2426	Virus-mimicking nanosystems: from design to biomedical applications. Chemical Society Reviews, 2023, 52, 8481-8499.	18.7	0
2440	Isolation and evaluation of antiviral plant compounds against respiratory disease-causing viruses: a review. Advances in Traditional Medicine, 0, , .	1.0	0
2488	Virus-Induced Cell Fusion and Syncytia Formation. Results and Problems in Cell Differentiation, 2024, , 283-318.	0.2	1
2513	Omicron: A SARS-CoV-2 Variant. , 0, , .		0

#	ARTICLE	IF	CITATIONS
2529	Computational approaches for identifying disease-causing mutations in proteins. <i>Advances in Protein Chemistry and Structural Biology</i> , 2024, , 141-171.	1.0	0
2533	Pathogen evolution, prevention/control strategy and clinical features of COVID-19: experiences from China. <i>Frontiers of Medicine</i> , 2023, 17, 1030-1046.	1.5	0
2537	Mannose-specific plant and microbial lectins as antiviral agents: A review. <i>Glycoconjugate Journal</i> , 2024, 41, 1-33.	1.4	0
2538	SARS-CoV-2 biology and host interactions. <i>Nature Reviews Microbiology</i> , 2024, 22, 206-225.	13.6	1
2540	Silver nanoparticles for treatment of COVID-19 and other viral diseases. , 2024, , 313-340.		0
2544	Structure-Based Screening of Potential Drugs against SARS-CoV-2 Variants. , 0, , .		0
2562	COVID-19 epidemiology and prevention. , 2024, , 2753-2759.		0
2587	Enhancing Immunological Memory: Unveiling Booster Doses to Bolster Vaccine Efficacy Against Evolving SARS-CoV-2 Mutant Variants. <i>Current Microbiology</i> , 2024, 81, .	1.0	0
2611	Applications of Mass Spectrometry in the Characterization, Screening, Diagnosis, and Prognosis of COVID-19. <i>Advances in Experimental Medicine and Biology</i> , 2024, , 33-61.	0.8	0
2615	Indigenous Knowledge and Phytochemistry: Deciphering the Healing Power of Herbal Medicine. <i>Reference Series in Phytochemistry</i> , 2023, , 1-53.	0.2	0